We are offering 19,818,972 shares of our common stock and warrants to purchase up 14,864,229 shares of our common stock. For each share of our common stock purchased by an investor in this offering, the investor will receive a warrant to purchase 0.75 shares of our common stock with an exercise price of $0.29 per share and a term of exercise of 30 months. We are not required to sell any specific dollar amount or number of shares of common stock or warrants, but will use our best efforts to sell all of the shares of common stock and warrants being offered.
Our common stock is traded on the OTCQB Bulletin Board under the symbol “BCLI”. On July 9, 2012, the last reported sales price for our common stock was $0.29 per share.
Per Share
|
Total
|
|||||||
Public
Offering Price
|
$ | 0.29 | $ | 5,747,502 | ||||
Placement
Agent fees (1)
|
$ | 0.0174 | $ | 344,850 | ||||
Offering
Proceeds before expenses (2)
|
$ | 0.2726 | $ | 5,402,652 |
(1) | For the purpose of estimating the placement agent’s fees, we have assumed that the placement agent will receive its maximum commission on all sales made in the offering. Does not include a corporate finance fee in the amount of 1.0%, or $0.0029 per share and $57,475 in the aggregate, of the gross proceeds of the offering payable to the placement agent. We have also agreed to issue warrants to the placement agent and to reimburse the placement agent for expenses incurred by them up to an aggregate of the lesser of (i) $100,000 or (ii) 3% of the gross proceeds of the offering. |
(2) | We estimate the total expenses of this offering will be approximately $835,825.14 See “Plan of Distribution” beginning on page 18 of this prospectus for more information on this offering. |
Page
|
||
PROSPECTUS SUMMARY
|
1
|
|
RISK FACTORS
|
4 | |
DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS
|
15 | |
EXCHANGE RATE INFORMATION
|
16 | |
USE OF PROCEEDS
|
16 | |
DIVIDEND POLICY
|
17 | |
DILUTION
|
17 | |
PLAN OF DISTRIBUTION
|
18 | |
DESCRIPTION OF SECURITIES
|
19 | |
OUR BUSINESS
|
21 | |
PROPERTIES
|
31 | |
LEGAL PROCEEDINGS
|
31 | |
MARKET FOR OUR COMMON EQUITY
|
32 | |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
34 | |
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
|
37 | |
MANAGEMENT
|
38 | |
EXECUTIVE COMPENSATION
|
44 | |
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
|
49 | |
RELATED PARTY TRANSACTIONS
|
50 | |
LEGAL MATTERS
|
54 | |
EXPERTS
|
54 | |
INDEMNIFICATION UNDER OUR CERTIFICATE OF INCORPORATION AND BYLAWS
|
54 | |
WHERE YOU CAN FIND MORE INFORMATION
|
55 |
·
|
Operating a Good Manufacturing Practice (“GMP”) compliant production process;
|
·
|
Demonstrating Safety Tolerability and Therapeutic effect of transplantation of Autologous cultured Bone Marrow Stromal Cells secreting Neurothrophic factors (MSC-NTF) in a Phase I/II Clinical trial in human ALS patients;
|
1 |
·
|
Setting up a centralized facility to provide the therapeutic products
and services for transplantation in patients in the US, as part of the clinical development program; and
|
·
|
Submitting an Investigational New Drug application (“IND”) to the FDA.
|
·
|
Bone marrow aspiration from patient;
|
·
|
Isolation and expansion of the mesenchymal stem cells;
|
·
|
Differentiation of the expanded stem cells into neurotrophic-factor secreting cells; and
|
·
|
Autologous transplantation into the patient into the site of damage.
|
2 |
Securities
Offered
|
19,818,972 shares
of common stock
|
|
Warrants
to purchase 14,864,229 shares of common stock
14,864,229 shares of common stock
issuable upon exercise of the warrants
|
||
Common
stock outstanding as of June 15, 2012
|
128,586,644
shares
|
|
Common stock to be outstanding after the offering assuming the sale of all shares covered hereby and assuming no exercise of the warrants for the shares covered by this prospectus
|
148,405,616 shares
|
|
Common stock to be outstanding after the offering assuming the sale of all shares covered hereby and assuming the exercise of all warrants for the shares covered by this prospectus
|
163,269,845 shares
|
|
Use
of proceeds
|
We
estimate that we will receive up to $4,911,676.86 in net proceeds from the sale of the securities
in this offering, based on a per share purchase price of $0.29 and after deducting
placement agent fees and commissions and estimated offering expenses payable by us. We
will use the proceeds from the sale of the securities for clinical trials
in the United States and Israel, research and development, working capital needs, capital expenditures
and other general corporate purposes. See “Use of Proceeds” for more information.
|
|
Risk factors
|
The shares of common stock offered hereby involve a high degree of risk. See “Risk Factors” beginning on page 4.
|
|
Dividend policy
|
We currently intend to retain any future earnings to fund the development and growth of our business. Therefore, we do not currently anticipate paying cash dividends on our common stock.
|
|
Trading Symbol
|
Our common stock currently trades on the OTCQB Bulletin Board under the symbol “BCLI.”
|
3 |
4 |
5 |
· | The FDA or similar foreign regulatory authorities may find that our product candidates are not sufficiently safe or effective or may find our processes or facilities unsatisfactory; | |
· | Officials at the MOH, the FDA or similar foreign regulatory authorities may interpret data from preclinical studies and clinical trials differently than we do; | |
· | Our clinical trials may produce negative or inconclusive results or may not meet the level of statistical significance required by the MOH, the FDA or other regulatory authorities, and we may decide, or regulators may require us, to conduct additional preclinical studies and/or clinical trials or to abandon one or more of our development programs; | |
· | The MOH, the FDA or similar foreign regulatory authorities may change their approval policies or adopt new regulations; | |
· | There may be delays or failure in obtaining approval of our clinical trial protocols from the MOH, the FDA or other regulatory authorities or obtaining institutional review board approvals or government approvals to conduct clinical trials at prospective sites; | |
· | We, or regulators, may suspend or terminate our clinical trials because the participating patients are being exposed to unacceptable health risks or undesirable side effects; | |
· | We may experience difficulties in managing multiple clinical sites; | |
· | Enrollment in our clinical trials for our product candidates may occur more slowly than we anticipate, or we may experience high drop-out rates of subjects in our clinical trials, resulting in significant delays; and | |
· | We may be unable to manufacture or obtain from third party manufacturers sufficient quantities of our product candidates for use in clinical trials. |
6 |
|
•
|
State and local licensing, registration and regulation of laboratories, the collection, processing and storage of human cells and tissue, and the development and manufacture of pharmaceuticals and biologics;
|
|
•
|
The federal Clinical Laboratory Improvement Act and amendments of 1988;
|
|
•
|
Laws and regulations administered by the FDA, including the Federal Food Drug and Cosmetic Act and related laws and regulations;
|
|
•
|
The Public Health Service Act and related laws and regulations;
|
|
•
|
Laws and regulations administered by the United States Department of Health and Human Services, including the Office for Human Research Protections;
|
|
•
|
State laws and regulations governing human subject research;
|
|
•
|
Occupational Safety and Health requirements; and
|
|
•
|
State and local laws and regulations dealing with the handling and disposal of medical waste.
|
7 |
8 |
9 |
|
•
|
Reducing reimbursement rates;
|
|
•
|
Challenging the prices charged for medical products and services;
|
|
•
|
Limiting services covered;
|
|
•
|
Decreasing utilization of services;
|
|
•
|
Negotiating prospective or discounted contract pricing;
|
|
•
|
Adopting capitation strategies; and
|
|
•
|
Seeking competitive bids.
|
10 |
11 |
12 |
If we fail to implement and maintain an effective system of internal controls, we may be unable to accurately report our results of operations or prevent fraud, and investor confidence and the market price of our Common Stock may be materially and adversely affected.
As a public company in the United States, we are subject to the reporting obligations under the U.S. securities laws. The Securities and Exchange Commission, or the SEC, as required under Section 404 of the Sarbanes-Oxley Act of 2002, has adopted rules requiring every public company to include a report of management on the effectiveness of such company’s internal control over financial reporting in its annual report. Our consolidated financial statements for the year ended December 31, 2011 and for the quarter ended March 31, 2012, provided that our management has performed an evaluation of the effectiveness of our disclosure controls and internal control over financial reporting for the periods covered by Forms 10-K and 10-Q, and concluded that our disclosure controls and procedures were not effective as of March 31, 2012 as a result of the material weaknesses in our internal control over financial reporting. The material weaknesses identified in our internal control over financial reporting are related to both the inadequate supervisory review structure and insufficient personnel with appropriate levels of accounting knowledge and experience to address the high volume of U.S. GAAP accounting issues and to prepare and review financial statements and related disclosures under U.S. GAAP. In response to the material weaknesses described above, we plan to develop and take several measures designed to remediate the material weaknesses in our internal control over financial reporting. The measures we intend to take in the future may not be sufficient to remediate the material weaknesses noted by our management and our independent registered public accounting firm and to avoid potential future material weaknesses. We may require more resources and incur more costs than currently expected to remediate our identified material weaknesses or any additional significant deficiencies or material weaknesses that may be identified, which may adversely affect our results of operations. If either of the material weaknesses is not remedied or recurs, or if we identify additional weaknesses or fail to timely and successfully implement new or improved controls, our ability to assure timely and accurate financial reporting may be adversely affected, and we could suffer a loss of investor confidence in the reliability of our financial statements, which in turn could negatively impact the trading price of our shares of common stock, result in lawsuits being filed against us by our shareholders, or otherwise harm our reputation. In addition, our auditor is not required to attest to the effectiveness of our internal controls over financial reporting due to our status of qualifying as a small reporting company. As a result, current and potential investors could lose confidence in our financial reporting, which could harm our business and have an adverse effect on our share price.
13 |
14 |
|
·
|
Statements as to the anticipated timing of clinical studies and other business developments;
|
|
·
|
Statements as to the development of new products;
|
|
·
|
Our expectations regarding federal, state and foreign regulatory requirements;
|
|
·
|
Our expectations regarding grants from federal resources; and
|
|
·
|
Statements regarding growth strategies, financial results, product development, competitive strengths, intellectual property rights, litigation, mergers and acquisitions, market acceptance or continued acceptance of our products, accounting estimates, financing activities and ongoing contractual obligations.
|
15 |
Year ended December 31, | Quarter ended March 31, | Quarter ended June 30, | |||||||||||||||||||||
2008 | 2009 | 2010 | 2011 | 2012 | 2012 | ||||||||||||||||||
Low | 3.230 | 3.690 | 3.549 | 3.363 | 3.700 | 3.715 | |||||||||||||||||
High | 4.022 | 4.256 | 3.894 | 3.821 | 3.854 | 3.947 | |||||||||||||||||
Period End | 3.802 | 3.775 | 3.549 | 3.821 | 3.715 | 3.923 | |||||||||||||||||
Average | 3.588 | 3.933 | 3.733 | 3.578 | 3.771 | 3.8928 |
16 |
Assumed
public offering price per share
|
$ | 0.29 | ||
Pro
forma net tangible book value per share as of March 31, 2012
|
$ | 0.006 | ||
Increase
per share attributable to new investors
|
$ | 0.033 | ||
Pro
forma as adjusted net tangible book value per share after this offering
|
$ | 0.039 | ||
Dilution
per share to new investors in this offering
|
$ | 0.257 |
17 |
Maxim Group LLC, which we refer to herein as the Placement Agent, has agreed to act as placement agent in connection with this offering subject to the terms and conditions of the placement agent agreement dated July 17, 2012. The Placement Agent is not purchasing or selling any securities offered by this prospectus, nor is it required to arrange the purchase or sale of any specific number or dollar amount of securities, but has agreed to use its best efforts to arrange for the sale of all of the securities offered hereby. The Placement Agent may retain other brokers or dealers to act as sub-agents or selected-dealers on its behalf in connection with the offering. Therefore, we will enter into a purchase agreement directly with investors in connection with this offering and we may not sell the entire amount of securities offered pursuant to this prospectus.
We have agreed to pay the Placement Agent a placement agent’s fee equal to six percent (6%) and a corporate finance fee equal to one percent (1%) of the aggregate purchase price of the shares sold in this offering.
In addition, we have agreed to issue to the Placement Agent, or its designees, warrants exercisable for a number of shares of common stock equal to 3% of the aggregate number of shares of common stock sold in this offering (excluding any shares of common stock issuable upon exercise of the warrants). The placement agent warrants will have the substantially same terms as the warrants offered hereunder, except that the placement agent warrants will have an exercise price of 120% of the public offering price per share, or $0.348 per share, and the expiration date shall be two years from the closing of this offering. Pursuant to FINRA Rule 5110(g)(1), neither the placement agent warrants nor any shares of common stock issued upon exercise of the placement agent warrants may be sold, transferred, assigned, pledged, or hypothecated, or be subject to any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of such securities by any person for a period of 180 days immediately following the date of effectiveness or commencement of sales of the public offering, except the transfer of any security:
§ | by operation of law or by reason of our reorganization; |
§ | to any FINRA member firm participating in the offering and the officers and partners thereof, if all securities so transferred remain subject to the lock-up restriction described above for the remainder of the time period; |
§ | if the aggregate amount of our securities held by the Placement Agent or related person does not exceed 1% of the securities being offered; |
§ | that is beneficially owned on a pro-rata basis by all equity owners of an investment fund, provided that no participating member manages or otherwise directs investments by the fund, and participating members in the aggregate do not own more than 10% of the equity in the fund; or |
§ | the exercise or conversion of any security, if all securities received remain subject to the lock-up restriction set forth above for the remainder of the time period. |
Subject to compliance with FINRA Rule 5110(f)(2)(D), we have also agreed to pay the Placement Agent a non-accountable expense reimbursement equal to the lesser of (i) $100,000 and (ii) 3% of the gross proceeds raised in the offering. Based on the gross proceeds in the offering, the Placement Agreement will receive a non-accountable expense reimbursement of 100,000. We have also agreed to reimburse the Placement Agent for its actual “roadshow” expenses; provided, however, that such expenses shall not exceed $2,000. We have reimbursed the Placement Agent for its actual road show expenses of $2000. In addition, subject to FINRA Rule 5110(f)(2)(D), we have granted to the Placement Agent a right of first refusal with respect to additional raises of funds by means of a public offering or a private placement of equity or debt securities using an underwriter or placement agent during the 12 months following this offering.
The following table shows the per share and total placement agent’s fees that we will pay to the Placement Agent in connection with the sale of the shares and warrants offered pursuant to this prospectus assuming the purchase of all of the shares offered hereby.
Per share placement agent’s fees (1) | $ | 0.02 | ||
Maximum offering total | $ | 344,850 |
(1) Does not include a corporate finance fee in the amount of 1%, or $0.0029 per share and $57,475 in the aggregate, of the gross proceeds of the offering payable to the placement agent.
Because there is no minimum amount required as a condition to the closing in this offering, the actual total offering commissions, if any, are not presently determinable and may be substantially less than the maximum amount set forth above.
Our obligations to issue and sell securities to the purchasers is subject to the conditions set forth in the securities purchase agreement attached as Annex A hereto, which may be waived by us at our discretion. A purchaser’s obligation to purchase securities is subject to the conditions set forth in the securities purchase agreement as well, which may also be waived.
We estimate the total offering expenses in this offering that will be payable by us, excluding the placement agent’s fees, will be approximately $4,911,676.86 which include legal, accounting and printing costs, various other fees and reimbursement of the placement agent’s expenses.
The foregoing does not purport to be a complete statement of the terms and conditions of the placement agent agreement and the securities purchase agreement. A form of the placement agent agreement and the form of securities purchase agreement with investors are included as exhibits to the registration statement of which this prospectus forms a part.
We have agreed to indemnify the Placement Agent against certain liabilities under the Securities Act of 1933, as amended. The Placement Agent may be deemed to be an underwriter within the meaning of Section 2(a)(11) of the Securities Act, and any commissions received by it and any profit realized on the resale of the securities sold by it while acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act.
As an underwriter, the Placement Agent would be required to comply with the Securities Act and the Securities Exchange Act of 1934, as amended, including without limitation, Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of shares of common stock and warrants by the Placement Agent acting as principal. Under these rules and regulations, the Placement Agent:
• | may not engage in any stabilization activity in connection with our securities; and |
• | may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted under the Exchange Act, until it has completed its participation in the distribution. |
The securities registered under the registration statement of which this prospectus forms a part may be offered and sold to investors in Israel. The offering of securities in Israel, if any, will be pursuant to an exemption from the registration requirements in Israel and will be considered a private placement in Israel under Israeli Law.
Leader Underwriters (1993) Ltd (“Leader”), an underwriter registered under the laws of Israel, acted as a sub-agent of the Placement Agent for the sole purpose of arranging for the sale of securities registered under the registration statement of which this prospectus forms a part to investors in Israel. The offering of securities in Israel will be pursuant to an exemption from the registration requirements in Israel and will be considered a private placement in Israel under Israeli law. Pursuant to the terms of a Selected Dealer Agreement, dated July 17, 2012, between the Placement Agent and Leader, Leader shall receive from the Placement Agent a cash payment equal to 5% of gross proceeds of securities placed by Leader, or $48,625, and warrants to purchase 3% of the shares of common stock placed by Leader, or warrants to purchase 100,603 shares of common stock.
Furthermore, all of our directors, executive officers, key consultants and affiliates, including ACCBT, have entered into lock-up agreements with Maxim Group LLC. Under those lock-up agreements, subject to certain exceptions, those holders of such stock may not, directly or indirectly, offer, sell, contract to sell (including short-selling), pledge or otherwise dispose of or hedge any common stock or securities convertible into or exchangeable for shares of common stock, without the prior written consent of Maxim Group LLC, for a period of 180 days from the closing date of this offering. In addition, we have agreed not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or securities exchangeable, convertible or exercisable into common stock for a period of 90 days following the closing date of this offering, subject to certain exceptions.
18 |
|
·
|
before such person became an interested stockholder, the board of directors of the corporation approved either the business combination or the transaction that resulted in the interested stockholder becoming an interested stockholder;
|
|
·
|
upon the consummation of the transaction that resulted in the interested stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding shares held by directors who also are officers of the corporation and shares held by employee stock plans; or
|
|
·
|
at or following the time such person became an interested stockholder, the business combination is approved by the board of directors of the corporation and authorized at a meeting of stockholders by the affirmative vote of the holders of 66 2/3% of the outstanding voting stock of the corporation which is not owned by the interested stockholder.
|
19 |
The Warrants offered in this offering will be issued in the form attached as Annex B hereto. You should review a copy of the form of warrant for a complete description of the terms and conditions applicable to the Warrants. The following is a brief summary of the Warrants and is subject in all respects to the provisions contained in the form of warrant.
20 |
|
·
|
Operating a GMP compliant production process;
|
|
·
|
Demonstrating Safety Tolerability and Therapeutic effect of transplantation of Autologous cultured Bone Marrow Stromal Cells secreting Neurothrophic factors (MSC-NTF) in a Phase I/II Clinical trial in human ALS patients;
|
|
·
|
Setting up a centralized facility to provide the therapeutic products
and services for transplantation in patients in the US, as part of the clinical development program; and
|
|
·
|
Submitting an IND to the FDA.
|
21 |
|
·
|
Bone marrow aspiration from patient;
|
|
·
|
Isolation and expansion of the mesenchymal stem cells;
|
|
·
|
Differentiation of the expanded stem cells into neurotrophic-factor secreting cells; and
|
|
·
|
Autologous transplantation into the patient into the site of damage.
|
22 |
23 |
On March 12, 2012, we announced plans to initiate a preclinical study assessing the efficiency of our NurOwn™ stem cell technology in patients with MS. Positive proof-of-concept results for MS have been confirmed in a set of in-vitro and in-vivo experiments, and we are working to advance MS into preclinical development in our second quarter in 2012.
24 |
|
·
|
Riluzole - the only medication approved by the FDA to slow the progress of ALS. While it does not reverse ALS, Riluzole has been shown to reduce nerve damage. Riluzole may extend the time before a patient needs a ventilator (a machine to assist breathing) and may prolong the patient's life by several months;
|
|
·
|
Baclofen or Diazepam - these medications may be used to control muscle spasms, stiffness or tightening (spasticity) that interfere with daily activities; and
|
|
·
|
Trihexyphenidyl or Amitriptyline - these medications may help patients who have excess saliva or secretions, and emotional changes.
|
25 |
|
·
|
Operating a GMP compliant production process;
|
|
·
|
Demonstrating Safety Tolerability and Therapeutic effect of transplantation of Autologous cultured Bone Marrow Stromal Cells secreting Neurothrophic factors (MSC-NTF) in a Phase I/II Clinical trial in human ALS patients;
|
·
|
Setting up a centralized facility to provide the therapeutic products
and services for transplantation in patients in the US, as part of the clinical development program; and
|
·
|
Submitting an IND to the FDA
|
26 |
|
·
|
Private Medical Center Chains - interested in expanding their service offerings and being associated with an innovative technology, thereby enhancing their professional standing and revenue potential; and
|
|
·
|
Major Pharmaceutical and/or Medical Device Companies - seeking new product opportunities and/or wishing to maintain interest in the market, which may shift away from drugs towards surgical treatment.
|
27 |
Patents:
We have filed for patents in (1) the United States; (2) Europe; (3) Israel; and (4) Hong Kong, resulting in the following:
In the United States, we co-own, with Ramot at Tel-Aviv University Ltd., pending patent application no. 12/994,761, filed on November 25, 2010, entitled “Mesenchymal Stem Cells for the Treatment of CNS Diseases.”
In Europe, we co-own, with Ramot at Tel-Aviv University Ltd., pending patent application no. 09754337.5, filed on May 26, 2009, entitled “Mesenchymal Stem Cells for the Treatment of CNS Diseases.”
In Israel, we co-own, with Ramot at Tel-Aviv University Ltd., pending patent application no. 209604, filed on May 26, 2009, entitled “Mesenchymal Stem Cells for the Treatment of CNS Diseases.”
In Hong Kong, we co-own, with Ramot at Tel-Aviv University Ltd., pending patent application no. 11107062.5, filed on May 26, 2009, entitled “Mesenchymal Stem Cells for the Treatment of CNS Diseases.”
We have also taken a license to several patents and patent applications from Ramot at Tel-Aviv University Ltd., resulting in the following:
We are a licensee of United States patent application no. 11/130,197, filed May 17, 2005, entitled “Methods, nucleic acid constructs and cells for treating neurodegenerative disorders.”
We are a licensee of European patent application no. 06766101.7, filed on June 18, 2006, entitled “Isolated Cells and Populations Comprising Same for the Treatment of CNS Diseases.”
We are a licensee of European patent application no. 11000994.1, filed on June 18, 2006, entitled “Isolated Cells and Populations Comprising Same for the Treatment of CNS Diseases.”
We are a licensee of United States patent application no. 11/727,583, filed on March 27, 2007, entitled “Isolated Cells and Populations Comprising Same for the Treatment of CNS Diseases.”
Trademarks:
We own a pending United States application to register the trademark NUROWN (application no. 85154891, filed October 18, 2010) for use in connection with “compositions of cells derived from stem cells for medical purposes; stem cells for medical purposes.” The application was filed based on an intent-to-use the mark, but has not matured to registration yet.
28 |
29 |
30 |
31 |
Quarter Ended | High | Low | ||||||
June 30, 2012 | $ | 0.30 | $ | 0.21 | ||||
March 31, 2012 | $ | 0.34 | $ | 0.20 | ||||
December 31, 2011 | $ | 0.40 | $ | 0.20 | ||||
September 30, 2011 | $ | 0.56 | $ | 0.27 | ||||
June 30, 2011 | $ | 0.60 | $ | 0.25 | ||||
March 31, 2011 | $ | 0.43 | $ | 0.18 | ||||
December 31, 2010 | $ | 0.30 | $ | 0.18 | ||||
September 30, 2010 | $ | 0.26 | $ | 0.16 | ||||
June 30, 2010 | $ | 0.34 | $ | 0.19 | ||||
March 31, 2010 | $ | 0.47 | $ | 0.21 |
32 |
33 |
|
·
|
Operating a GMP compliant production process;
|
|
·
|
Demonstrating Safety Tolerability and Therapeutic effect of transplantation of Autologous cultured Bone Marrow Stromal Cells secreting Neurothrophic factors (MSC-NTF) in a Phase I/II Clinical trial in human ALS patients;
|
|
·
|
Setting up a centralized facility to provide the therapeutic products
and services for transplantation in patients in the US, as part of the clinical development program; and
|
|
·
|
Submitting an IND to the FDA.
|
34 |
Research and Development, net:
Research and development expenses, net for the year ended December 31, 2011 and 2010 were $1,689,000 and $1,045,000, respectively. In addition, our grant from The Office of the Chief Scientist increased by $48,000 to $388,000 for the year ended December 31, 2011 from $340,000 for the year ended December 31, 2010.
The increase in research and development expenses, net for the year ended December 31, 2011 is primarily due to: (i) in June 2011, the Company began clinical trials in ALS patients, in Hadassah, under which the Company paid $350,000 in 2011; (ii) development and clinical trials conducted in GMP in Hadassah in the amount of $370,000 in the year ended December 31, 2011 compared to $250,000 in the year ended December 31, 2010; and (iii) an increase of $190,000 in payroll costs due to recruitment of four additional employees to conduct the clinical trials.
General and Administrative
General and administrative expenses for the years ended December 31, 2011 and 2010 were $2,205,000 and $1,544,000, respectively. The increase in General and administrative expenses, for the year ended December 31, 2011, is mainly due to: (i) an increase of $515,000 in stock-based compensation expenses, to $1,076,000 in the year ended December 31, 2011; and (ii) an increase of $140,000 in legal and audit expenses from $230,000 in the year ended December 31, 2010 to $370,000 in the year ended December 31, 2011; this increase was partially offset by a reduction of $60,000 in public and investor relations expenses from $120,000 in the year ended December 31, 2010 to $60,000 in the year ended December 31, 2011.
Financial Expenses
Financial expense for the year ended December 31, 2011 was $151,000 compared to financial income of $189,000 for the year ended December 31, 2010.
The increase in financial expense for the year ended December 31, 2011 is primarily due to $192,000 financial expense from conversion of debt to a subcontractor to our common stock. The issuance of stock to the subcontractor was in an amount that was lower than the amount owed to the supplier. The value of the amount issued was based on the per share price on the date of the grant. The above was balanced by financial income of $41,000 due to the conversion exchange rate.
Net Loss
Net loss for the year ended December 31, 2011 was $3,918,000, as compared to a net loss of $2,419,000 for the year ended December 31, 2010. Net loss per share for the year ended December 31, 2011 was $0.03, as it was for the year ended December 31, 2010.
The increase in the net loss for the year ended December 31, 2011 is due to (i) the beginning of clinical trials, (ii) development in GMP in Hadassah facilities, and (iii) stock-based compensation expenses.
The weighted average number of shares of common stock used in computing basic and diluted net loss per share for the year ended December 31, 2011 was 120,117,724, compared to 89,094,403 for the year ended December 31, 2010.
The increase in the weighted average number of shares of common stock used in computing basic and diluted net loss per share for the year ended December 31, 2011 was due to (i) the issuance of shares in a private placement, (ii) the exercise of warrants and (iii) the issuance of shares to service providers.
Research and Development, net:
Research and development expenses, net for the three months ended March 31, 2012 and 2011 were $369,000 and $270,000, respectively. In addition, our grant from The Office of the Chief Scientist increased by $140,000 to $240,000 for the three months ended March 31, 2012 from $100,000 for the three months ended March 31, 2011.
The increase in research and development expenses for the three months ended March 31, 2012 is primarily due to: (i) in June 2011, the Company began clinical trials in ALS patients, in Hadassah, under which the Company paid $340,000 in the three months ended March 31, 2012; (ii) an increase of $65,000 in payroll costs due to recruitment of four additional employees to conduct the clinical trials.
General and Administrative:
General and administrative expenses for the three months ended March 31, 2012 and 2011 were $510,000 and $258,000, respectively.
The increase in general and administrative expenses for the three month period ended March 31, 2012 from the three month period ended March 31, 2011 is primarily due to: (i) an increase of $170,000 in compensation expenses for stock granted to directors and employees; (ii) an increase of $70,000 in legal, audit and public relations activity.
Financial Expenses:
Financial income for the three months ended March 31, 2012 was $11,000, compared to a financial expense of $177,000 for the three months ended March 31, 2011.
The financial income for the three months ended March 31, 2012 is mainly from conversion exchange rate and income on deposits in banks. The financial expense for the three months ended March 31, 2011 is primarily attributable to $192,000 financial expense from conversion of debt to a subcontractor to our common stock, balanced by financial income of $15,000 due to the conversion exchange rate.
35 |
Net Loss:
Net loss for the three months ended on March 31, 2012 was $872,000, as compared to a net loss of $705,000 for the three months ended March 31, 2011. Net loss per share for the three months ended March 31, 2012 was $0.01, as it also was for the three months ended March 31, 2011.
The weighted average number of shares of common stock used in computing basic and diluted net loss per share for the three months ended March 31, 2012 was 126,591,262, compared to 108,895,199 for the three months ended March 31, 2011.
The increase in the weighted average number of shares of common stock used in computing basic and diluted net loss per share for the three months ended March 31, 2012 was due to (i) the issuance of shares in a private placement, (ii) the exercise of options and warrants and (iii) the issuance of shares to service providers.
The Company has financed its operations since inception primarily through private sales of its common stock and warrants and the issuance of convertible promissory notes. At March 31, 2012, we had $1,775,000 in total current assets and $1,290,000 in total current liabilities.
Net cash used in operating activities was $746,000 for the three months ended March 31, 2012. Cash used for operating activities in the three months ended March 31, 2012 was primarily attributed to clinical trial costs, payroll costs, rent, outside legal and audit fee expenses and public relations expenses.
Net cash used in investing activities was $52,000 for the three months ended March 31, 2012.
Net cash provided by financing activities was $20,000 for the three months ended March 31, 2012 is primarily attributable to exercise of options to common stock.
Our material cash needs for the next 12 months include the payments due under an agreement with Hadassah to conduct clinical trials in ALS patients, under which we must pay to Hadassah an amount of (i) up to $32,225 per patient (up to $773,400 in the aggregate) and (ii) $65,000 per month for rent and operation of the GMP facilities in anticipation of Hadassah's clinical trials.
Our other material cash needs for the next 12 months will include payments of (i) employee salaries, (ii) patents, (iii) construction fees for facilities to be used in our research and development and (iv) fees to our consultants and legal advisors.
We will need to raise substantial additional capital in order to meet our anticipated expenses. If we are not able to raise substantial additional capital, we may not be able to continue to function as a going concern and we may have to cease operations. Even if we obtain funding sufficient to continue functioning as a going concern, we will be required to raise a substantial amount of capital in the future in order to reach profitability and to complete the commercialization of our products. Our ability to fund these future capital requirements will depend on many factors, including the following:
· | our ability to obtain funding from third parties, including any future collaborative partners; |
· | the scope, rate of progress and cost of our clinical trials and other research and development programs; |
· | the time and costs required to gain regulatory approvals; |
· | the terms and timing of any collaborative, licensing and other arrangements that we may establish; |
· | the costs of filing, prosecuting, defending and enforcing patents, patent applications, patent claims, trademarks and other intellectual property rights; |
· | the effect of competition and market developments; and |
· | future pre-clinical and clinical trial results. |
36 |
37 |
Name
|
Age
|
Position
|
||
Adrian
Harel
|
55
|
Chief
Executive Officer and Director of Research and Development
|
||
Chaim
Lebovits
|
43
|
President
|
||
Liat
Sossover
|
44
|
Chief
Financial Officer
|
||
Dr.
Irit Arbel
|
52
|
Director
|
||
Mordechai
Friedman
|
59
|
Director
|
||
Dr.
Abraham Israeli
|
58
|
Chairman
and Director
|
||
Alon
Pinkas
|
50
|
Director
|
||
Chen
Schor
|
39
|
Director
|
||
Dr.
Robert Shorr
|
58
|
Director
|
||
Malcolm
Taub
|
66
|
Director
|
38 |
39 |
40 |
|
·
|
been convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other minor offences);
|
|
·
|
had any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or business association of which he was a general partner or executive officer, either at the time of the bankruptcy filing or within two years prior to that time;
|
|
·
|
been subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be associated with persons engaged in any such activity;
|
|
·
|
been found by a court of competent jurisdiction in a civil action or by the Securities and Exchange Commission or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;
|
|
·
|
been the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or
|
|
·
|
been the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act, any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.
|
41 |
42 |
43 |
Name and Principal Position
|
Year
|
Salary
($)
|
Option
Awards
($) (1)
(2)
|
All Other
Compensation
($)(3)
|
Total ($)
|
||||||||
Adrian Harel(4) | 2011
|
117,000 | 203,026 | 65,000 | 385,026 | ||||||||
Chief Executive Officer and Director of Research and Development | |||||||||||||
Liat Sossover(5) | 2011
|
98,000 | - | 46,000 | 144,000 | ||||||||
Chief Financial Officer | 2010 | 47,000 | 67,584 | 12,000 | 126,584 | ||||||||
Abraham
Efrati(6)
|
2011
|
264,000
|
30,481
|
25,000
|
319,481
|
||||||||
Former
Chief Executive Officer and Director
|
2010 | 167,000 | - | 13,000 | 180,000 |
Adrian Harel. Pursuant to his employment agreement dated January 23, 2011, Dr. Harel is entitled to a monthly salary of 39,000 NIS (approximately $10,000) (including benefits for monthly totals of approximately 60,300 NIS (approximately $15,900)). Dr. Harel also receives other benefits that are generally made available to our employees. Dr. Harel is provided with a company car and a gross-up payment for any taxes relating thereto.
Liat Sossover. Pursuant to her employment agreement dated June 23, 2011, Ms. Sossover is entitled to a salary of 32,000 NIS (approximately $8,290) per month. Ms. Sossover is also entitled to contributions on her behalf by the Company into a manager’s insurance fund, disability insurance and an education fund.
44 |
On June 27, 2011, Dr. Harel was granted, pursuant to our Global Plan, an option to purchase 450,000 shares of our common stock at a price per share of $0.20 each. One-third of such option vested and became exercisable on January 23, 2012 and the remainder of the shares subject to the option will vest and become exercisable over the following 24 months in equal installments. The option shall expire on the tenth anniversary of the grant date.
On August 10, 2011, Dr. Harel was granted, pursuant to our Global Plan, an option to purchase 70,000 shares of our common stock at a price per share of $0.20 each. Such option became fully vested and exercisable upon our receipt of clean room approval in connection with the Hadassah trial. The option shall expire on the tenth anniversary of the grant date.
On June 23, 2010, Ms. Sossover was granted, pursuant to our Global Plan, an option to purchase 400,000 shares of our common stock at a price per share of $0.18 each. One-third of such option vested and became exercisable on June 23, 2011 and the remainder of the shares subject to the option vest and become exercisable over the following 24 months in equal installments. The option shall expire on the tenth anniversary of the grant date.
Option Awards
|
||||||||||||||
Name
|
Number of
Securities
Underlying
Unexercised
Options
(#)
Exercisable
|
Number of
Securities
Underlying
Unexercised
Options
(#)
Unexercisable
|
Option
Exercise
Price
($)
|
Option Expiration Date
|
||||||||||
Adrian Harel | — | 450,000 | (1) | 0.20 | 6/26/2021 | |||||||||
70,000 | — | 0.20 | 8/9/2021 | |||||||||||
Liat Sossover | 200,000 | 200,000 | (2) | 0.18 | 6/22/2020 | |||||||||
Abraham
Efrati(3)
|
699,273 | — | 0.15 | 4/30/2012
|
||||||||||
483,333 | — | 0.067 | 4/30/2012
|
45 |
On May 6, 2012, the Board approved another amendment and restatement of the Plans to increase the number of shares available for issuance under the Plans by an additional 9,000,000 shares, subject to the approval of the Company’s stockholders. Our stockholders approved the amendment and restatement of the Plans on June 12, 2012.
Name
|
Stock
Awards
($) (1)
|
Option
Awards
($) (1)
|
Total
($)
|
|||||||||
Dr.
Irit Arbel
|
—
|
130,365
|
(2)
|
130,365
|
||||||||
Mr.
Mordechai Friedman
|
—
|
75,355
|
(3) | 75,355
|
||||||||
Dr.
Abraham Israeli
|
—
|
48,326
|
(4)
|
48,326
|
||||||||
Mr.
Alon Pinkas
|
—
|
81,384
|
(5) | 81,384
|
||||||||
Mr.
Chen Schor
|
443,220
|
(6) | —
|
443,220
|
||||||||
Dr.
Robert Shorr
|
114,400
|
(7) | —
|
114,400
|
||||||||
Mr.
Malcolm Taub
|
114,400
|
(8) | —
|
114,400
|
(7) At December 31, 2011, Dr. Shorr had 230,000 shares of restricted common stock.
(8) At December 31, 2011, Mr. Taub had vested options to purchase 100,000 shares of common stock and 238,333 shares of restricted common stock.
46 |
47 |
48 |
Shares Beneficially Owned | ||||||||
Name of Beneficial Owner | Number of Shares | Percentage of
Class | ||||||
Directors and Named Executive Officers | ||||||||
Adrian Harel | 295,000 | (1) | * | |||||
Liat Sossover | 277,777 | (1) | * | |||||
Abraham Efrati | 483,333 | (2) | * | |||||
Irit Arbel | 3,255,000 | (3) | 2.5 | % | ||||
Mordechai Friedman | 166,667 | (1) | * | |||||
Abraham Israeli | 588,888 | (1) | * | |||||
Alon Pinkas | 180,000 | (1) | * | |||||
Chen Schor | 923,374 | (4) | * | |||||
Robert Shorr | 230,000 | (5) | * | |||||
Malcolm Taub | 538,333 | (6) | * | |||||
All current directors and officers as a group (10 persons) | 66,011,963 | (7) | 41.0 | % | ||||
5% Shareholders | ||||||||
ACCBT Corp. Morgan & Morgan Building Pasea Estate, Road Town Tortola British Virgin Islands | 59,556,924 (8) | 37.5 | % |
*
|
Less than 1%.
|
(1)
|
Consists of shares of common stock issuable upon the exercise of
Presently Exercisable Options.
|
49 |
(2)
|
Mr. Efrati resigned as Chief Executive Officer effective February 28, 2011.
|
(3)
|
Includes 955,000 shares of common stock issuable upon the
exercise of Presently Exercisable Options. Dr. Arbel’s address is 6 Hadishon Street, Jerusalem, Israel.
|
(4)
|
Consists of shares of restricted common stock. If the Company successfully raises $10,000,000 of proceeds through the issuance of equity securities in a private or public offering after August 22, 2011, or enters into a deal with a strategic partner that brings in at least $10,000,000 of gross proceeds after August 22, 2011, then 307,791 of the shares will vest upon such event, 307,791 of the shares will vest on August 22, 2012 and the remaining 307,792 shares will vest on August 22, 2013. If such capital is not raised by the Company prior to August 22, 2012, then 307,791 of the shares will vest on August 22, 2012, 307,791 of the shares will vest on August 22, 2013 and the remaining 307,792 shares will vest on August 22, 2014.
|
(5)
|
Consists of shares of restricted common stock. The shares
of restricted stock vest in 12 consecutive, equal monthly installments commencing on July 27, 2011 until fully vested on the first
anniversary of the date of grant, provided that Mr. Shorr remains a director of the Company on each vesting date.
|
(6)
|
Consists of 100,000 shares of common stock issuable upon the exercise of Presently Exercisable Options and 238,333 shares of restricted common stock. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on July 27, 2011 until fully vested on the first anniversary of the date of grant, provided that Mr. Taub remains a director of the Company on each vesting date.
|
(7)
|
Includes (i) 29,006,924 shares of common stock owned by ACCBT
Corp. (Chaim Lebovits, our President, may be deemed to be the beneficial owner of these shares), (ii) 30,250,000 shares of
common stock issuable to ACCBT Corp. upon the exercise of Presently Exercisable Warrants, (iii) 300,000 shares of common stock
owned by ACC International Holdings Ltd. (Chaim Lebovits, our President, may be deemed to be the beneficial owner of these
shares) and (iv) 2,563,332 shares of common stock issuable upon the exercise of Presently Exercisable Options.
|
(8)
|
Consists of (i) 29,006,924 shares of common stock owned by ACCBT Corp., (ii) 30,250,000 shares of common stock issuable to ACCBT Corp. upon the exercise of Presently Exercisable Warrants and (iii) 300,000 shares of common stock owned by ACC International Holdings Ltd. ACC International Holdings Ltd. and Chaim Lebovits, our President, may each be deemed the beneficial owners of these shares.
|
50 |
|
·
|
An up-front license fee payment of $100,000;
|
|
·
|
An amount equal to 5% of all net sales of products; and
|
|
·
|
An amount equal to 30% of all sublicense receipts.
|
51 |
Pursuant to the terms of the Subscription Agreement, as amended, and a related registration rights agreement, ACCBT has the following rights for so long as ACCBT or its affiliates hold at least 5% of our issued and outstanding share capital:
· | Board Appointment Right: ACCBT has the right to appoint 50.1% (any fractions to be rounded up to the nearest whole number) of the members of our Board of Directors and any of our committees and the Board of Directors of our subsidiary. |
· | Preemptive Right: ACCBT has the right to receive thirty day notice of, and to purchase a pro rata portion (or greater under certain circumstances where offered shares are not purchased by other subscribers) of, securities issued by us, including options and rights to purchase shares. This preemptive right does not include issuances under our equity incentive plans. |
· | Consent Right: ACCBT’s written consent is required for certain corporate actions, including issuance of shares (other than existing warrants and issuances under our incentive plans), amendment of our charter or bylaws, repurchase of shares, declaration or payment of dividends or distributions, related party transactions, non-ordinary course transactions involving $25,000 or more, liquidation or dissolution, the creation, acquisition or disposition of a subsidiary or entry into a joint venture or strategic alliance, a material change to our business, merger, change of control, sale of the company, any acquisition, and any payment of cash compensation over $60,000 per year. |
In addition ACCBT is entitled to demand and piggyback registration rights, whereby ACCBT may request, upon ten days written notice, that we file, or include within a registration statement to be filed, with the Securities and Exchange Commission for ACCBT’s resale of the Subscription Shares, as adjusted, and the shares of our common stock issuable upon exercise of the Warrants.
52 |
On May 10, 2012, we entered into a Warrant Amendment Agreement with ACCBT pursuant to which we agreed, upon the effectiveness of a six month lock-up agreement entered into by ACCBT in connection with this proposed offering, the then current expiration date of each Warrant shall be automatically extended by an additional 18 months.
53 |
|
·
|
an option for the purchase of 166,666 shares of common stock at an exercise price equal to $0.00005 per share to Dr. Israeli; and
|
·
|
warrants for the purchase of 33,334 shares of common stock at an
exercise price equal to $0.00005 per share to Hadasit,
|
54 |
55 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2011
U.S. DOLLARS IN THOUSANDS
(Except share data)
INDEX
Page | |
Reports of Independent Registered Public Accounting Firms | F-2 - F-3 |
Consolidated Financial Statements | |
Consolidated Balance Sheets | F-4 |
Consolidated Statements of Operations | F-5 |
Statements of Changes in Stockholders' Equity (Deficiency) | F-6 |
Consolidated Statements of Cash Flows | F-15 |
Notes to Consolidated Financial Statements | F-16 - F-47 |
Unaudited Consolidated Financial Statements | |
Consolidated Balance Sheets as of March 31, 2012 and December 31, 2011 | F-48 |
Consolidated Statements of Operations for the three months ended March 31, 2012 and 2011 | F-49 |
Statements of Changes in Stockholders’ Equity (Deficiency) | F-50 |
Consolidated Statements of Cash Flows for the three months ended March 31, 2012 and 2011 | F-59 |
Notes to Consolidated Financial Statements (Unaudited) | F-60 - F-78 |
F-1 |
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders of
BRAINSTORM CELL THERAPEUTICS Inc. (A Development Stage Company)
We have audited the accompanying consolidated balance sheet of BRAINSTORM CELL THERAPEUTICS Inc. and subsidiary (a development stage company) (the “Company”) as of December 31, 2011 and 2010, and the related consolidated statement of income, stockholders' deficiency, and cash flows for each of the two years in the period ended December 31, 2011 and for the period from April 1, 2004 to December 31, 2011. These financial statements are the responsibility of the Company's Board of Directors and management. Our responsibility is to express an opinion on the financial statements based on our audits.
The financial statements for the period from April 1, 2004 through December 31, 2007, were audited by other auditors. The consolidated financial statements for the period from April 1, 2004 through December 31, 2007 included a net loss of $32,325,000. Our opinion on the consolidated statements of operations, changes in stockholders' deficiency and cash flows for the period from April 1, 2004 through December 31, 2011, insofar as it relates to amounts for prior periods through December 31, 2007, is based solely on the report of other auditors. The other auditors report dated April 13, 2008 expressed an unqualified opinion, and included an explanatory paragraph concerning an uncertainty about the Company's ability to continue as a going concern, and regarding the status of the Company research and development license agreement with Ramot.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, based on our audits and the report of other auditor, such consolidated financial statements present fairly, in all material respects, the financial position of BRAINSTORM CELL THERAPEUTICS Inc. and subsidiary as of December 31, 2011 and 2010, and the results of their operations and their cash flows for each of the two years in the period ended December 31, 2011 and for the period from April 1, 2004 to December 31, 2011, in conformity with accounting principles generally accepted in the United States of America.
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company is a development stage enterprise engaged in development innovative stem cell therapeutic products based on technologies enabling the in-vitro differentiation of bone marrow stem cells into neural-like cells, based on the acquired technology and research to be conducted and funded by the Company as discussed in Note 1 to the financial statements. The Company's working capital deficiency and operating losses since inception through December 31, 2011 raise substantial doubts about its ability to continue as a going concern. Management's plans concerning these matters are also described in Note 1 to the financial statements. The financial statements do not include any adjustments that might result from the outcome of' these uncertainties.
/s/ Brightman Almagor Zohar & Co.
Brightman Almagor Zohar & Co.
Certified Public Accountants
A Member Firm of Deloitte Touche Tohmatsu
Tel Aviv, Israel
March 13, 2012
Audit.Tax.Consulting.Financial Advisory. | Member of Deloitte Touche Tohmatsu |
F-2 |
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and Board of Directors of
BRAINSTORM CELL THERAPEUTICS INC.
(A development stage company)
We have audited the accompanying consolidated balance sheet of Brainstorm Cell Therapeutics Inc. (a development stage company) ("the Company") and its subsidiary as of December 31, 2007, and the related consolidated statements of operations, statements of changes in stockholders' equity (deficiency) and the consolidated statements of cash flows for the year ended December 31, 2007, for the nine months ended December 31, 2006 and 2005 and for the period from March 31, 2004 through December 31, 2007. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company's internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits and the report of the other auditors provide a reasonable basis for our opinion.
In our opinion, based on our audits, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of the Company and its subsidiary as of December 31, 2007, and the consolidated results of their operations and cash flows for the year ended December 31, 2007, for the nine months ended December 31, 2006 and 2005 and for the period from March 31, 2004 through December 31, 2007, in conformity with U.S generally accepted accounting principles.
As discussed in Note 2 to the consolidated financial statements, in 2007, the Company adopted Financial Accounting Standard Board Statement No. 123(R), "Share-Based Payment".
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 1h, the Company has incurred operating losses and has a negative cash flow from operating activities and has a working capital deficiency. As for the Company research and development license agreement with Ramot, see Note 3. These conditions raise substantial doubt about the Company's ability to continue to operate as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.
/s/ Kost Forer Gabbay & Kasierer | |
Tel-Aviv, Israel | KOST FORER GABBAY & KASIERER |
April 13, 2008 | A Member of Ernst & Young Global |
F-3 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands
(Except share data)
December 31, | ||||||||
2011 | 2010 | |||||||
U.S. $ in thousands | ||||||||
ASSETS | ||||||||
Current Assets: | ||||||||
Cash and cash equivalents | 1,923 | 93 | ||||||
Account receivable (Note 5) | 312 | 427 | ||||||
Prepaid expenses | 69 | 59 | ||||||
Total current assets | 2,304 | 579 | ||||||
Long-Term Investments: | ||||||||
Prepaid expenses | 17 | 1 | ||||||
Severance payment fund | 109 | 90 | ||||||
Total long-term investments | 126 | 91 | ||||||
Property and Equipment, Net (Note 6) | 314 | 419 | ||||||
Total assets | 2,744 | 1,089 | ||||||
LIABILITIES AND STOCKHOLDERS' DEFICIENCY | ||||||||
Current Liabilities: | ||||||||
Trade payables | 244 | 307 | ||||||
Accrued expenses | 750 | 448 | ||||||
Other accounts payable (Note 7) | 141 | 531 | ||||||
Short-term convertible note (Note 8) | - | 137 | ||||||
Total current liabilities | 1,135 | 1,423 | ||||||
Accrued Severance Pay | 121 | 125 | ||||||
Total liabilities | 1,256 | 1,548 | ||||||
Stockholders' Equity (deficiency): | ||||||||
Stock capital: (Note 11) | 6 | 5 | ||||||
Common stock $0.00005 par value - Authorized: 800,000,000 shares at December 31, 2011 and December 31, 2010; Issued and outstanding: 126,444,309 and 95,832,978 shares | ||||||||
Additional paid-in-capital | 45,560 | 39,696 | ||||||
Deficit accumulated during the development stage | (44,078 | ) | (40,160 | ) | ||||
Total stockholders' deficiency | 1,488 | (459 | ) | |||||
Total liabilities and stockholders' Equity (deficiency) | 2,744 | 1,089 |
The accompanying notes are an integral part of the consolidated financial statements.
F-4 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
CONSOLIDATED STATEMENTS OF OPERATIONS
U.S. dollars in thousands
(Except share data)
Year ended December 31, | Period from September 22, 2000 (inception date) through December 31, | |||||||||||
2011 | 2010 | 2011(*) | ||||||||||
U.S. $ in thousands | ||||||||||||
Operating costs and expenses: | ||||||||||||
Research and development, net (Note 12) | 1,689 | 1,045 | 24,419 | |||||||||
General and administrative | 2,205 | 1,544 | 17,003 | |||||||||
Total operating costs and expenses | 3,894 | 2,589 | 41,422 | |||||||||
Financial expense (income), net | 151 | (189 | ) | 2,547 | ||||||||
Other income | (132 | ) | - | (132 | ) | |||||||
Operating loss | 3,913 | 2,400 | 43,837 | |||||||||
Taxes on income (Note 13) | 5 | 19 | 77 | |||||||||
Loss from continuing operations | 3,918 | 2,419 | 43,914 | |||||||||
Net loss from discontinued operations | - | - | 164 | |||||||||
Net loss | 3,918 | 2,419 | 44,078 | |||||||||
Basic and diluted net loss per share from continuing operations | 0.03 | 0.03 | ||||||||||
Weighted average number of shares outstanding used in computing basic and diluted net loss per share | 120,117,724 | 89,094,403 |
(*) Out of which, $163, relating to the period from inception to March 31, 2004, is unaudited.
The accompanying notes are an integral part of the consolidated financial statements
F-5 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)
U.S. dollars in thousands
(Except share data)
Deficit | ||||||||||||||||||||||||
accumulated | Total | |||||||||||||||||||||||
Common stock | Additional paid-in | Deferred Stock - based | during the development | stockholders' equity | ||||||||||||||||||||
Number | Amount | capital | compensation | stage | (deficiency) | |||||||||||||||||||
Balance as of September 22, 2000 (date of inception) (unaudited) | - | - | - | - | - | - | ||||||||||||||||||
Stock issued on September 22, 2000 for cash at $0.00188 per share | 8,500,000 | 1 | 16 | - | - | 17 | ||||||||||||||||||
Stock issued on June 30, 2001 for cash at $0.0375 per share | 1,600,000 | * | 60 | - | - | 60 | ||||||||||||||||||
Contribution of capital | - | - | 8 | - | - | 8 | ||||||||||||||||||
Net loss | - | - | - | - | (17 | ) | (17 | ) | ||||||||||||||||
Balance as of March 31, 2001 (unaudited) | 10,100,000 | 1 | 84 | - | (17 | ) | 68 | |||||||||||||||||
Contribution of capital | - | - | 11 | - | - | 11 | ||||||||||||||||||
Net loss | - | - | - | - | (26 | ) | (26 | ) | ||||||||||||||||
Balance as of March 31, 2002 (unaudited) | 10,100,000 | 1 | 95 | - | (43 | ) | 53 | |||||||||||||||||
Contribution of capital | - | - | 15 | - | - | 15 | ||||||||||||||||||
Net loss | - | - | - | - | (47 | ) | (47 | ) | ||||||||||||||||
Balance as of March 31, 2003 (unaudited) | 10,100,000 | 1 | 110 | - | (90 | ) | 21 | |||||||||||||||||
2-for-1 stock split | 10,100,000 | * | - | - | - | - | ||||||||||||||||||
Stock issued on August 31, 2003 to purchase mineral option at $0.065 per share | 100,000 | * | 6 | - | - | 6 | ||||||||||||||||||
Cancellation of shares granted to Company's President | (10,062,000 | ) | * | * | - | - | - | |||||||||||||||||
Contribution of capital | - | * | 15 | - | - | 15 | ||||||||||||||||||
Net loss | - | - | - | - | (73 | ) | (73 | ) | ||||||||||||||||
Balance as of March 31, 2004 (unaudited) | 10,238,000 | 1 | 131 | - | (163 | ) | (31 | ) |
* Represents an amount less than $1.
The accompanying notes are an integral part of the consolidated financial statements
F-6 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)
U.S. dollars in thousands
(Except share data)
Deficit | ||||||||||||||||||||||||
accumulated | Total | |||||||||||||||||||||||
Common stock | Additional paid-in | Deferred Stock - based | during the development | stockholders' equity | ||||||||||||||||||||
Number | Amount | capital | compensation | stage | (deficiency) | |||||||||||||||||||
Balance as of March 31, 2004 | 10,238,000 | 1 | 131 | - | (163 | ) | (31 | ) | ||||||||||||||||
Stock issued on June 24, 2004 for private placement at $0.01 per share, net of $25,000 issuance expenses | 8,510,000 | * | 60 | - | - | 60 | ||||||||||||||||||
Contribution capital | - | - | 7 | - | - | 7 | ||||||||||||||||||
Stock issued in 2004 for private placement at $0.75 per unit | 1,894,808 | * | 1,418 | - | - | 1,418 | ||||||||||||||||||
Cancellation of shares granted to service providers | (1,800,000 | ) | * | - | - | - | ||||||||||||||||||
Deferred stock-based compensation related to options granted to employees | - | - | 5,979 | (5,979 | ) | - | - | |||||||||||||||||
Amortization of deferred stock-based compensation related to shares and options granted to employees | - | - | - | 584 | - | 584 | ||||||||||||||||||
Compensation related to shares and options granted to service providers | 2,025,000 | * | 17,506 | - | - | 17,506 | ||||||||||||||||||
Net loss | - | - | - | - | (18,840 | ) | (18,840 | ) | ||||||||||||||||
Balance as of March 31, 2005 | 20,867,808 | 1 | 25,101 | (5,395 | ) | (19,003 | ) | 704 |
* Represents an amount less than $1.
The accompanying notes are an integral part of the consolidated financial statements
F-7 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)
U.S. dollars in thousands
(Except share data)
Deficit | ||||||||||||||||||||||||
accumulated | Total | |||||||||||||||||||||||
Common stock | Additional paid-in | Deferred Stock - based | during the development | stockholders' equity | ||||||||||||||||||||
Number | Amount | capital | compensation | stage | (deficiency) | |||||||||||||||||||
Balance as of March 31, 2005 | 20,867,808 | 1 | 25,101 | (5,395 | ) | (19,003 | ) | 704 | ||||||||||||||||
Stock issued on May 12, 2005 for private placement at $0.80 per share | 186,875 | - | * | 149 | - | - | 149 | |||||||||||||||||
Stock issued on July 27, 2005 for private placement at $0.60 per share | 165,000 | - | * | 99 | - | - | 99 | |||||||||||||||||
Stock issued on September 30, 2005 for private placement at $0.80 per share | 312,500 | - | * | 225 | - | - | 225 | |||||||||||||||||
Stock issued on December 7, 2005 for private placement at $0.80 per share | 187,500 | - | * | 135 | - | - | 135 | |||||||||||||||||
Forfeiture of options granted to employees | - | - | (3,363 | ) | 3,363 | - | - | |||||||||||||||||
Deferred stock-based compensation related to shares and options granted to directors and employees | 200,000 | - | * | 486 | (486 | ) | - | - | ||||||||||||||||
Amortization of deferred stock-based compensation related to options and shares granted to employees and directors | - | - | 51 | 1,123 | - | 1,174 | ||||||||||||||||||
Stock-based compensation related to options and shares granted to service providers | 934,904 | - | * | 662 | - | - | 662 | |||||||||||||||||
Reclassification due to application of ASC 815-40-25 (formerly EITF 00-19) | - | - | (7,906 | ) | (7,906 | ) | ||||||||||||||||||
Beneficial conversion feature related to a convertible bridge loan | - | - | 164 | - | - | 164 | ||||||||||||||||||
Net loss | - | - | - | - | (3,317 | ) | (3,317 | ) | ||||||||||||||||
Balance as of March 31, 2006 | 22,854,587 | 1 | 15,803 | (1,395 | ) | (22,320 | ) | (7,911 | ) |
* Represents an amount less than $1.
The accompanying notes are an integral part of the consolidated financial statements
F-8 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)
U.S. dollars in thousands
(Except share data)
Deficit | ||||||||||||||||||||||||
accumulated | Total | |||||||||||||||||||||||
Common stock | Additional paid-in | Deferred Stock - based | during the development | stockholders' equity | ||||||||||||||||||||
Number | Amount | capital | compensation | stage | (deficiency) | |||||||||||||||||||
Balance as of March 31, 2006 | 22,854,587 | 1 | 15,803 | (1,395 | ) | (22,320 | ) | (7,911 | ) | |||||||||||||||
Elimination of deferred stock compensation due to implementation of ASC 718-10 (formerly SFAS 123(R)) | - | - | (1,395 | ) | 1,395 | - | - | |||||||||||||||||
Stock-based compensation related to shares and options granted to directors and employees | 200,000 | - | * | 1,168 | - | - | 1,168 | |||||||||||||||||
Reclassification due to application of ASC 815-40-25 (formerly EITF 00-19) | - | - | 7,191 | - | - | 7,191 | ||||||||||||||||||
Stock-based compensation related to options and shares granted to service providers | 1,147,225 | - | 453 | - | - | 453 | ||||||||||||||||||
Warrants issued to convertible note holder | - | - | 11 | - | - | 11 | ||||||||||||||||||
Warrants issued to loan holder | - | - | 110 | - | - | 110 | ||||||||||||||||||
Beneficial conversion feature related to convertible bridge loans | - | - | 1,086 | - | - | 1,086 | ||||||||||||||||||
Net loss | - | - | - | - | (3,924 | ) | (3,924 | ) | ||||||||||||||||
Balance as of December 31, 2006 | 24,201,812 | 1 | 24,427 | - | (26,244 | ) | (1,816 | ) |
* Represents an amount less than $1.
The accompanying notes are an integral part of the consolidated financial statements
F-9 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)
U.S. dollars in thousands
(Except share data)
Deficit | ||||||||||||||||||||||||
accumulated | Total | |||||||||||||||||||||||
Common stock | Additional paid-in | Deferred Stock - based | during the development | stockholders' equity | ||||||||||||||||||||
Number | Amount | capital | compensation | stage | (deficiency) | |||||||||||||||||||
Balance as of December 31, 2006 | 24,201,812 | 1 | 24,427 | - | (26,244 | ) | (1,816 | ) | ||||||||||||||||
Stock-based compensation related to options and shares granted to service providers | 544,095 | 1,446 | - | - | 1,446 | |||||||||||||||||||
Warrants issued to convertible note holder | - | - | 109 | - | - | 109 | ||||||||||||||||||
Stock-based compensation related to shares and options granted to directors and employees | 200,000 | * | 1,232 | - | - | 1,232 | ||||||||||||||||||
Beneficial conversion feature related to convertible loans | - | - | 407 | - | - | 407 | ||||||||||||||||||
Conversion of convertible loans | 725,881 | * | 224 | - | - | 224 | ||||||||||||||||||
Exercise of warrants | 3,832,621 | * | 214 | - | - | 214 | ||||||||||||||||||
Stock issued for private placement at $0.1818 per unit, net of finder's fee | 11,500,000 | 1 | 1,999 | - | - | 2,000 | ||||||||||||||||||
Net loss | - | - | - | - | (6,244 | ) | (6,244 | ) | ||||||||||||||||
Balance as of December 31, 2007 | 41,004,409 | 2 | 30,058 | - | (32,488 | ) | (2,428 | ) |
* Represents an amount less than $1.
The accompanying notes are an integral part of the consolidated financial statements
F-10 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)
U.S. dollars in thousands
(Except share data)
Deficit | ||||||||||||||||||||||||
accumulated | Total | |||||||||||||||||||||||
Common stock | Additional paid-in | Deferred Stock - based | during the development | stockholders' equity | ||||||||||||||||||||
Number | Amount | capital | compensation | stage | (deficiency) | |||||||||||||||||||
Balance as of December 31, 2007 | 41,004,409 | 2 | 30,058 | - | (32,488 | ) | (2,428 | ) | ||||||||||||||||
Stock-based compensation related to options and stock granted to service providers | 90,000 | - | 33 | - | - | 33 | ||||||||||||||||||
Stock-based compensation related to stock and options granted to directors and employees | - | - | 731 | - | - | 731 | ||||||||||||||||||
Conversion of convertible loans | 3,644,610 | * | 1,276 | - | - | 1,276 | ||||||||||||||||||
Exercise of warrants | 1,860,000 | * | - | - | - | - | ||||||||||||||||||
Exercise of options | 17,399 | * | 3 | - | - | 3 | ||||||||||||||||||
Stock issued for private placement at $0.1818 per unit, net of finder's fee | 8,625,000 | 1 | 1,499 | - | - | 1,500 | ||||||||||||||||||
Subscription of shares for private placement at $0.1818 per unit | - | - | 281 | - | - | 281 | ||||||||||||||||||
Net loss | - | - | - | - | (3,472 | ) | (3,472 | ) | ||||||||||||||||
Balance as of December 31, 2008 | 55,241,418 | 3 | 33,881 | - | (35,960 | ) | (2,076 | ) |
* Represents an amount less than $1.
The accompanying notes are an integral part of the consolidated financial statements
F-11 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)
U.S. dollars in thousands
(Except share data)
Deficit | ||||||||||||||||||||||||
accumulated | Total | |||||||||||||||||||||||
Common stock | Additional paid-in | Deferred Stock - based | during the development | stockholders' equity | ||||||||||||||||||||
Number | Amount | capital | compensation | stage | (deficiency) | |||||||||||||||||||
Balance as of December 31, 2008 | 55,241,418 | 3 | 33,881 | - | (35,960 | ) | (2,076 | ) | ||||||||||||||||
Stock-based compensation related to options and stock granted to service providers | 5,284,284 | * | 775 | - | 775 | |||||||||||||||||||
Stock-based compensation related to stock and options granted to directors and employees | - | - | 409 | - | 409 | |||||||||||||||||||
Conversion of convertible loans | 2,500,000 | * | 200 | - | 200 | |||||||||||||||||||
Exercise of warrants | 3,366,783 | * | - | - | - | |||||||||||||||||||
Stock issued for amendment of private placement | 9,916,667 | 1 | - | - | 1 | |||||||||||||||||||
Subscription of shares | - | - | 729 | - | 729 | |||||||||||||||||||
Net loss | - | - | - | - | (1,781 | ) | (1,781 | ) | ||||||||||||||||
Balance as of December 31, 2009 | 76,309,152 | 4 | 35,994 | - | (37,741 | ) | (1,743 | ) |
* Represents an amount less than $1.
The accompanying notes are an integral part of the consolidated financial statements
F-12 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)
U.S. dollars in thousands
(Except share data)
Deficit | ||||||||||||||||||||||||
accumulated | Total | |||||||||||||||||||||||
Common stock | Additional paid-in | Deferred Stock - based | during the development | stockholders' equity | ||||||||||||||||||||
Number | Amount | capital | compensation | stage | (deficiency) | |||||||||||||||||||
Balance as of December 31, 2009 | 76,309,152 | 4 | 35,994 | (37,741 | ) | (1,743 | ) | |||||||||||||||||
Stock-based compensation related to options and stock granted to service providers | 443,333 | - | * | 96 | - | - | 96 | |||||||||||||||||
Stock-based compensation related to stock and options granted to directors and employees | 466,667 | - | * | 388 | - | - | 388 | |||||||||||||||||
Stock issued for amendment of private placement | 7,250,000 | 1 | 1,750 | - | - | 1,751 | ||||||||||||||||||
Conversion of convertible note | 402,385 | - | * | 135 | - | - | 135 | |||||||||||||||||
Conversion of convertible loans | 1,016,109 | - | * | 189 | - | - | 189 | |||||||||||||||||
Issuance of shares | 2,475,000 | 400 | 400 | |||||||||||||||||||||
Exercise of options | 1,540,885 | - | * | 77 | - | - | 77 | |||||||||||||||||
Exercise of warrants | 3,929,446 | - | * | 11 | - | - | 11 | |||||||||||||||||
Subscription of shares for private placement at $0.12 per unit | 455 | - | - | 455 | ||||||||||||||||||||
Conversion of trade payable to stock | 201 | 201 | ||||||||||||||||||||||
Issuance of shares on account of previously subscribed shares (See also Note 11B.1.f) | 2,000,001 | - | * | - | - | - | - | |||||||||||||||||
Net loss | (2,419 | ) | (2,419 | ) | ||||||||||||||||||||
Balance as of December 31, 2010 | 95,832,978 | 5 | 39,696 | - | (40,160 | ) | (459 | ) |
* Represents an amount less than $1.
The accompanying notes are an integral part of the consolidated financial statements.
F-13 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)
U.S. dollars in thousands
(Except share data)
Deficit | ||||||||||||||||||||||||
accumulated | Total | |||||||||||||||||||||||
Common stock | Additional
paid-in | Deferred
Stock - based | during the
development | stockholders'
equity | ||||||||||||||||||||
Number | Amount | capital | compensation | stage | (deficiency) | |||||||||||||||||||
Balance as of December 31, 2010 | 95,832,978 | $ | 5 | $ | 39,696 | $ | - | $ | (40,160 | ) | $ | (459 | ) | |||||||||||
Stock-based compensation related to options and stock granted to service providers | 474,203 | - | 449 | - | - | 449 | ||||||||||||||||||
Stock-based compensation related to stock and options granted to directors and employees | 2,025,040 | - | 1,135 | - | - | 1,135 | ||||||||||||||||||
Conversion of convertible note | 755,594 | - | 140 | - | - | 140 | ||||||||||||||||||
Exercise of options | 1,648,728 | - | 243 | - | - | 243 | ||||||||||||||||||
Exercise of warrants | 1,046,834 | - | 272 | - | - | 272 | ||||||||||||||||||
Issuance of shares for private placement | 14,160,933 | 1 | 3,601 | - | - | 3,602 | ||||||||||||||||||
Issuance of shares on account of previously subscribed shares (See also Note 11B.1.f) | 10,499,999 | - | 24 | - | - | 24 | ||||||||||||||||||
Net loss | - | - | - | - | (3,918 | ) | (3,918 | ) | ||||||||||||||||
Balance as of December 31, 2011 | 126,444,309 | $ | 6 | $ | 45,560 | $ | - | $ | (44,078 | ) | $ | 1,488 |
* Represents an amount less than $1.
The accompanying notes are an integral part of the consolidated financial statements.
F-14 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
CONSOLIDATED STATEMENTS OF CASH FLOWS
U.S. dollars in thousands
(Except share data)
Year ended December 31, | Period from September 22, 2000 (inception date) through December 31, | |||||||||||
2 0 1 1 | 2 0 1 0 | 2 0 1 1(*) | ||||||||||
U.S. $ in thousands | ||||||||||||
Cash flows from operating activities: | ||||||||||||
Net loss | $ | (3,918 | ) | $ | (2,419 | ) | $ | (44,078 | ) | |||
Less - loss for the period from discontinued operations | - | - | 164 | |||||||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||||||
Depreciation and amortization of deferred charges | 153 | 162 | 1,001 | |||||||||
Severance pay, net | (23 | ) | 11 | 12 | ||||||||
Accrued interest on loans | 3 | - | 451 | |||||||||
Amortization of discount on short-term loans | - | - | 1,864 | |||||||||
Change in fair value of options and warrants | - | - | (795 | ) | ||||||||
Expenses related to shares and options granted to service providers | 449 | 96 | 21,486 | |||||||||
Stock-based compensation related to options granted to employees | 1,135 | 388 | 6,821 | |||||||||
Decrease (increase) in accounts receivable and prepaid expenses | 105 | (400 | ) | (381 | ) | |||||||
Increase (decrease) in trade payables and convertible note | (63 | ) | 45 | 717 | ||||||||
Increase (decrease) in other accounts payable and accrued expenses | (64 | ) | 48 | 1,397 | ||||||||
Erosion of restricted cash | - | - | (6 | ) | ||||||||
Net cash used in continuing operating activities | (2,223 | ) | (2,069 | ) | (11,347 | ) | ||||||
Net cash used in discontinued operating activities | - | - | (23 | ) | ||||||||
Total net cash used in operating activities | (2,223 | ) | (2,069 | ) | (11,370 | ) | ||||||
Cash flows from investing activities: | ||||||||||||
Purchase of property and equipment | (48 | ) | (5) | (1,133 | ) | |||||||
Restricted cash | - | - | 6 | |||||||||
Investment in lease deposit | (16 | ) | 6 | (17 | ) | |||||||
Net cash used in continuing investing activities | (64 | ) | 1 | (1,144 | ) | |||||||
Net cash used in discontinued investing activities | - | - | (16 | ) | ||||||||
Total net cash provided by (used in) investing activities | (64 | ) | 1 | (1,160 | ) | |||||||
Cash flows from financing activities: | ||||||||||||
Proceeds from issuance of Common stock, net | 3,602 | 2,118 | 12,319 | |||||||||
Proceeds from loans, notes and issuance of warrants, net | - | - | 2,061 | |||||||||
Credit from bank | - | (46 | ) | - | ||||||||
Proceeds from exercise of warrants and options | 515 | 88 | 631 | |||||||||
Repayment of short-term loans | - | - | (601 | ) | ||||||||
Net cash provided by continuing financing activities | 4,117 | 2,160 | 14,410 | |||||||||
Net cash provided by discontinued financing activities | - | - | 43 | |||||||||
Total net cash provided by financing activities | 4,117 | 2,160 | 14,453 | |||||||||
Increase in cash and cash equivalents | 1,830 | 92 | 1,923 | |||||||||
Cash and cash equivalents at the beginning of the period | 93 | 1 | - | |||||||||
Cash and cash equivalents at end of the period | $ | 1,923 | $ | 93 | $ | 1,923 | ||||||
Non-cash financing activities: | ||||||||||||
Conversion of convertible
loan and convertible note to shares | $ | 140 | $ | 324 | ||||||||
Conversion of other accounts payable to Common Stock | $ | 24 | $ | 487 | ||||||||
Conversion of a trade payable to Common Stock | $ | - | $ | 200 | ||||||||
(*) Out of the which, cash flows used in discontinued operating activities of $36, cash flows used in discontinued investing activities of $16 and cash flows provided in discontinued financing activities of $57, relating to the period from inception to March 31, 2004, is unaudited.
The accompanying notes are an integral part of the consolidated financial statements.
F-15 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
NOTE 1 - | GENERAL: |
A. | Brainstorm Cell Therapeutics Inc. (formerly: Golden Hand Resources Inc.) (the "Company") was incorporated in the State of Washington on September 22, 2000. |
B. | On May 21, 2004, the former major stockholders of the Company entered into a purchase agreement with a group of private investors, who purchased from the former major stockholders 6,880,000 shares of the then issued and outstanding 10,238,000 shares of Common Stock. |
C. | On July 8, 2004, the Company entered into a licensing agreement with Ramot of Tel Aviv University Ltd. ("Ramot"), to acquire certain stem cell technology (see Note 3). Subsequent to this agreement, the Company decided to focus on the development of novel cell therapies for neurodegenerative diseases based on the acquired technology and research to be conducted and funded by the Company. |
Following the licensing agreement dated July 8, 2004, the management of the Company decided to abandon all old activities related to the sale of the digital data recorder product. The discontinuation of this activity was accounted for under the provision of Statement of Financial Accounting Standard ASC 360-10 (formerly "SFAS" 144), "Accounting for the Impairment or Disposal of Long-Lived Assets".
D. | On October 25, 2004, the Company formed a wholly-owned subsidiary in Israel, Brainstorm Cell Therapeutics Ltd. ("BCT"). |
E. | On November 22, 2004, the Company changed its name from Golden Hand Resources Inc. to Brainstorm Cell Therapeutics Inc. to better reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. BCT, as defined below, owns all operational property and equipment. |
F. | On September 17, 2006, the Company changed the Company's fiscal year-end from March 31 to December 31. |
G. | In December 2006, the Company changed its state of incorporation from Washington to Delaware. |
H. | Since its inception, the Company has devoted substantially all of its efforts to research and development, recruiting management and technical staff, acquiring assets and raising capital. In addition, the Company has not generated revenues. Accordingly, the Company is considered to be in the development stage, as defined in Statement of Financial Accounting Standards No. 7, "Accounting and reporting by development Stage Enterprises" ASC 915-10 (formerly "SFAS No. 7"). |
I. | In October 2010, the Israeli Ministry of Health (“MOH”) granted clearance for a Phase I/II clinical trial using the Company’s autologous NurOwn™ stem cell therapy in patients with amyotrophic lateral sclerosis (“ALS”), subject to some additional process specifications as well as completion of the sterility validation study for tests performed. |
On February 23, 2011, the Company submitted, to the MOH, all the required documents. Following approval of the MOH, a Phase I/II clinical study for ALS patients using the Company’s autologous NurOwn™ stem cell therapy (the “Clinical Trial”) was initiated in June 2011. |
After the balance sheet date, in January 2012, the Company reported on an interim safety follow-up of the first 4 patients enrolled in its Clinical Trial indicating that no significant treatment-related adverse events were reported. The NurOwn™ treatment has thus so far proven to be safe, and has shown some initial indications of beneficial clinical effects. |
J. | In February 2011, the U.S. Food and Drug Administration (“FDA”) granted orphan drug designation to the Company’s NurOwn™ autologous adult stem cell product candidate for the treatment of ALS. |
F-16 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
NOTE 1 - | GENERAL (Cont.) |
GOING CONCERN:
As reflected in the accompanying financial statements, the Company’s operations for the year ended December 31, 2011, resulted in a net loss of $3,918. The Company’s balance sheet reflects an accumulated deficit of $44,078. These conditions, together with the fact that the Company is a development stage Company and has no revenues nor are revenues expected in the near future, raise substantial doubt about the Company's ability to continue to operate as a going concern. The Company’s ability to continue operating as a “going concern” is dependent on several factors, among them is its ability to raise sufficient additional working capital.
In 2009, the Company decided to focus only on the effort to commence clinical trials for ALS and such trials did commence in 2011.
In February 2011, the Company raised approximately $3.8 million from institutional and private investors. However, there can be no assurance that additional funds will be available on terms acceptable to the Company, or at all.
These financial statements do not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount and classification of liabilities that may be required should the Company be unable to continue as a going concern.
NOTE 2 - | SIGNIFICANT ACCOUNTING POLICIES |
A. | Basis of presentation: |
The consolidated financial statements have been prepared in accordance with United States Generally Accepted Accounting Principles (“GAAP”) applied on a consistent basis.
B. | Use of estimates: |
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
C. | Financial statement in U.S. dollars: |
The functional currency of the Company is the U.S dollar ("dollar") since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future. Part of the transactions of BCT are recorded in new Israeli shekels ("NIS"); however, a substantial portion of BCT’s costs are incurred in dollars or linked to the dollar. Accordingly, management has designated the dollar as the currency of BCT’s primary economic environment and thus it is their functional and reporting currency.
Transactions and balances denominated in dollars are presented at their original amounts. Non-dollar transactions and balances have been re-measured to dollars in accordance with the provisions of ASC 830-10 (formerly Statement of Financial Accounting Standard 52), "Foreign Currency Translation". All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate.
D. | Principles of consolidation: |
The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, BCT. Intercompany balances and transactions have been eliminated upon consolidation.
F-17 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
NOTE 2 - | SIGNIFICANT ACCOUNTING POLICIES (Cont.) |
E. | Cash equivalents: |
Cash equivalents are short-term highly liquid investments that are readily convertible to cash with maturities of three months or less as of the date acquired.
F. | Property and equipment: |
Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated by the straight-line method over the estimated useful lives of the assets.
The annual depreciation rates are as follows:
% |
||
Office furniture and equipment | 7 | |
Computer software and electronic equipment | 33 | |
Laboratory equipment | 15 | |
Leasehold improvements | Over the shorter of the lease term (including the option) or useful life |
G. | Impairment of long-lived assets: |
The Company’s and BCT’s long-lived assets are reviewed for impairment in accordance with ASC 360-10 (formerly Statement of Financial Accounting Standard 144), "Accounting for the Impairment or Disposal of Long-Lived Assets," whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds their fair value. During 2010 and 2011, no impairment losses were identified.
H. | Research and development expenses, net: |
Research and development expenses, are charged to the statement of operations as incurred.
Royalty-bearing grants from the Government of Israel for funding approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred and applied as a deduction from research and development expenses. Such grants are included as a deduction of research and development costs since at the time received it is not probable the Company will generate sales from these projects and pay the royalties resulting from such sales.
I. | Severance pay: |
The liability of BCT for severance pay is calculated pursuant to the Severance Pay Law in Israel, based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date and is presented on an undiscounted basis.
BCT’s employees are entitled to one month's salary for each year of employment or a portion thereof. BCT’s liability for all of its employees is fully provided by monthly deposits with insurance policies and by an accrual. The value of these policies is recorded as an asset in the Company's balance sheet.
The deposited funds may be withdrawn only upon the fulfillment of the obligation pursuant to Severance Pay Law in Israel or labor agreements. The value of the deposited funds is based on the cash surrendered value of these policies.
Severance expenses for the year ended December 31, 2011 were $20.
F-18 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
NOTE 2 - | SIGNIFICANT ACCOUNTING POLICIES (Cont.) |
J. | Accounting for stock-based compensation: |
Effective April 1, 2006, the Company adopted ASC 718-10 (formerly Statement of Financial Accounting Standards 123 (Revised 2004)), "Share-Based Payment,” which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options under the Company's stock plans based on estimated fair values. ASC 718-10 supersedes the Company's previous accounting under Accounting Principles Board Opinion 25, "Accounting for Stock Issued to Employees" ("APB 25"). In March 2005, the Securities and Exchange Commission issued Staff Accounting Bulletin 107 ("SAB 107") relating to ASC 718-10. The Company has applied the provisions of SAB 107 in its adoption of ASC 718-10.
ASC 718-10 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company's consolidated statement of operations.
The Company recognizes compensation expense for the value of non-employee awards, which have graded vesting, based on the accelerated attribution method over the requisite service period of each award, net of estimated forfeitures.
The Company recognizes compensation expense for the value of employee awards that have graded vesting, based on the straight-line method over the requisite service period of each of the awards, net of estimated forfeitures.
The Company estimates the fair value of restricted shares based on the market price of the shares at the grant date and estimates the fair value of stock options granted using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are, expected stock price volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility was calculated based upon actual historical stock price movements over the period, equal to the expected option term. The expected option term was calculated for options granted to employees and directors in accordance with SAB 107 and SAB 110, using the "simplified" method. Grants to non-employees are based on the contractual term. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from U.S. Treasury zero-coupon bonds with an equivalent term.
K. | Basic and diluted net loss per share: |
Basic net loss per share is computed based on the weighted average number of shares outstanding during each year. Diluted net loss per share is computed based on the weighted average number of shares outstanding during each year, plus the dilutive potential of the Common Stock considered outstanding during the year, in accordance with ASC 260-10 (formerly Statement of Financial Accounting Standard 128), "Earnings per Share".
All outstanding stock options and warrants have been excluded from the calculation of the diluted loss per share for the year ended December 31, 2011 and December 31, 2010, since all such securities have an anti-dilutive effect.
F-19 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
NOTE 2 - | SIGNIFICANT ACCOUNTING POLICIES (Cont.) |
L. | Income taxes: |
The Company and BCT account for income taxes in accordance with ASC 740-10 (formerly Statement of Financial Accounting Standard 109), "Accounting for Income Taxes." This Statement requires the use of the liability method of accounting for income taxes, whereby deferred tax asset and liability account balances are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company and BCT provide a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value.
In September 2006, the Financial Accounting Standards Board ("FASB") issued ASC 740-10 (formerly FASB interpretation ("FIN") 48), "Accounting for Uncertainty in Income Taxes - an Interpretation of FASB Statement 109". ASC 740-10 establishes a single model to address accounting for uncertain tax positions. ASC 740-10 clarified the accounting for income taxes by prescribing the minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. ASC 740-10 also provides guidance on recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition. The adoption of the provisions of ASC 740-10 did not have an impact on the Company's consolidated financial position and results of operations.
M. | Fair value of financial instruments: |
The carrying values of cash and cash equivalents, accounts receivable and prepaid expenses, trade payables and other accounts payable approximate their fair value due to the short-term maturity of these instruments.
F-20 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
NOTE 3 - | RESEARCH AND LICENSE AGREEMENT |
On July 8, 2004, the Company entered into a research and license agreement (the "Original Agreement") with Ramot. The license agreement grants the Company an exclusive, worldwide, royalty-bearing license to develop, use and sell certain stem cell technology. In consideration of the license, the Company was required to remit an upfront license fee payment of $100; royalties at a rate of 5% of all net sales of products and 30% of all sublicense receipts. In addition, the Company granted Ramot and certain of its designees fully vested warrants to purchase 10,606,415 shares of Common Stock at an exercise price of $0.01 per share. The Company also agreed to fund, through Ramot, further research in consideration of $570 per year for an initial two-year period (“initial research period”). The Company also agreed to fund research for a further two-year period if certain research milestones are met for an additional $1,140 (“extended research period”).
The warrants issued pursuant to the agreement were issued to Ramot and its designees effective as of November 4, 2004. Each of the warrants is exercisable for a seven-year period beginning on November 4, 2005.
On March 30, 2006, the Company entered into an Amended Research and License Agreement with Ramot, for the purpose of amending and restating the Original Agreement. According to the agreement, the initial period was amended to an initial research period of three years. The Amended Research and License Agreement also extends the additional two-year research period in the Original Agreement to an additional three-year research period if certain research milestones are met. The Amended Research and License Agreement retroactively amended the consideration to $380 per year, instead of $570 per year. As a consequence, an amount of $300 was charged to the statement of operations as research and development expenses in the year ended in March 31, 2006. In addition, the Amended Research and License Agreement reduced royalties that the Company may have to pay Ramot, in certain cases, from 5% to 3% of net sales and also reduces the sublicenses receipt from 30% to 20%-25% of sublicense receipts.
On July 26, 2007, the Company entered into a Second Amended and Restated Research and License Agreement with Ramot. On August 1, 2007, the Company obtained a waiver and release from Ramot pursuant to which Ramot agreed to an amended payment schedule regarding the Company's payment obligations under the Amended Research and License Agreement, dated March 30, 2006, and waived all claims against the Company resulting from the Company's previous defaults and non-payment under the Original Agreement and the Amended Research and License Agreement. The payments described in the waiver and release covered all payment obligations that were past due and not yet due pursuant to the Original Agreement. The waiver and release amended and restated the remaining unpaid balance of $240 of the original payment schedule for the initial research period.
As of December 24, 2009, the Company had not made the payments totaling $240.
On December 24, 2009, the Company and Ramot entered into a settlement under which, among other things, the following matters were agreed upon:
a) | Ramot released the Company from the Company’s obligation to fund the extended research period in the total amount of $1,140.Therefore, the Company removed an amount of $760 from its research and development expenses that had accumulated in the past. |
b) | Past due amounts of $240 for the initial research period plus interest of $32 owed by the Company to Ramot was converted into 1,120,000 restricted shares of common stock on December 30, 2009. Ramot deposited the shares with a broker and may sell the shares in the free market after 185 days from the issuance date. |
F-21 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
NOTE 3 - | RESEARCH AND LICENSE AGREEMENT (Cont.) |
In the event that the total proceeds generated by sales of the shares are less than $120 on or prior to September 30, 2010 ("September Payment"), then on such date the Company had to pay to Ramot the difference between the aggregate proceeds that had been received by Ramot up to such date, and $120. In the event that the total proceeds generated by sales of the shares, together with the September 30, 2010 payment, are less than $240 on or prior to December 31, 2010, then the Company had to pay to Ramot the difference between the proceeds that Ramot had received from sales of the shares up to such date together with the September Payment (if any) that had been transferred to Ramot up to such date, and $240. Related compensation in the amount of $51 was recorded as research and development expenses.
As of December 31, 2011, Ramot had sold all 1,120,000 shares of Common Stock of the Company issued under the settlement agreement for $235. The Company paid the remaining balance of $5 and finalized the balance due to Ramot according to the settlement agreement between the parties dated December 24, 2009.
In December 2011, the Company signed an agreement with BCT and Ramot, in which the Company assigned to BCT its rights under the License Agreement with Ramot, as well as its ownership rights in the joint patent application with Ramot. The Company guarantees all BCT obligations under the License Agreement towards Ramot.
NOTE 4 - | CONSULTING AGREEMENTS |
A. | On July 8, 2004, the Company entered into two consulting agreements with Prof. Eldad Melamed and Prof. Daniel Offen (together, the "Consultants"), upon which the Consultants shall provide the Company scientific and medical consulting services in consideration for a monthly payment of $6 each. In addition, the Company granted each of the Consultants, a fully vested warrant to purchase 1,097,215 shares of Common Stock at an exercise price of $0.01 per share. The warrants issued pursuant to the agreement were issued to the Consultants effective as of November 4, 2004. Each of the warrants is exercisable for a seven-year period beginning on November 4, 2005. As of December 31, 2010, the two Consultants exercised the above warrants to Common Stock of the Company. |
B. | On December 16, 2010, the Company approved a grant of 1,100,000 shares of the Company's Common Stock to the two Consultants, for services rendered through December 31, 2010. Related compensation in the amount of $220 was recorded as research and development expense. A sum of $487 was cancelled concurrently with the issuance of the 1,100,000 shares of Common Stock of the Company. |
C. | On June 27, 2011, the Company approved an additional grant of 400,000 shares of the Company's Common Stock to Prof. Daniel Offen, for services rendered through December 31, 2009. Related compensation in the amount of $192 is recorded as research and development expense. |
NOTE 5 - | ACCOUNTS RECEIVABLE |
December 31, | ||||||||
2011 | 2010 | |||||||
U.S. $ in thousands | ||||||||
Government authorities | 76 | 36 | ||||||
Grants receivable from the CSO | 236 | 391 | ||||||
312 | 427 |
F-22 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
NOTE 6 - | PROPERTY AND EQUIPMENT |
December 31, | ||||||||
2011 | 2010 | |||||||
U.S. $ in thousands | ||||||||
Cost: | ||||||||
Office furniture and equipment | 9 | 9 | ||||||
Computer software and electronic equipment | 106 | 105 | ||||||
Laboratory equipment | 361 | 349 | ||||||
Leasehold improvements | 690 | 655 | ||||||
1,166 | 1,118 | |||||||
Accumulated depreciation: | ||||||||
Office furniture and equipment | 4 | 3 | ||||||
Computer software and electronic equipment | 103 | 100 | ||||||
Laboratory equipment | 252 | 200 | ||||||
Leasehold improvements | 493 | 396 | ||||||
852 | 699 | |||||||
Depreciated cost | 314 | 419 |
Depreciation expenses for the year ended December 31, 2011 and December 31, 2010 were $153, and $162, respectively.
NOTE 7 - | OTHER ACCOUNTS PAYABLE |
December 31, | ||||||||
2011 | 2010 | |||||||
U.S. $ in thousands | ||||||||
Employee and payroll accruals | 141 | 471 | ||||||
Ramot accrued expenses | - | 60 | ||||||
141 | 531 |
NOTE 8 - | SHORT-TERM CONVERTIBLE NOTE |
On December 13, 2009, the Company issued a $135 Convertible Promissory Note to its legal advisor for $217 in legal fees accrued through October 31, 2009. Interest on the Note accrued at the rate of 4%. The legal advisor has the right at any time to convert all or part of the outstanding principal and interest amount of the note into shares of Common Stock based on the five day average closing stock price prior to conversion election.
The gap between the amount the Company owed to the legal advisor and the principal of the Convertible Promissory Note in the amount of $82 was deducted from general and administrative expenses.
F-23 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
NOTE 8 - | SHORT-TERM CONVERTIBLE NOTE (Cont.) |
On February 19, 2010, the Company's legal advisor converted the entire accrued principal and interest of $135 Convertible Promissory Note into 402,385 shares of Common Stock.
On September 15, 2010, the Company issued a $135 Convertible Promissory Note to its legal advisor for legal fees accrued through December 31, 2010. Interest on the Note was at the rate of 4%. The legal advisor has the right at any time to convert all or part of the outstanding principal and interest amount of the note into shares of Common Stock based on the five day average closing stock price prior to conversion election.
On February 18, 2011, the legal advisor converted the entire accrued principal and interest into 445,617 shares of Common Stock.
NOTE 9 - | SHORT-TERM CONVERTIBLE LOANS |
On March 5, 2007, the Company issued a $150 Convertible Promissory Note to a third party. Interest on the note accrues at the rate of 8% per annum for the first year and 10% per annum afterward. The note will become immediately due and payable upon the occurrence of certain events of default, as defined in the note. The third party has the right at any time prior to the close of business on the maturity date to convert all or part of the outstanding principal and interest amount of the note into shares of Common Stock. The conversion price, as defined in the note, will be 75% (60% upon the occurrence of an event of default) of the average of the last bid and ask price of the Common Stock as quoted on the Over-the-Counter Bulletin Board for the five trading days prior to the Company's receipt of the third party written notice of election to convert, but in no event shall the conversion price be greater than $0.35 or more than 3,000,000 shares of Common Stock be issued. The conversion price will be adjusted in the event of a stock dividend, subdivision, combination or stock split of the outstanding shares.
In addition, the Company granted to the third party warrants to purchase 150,000 shares of Common Stock at an exercise price of $0.45 per share. The warrants are fully vested and are exercisable at any time after March 5, 2007 until the second anniversary of the issue date. The fair value of the warrants is $43.
In accordance with ASC 470-20, the Company allocated the proceeds of the convertible note issued with detachable warrants based on the relative fair values of the two securities at the time of issuance. As a result, the Company recorded in its statement of changes in stockholders' equity for 2007 an amount of $22 with respect to the warrants and the convertible note was recorded in the amount of $128.
The Company agreed to pay a finder's fee of $15; $13 was allocated to deferred charges and is amortized as financial expense over the note period and $2 was allocated to stockholder's equity.
The Beneficial Conversion Feature in the amount of $122, embedded in the note was calculated based on a conversion rate of 60%, as defined upon the occurrence of an event of default and according to the notes’ effective conversion price. The amount was recorded as discount on the note against additional paid-in capital and is amortized to financial expense over the note period.
F-24 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
NOTE 9 - | SHORT-TERM CONVERTIBLE LOANS (Cont.) |
On January 27, 2010, the third party converted the entire accrued principal and interest of the note, into 1,016,109 shares of Common Stock.
In July 2011, the Company issued to the lender an additional 309,977 shares of Common Stock of the Company with regard to the above conversion.
F-25 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
NOTE 10 - | COMMITMENTS AND CONTINGENCIES |
A. | On December 1, 2004, BCT entered into a lease agreement for the lease of its facilities. The term of the lease was 36 months, with two options to extend. Rent is paid on a quarterly basis in the amount of NIS 28,373 (approximately $8) per month. |
The facilities and vehicles of the Company and BCT are rented under operating leases that expire on various dates. Aggregate minimum rental commitments under non-cancelable leases as of December 31, 2011 are as follows:
Period ending December 31, | Facilities | Vehicles | Total | |||||||||
2012 | 99 | 43 | 142 | |||||||||
2013 | - | 43 | 43 | |||||||||
2014 | - | 22 | 22 | |||||||||
99 | 109 | 207 |
Total facilities rent expenses for the year ended December 31, 2011 and 2010 were $111 and $135 respectively.
B. | On March 20, 2006, the Company entered into a Termination Agreement and General Release (the "Termination Agreement") with Dr. Yaffa Beck, the Company's former President and Chief Executive Officer who resigned her position as an officer and director of the Company on November 10, 2005. |
As of December 31, 2011, there was still an unpaid balance of $17 to Dr. Beck under this Termination Agreement.
C. | Commitments to pay royalties to the Chief Scientist: |
BCT obtained from the Chief Scientist of the State of Israel grants for participation in research and development for the years 2007 through 2011, and, in return, BCT is obligated to pay royalties amounting to 3% of its future sales up to the amount of the grant. The grant is linked to the exchange rate of the dollar and bears interest of Libor per annum.
Through December 31, 2011, total grants obtained amounted to $1,472.
D. | On February 17, 2010, BCT entered into an agreement with Hadasit Medical Research Services and Development Ltd ("Hadasit") to conduct clinical trials in ALS patients. The agreement was revised in June 2011 according to which, in connection with the trials BCT will pay Hadasit $32,225 per patient totaling up to $773,400, as well as $64,915 per month for rental and operation of two clean rooms. The Company has the right to cease the rental of the clean rooms at any time upon 30 days prior notice. |
F-26 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
NOTE 10 - | COMMITMENTS AND CONTINGENCIES (Cont.) |
E. | On April 17, 2008, Chapman, Spira & Carson, LLC (“CSC”) filed a breach of contract complaint in the Supreme Court of the State of New York (the “Court”) against the Company. The complaint alleges that CSC performed its obligations to the Company under a consulting agreement entered into between the parties and that the Company failed to provide CSC with the compensation outlined in the consulting agreement. The complaint seeks compensatory damages in an amount up to approximately $897, as well as costs and attorneys’ fees. On June 5, 2008, the Company filed an answer with the Court. The Company believes CSC’s claims are without merit and cannot predict what impact, if any, this matter may have on the business, its financial condition and results of operations and cash flow. Provision is included in the financial statements that Management believes is sufficient to address the risk. |
NOTE 11 - | STOCK CAPITAL |
A. | The rights of Common Stock are as follows: |
Holders of Common Stock have the right to receive notice to participate and vote in general meetings of the Company, the right to a share in the excess of assets upon liquidation of the Company and the right to receive dividends, if declared.
The Common Stock is registered and publicly traded on the OTC Markets Group service of the National Association of Securities Dealers, Inc. under the symbol BCLI.
B. | Issuance of shares, warrants and options: |
1. | Private Placements: |
a) | On June 24, 2004, the Company issued to investors 8,510,000 shares of Common Stock for total proceeds of $60 (net of $25 issuance expenses). |
b) | On February 23, 2005, the Company completed a private placement for sale of 1,894,808 units for total proceeds of $1,418. Each unit consisted of one share of Common Stock and a three-year warrant to purchase one share of Common Stock |
at $2.50 per share. This private placement was consummated in three tranches which closed in October 2004, November 2004 and February 2005.
c) | On May 12, 2005, the Company issued to an investor 186,875 shares of Common Stock for total proceeds of $149 at a price of $0.80 per share. |
d) | On July 27, 2005, the Company issued to investors 165,000 shares of Common Stock for total proceeds of $99 at a price of $0.60 per share. |
e) | On August 11, 2005, the Company signed a private placement agreement with investors for the sale of up to 1,250,000 units at a price of $0.80 per unit. Each unit consisted of one share of Common Stock and one warrant to purchase one share of Common Stock at $1.00 per share. The warrants were exercisable for a period of three years from issuance. On September 30, 2005, the Company sold 312,500 units for total net proceeds of $225. On December 7, 2005, the Company sold 187,500 units for total net proceeds of $135. |
f) | On July 2, 2007, the Company entered into an investment agreement, pursuant to which the Company agreed to sell up to 27,500,000 shares of Common Stock, for an aggregate subscription price of up to $5 million and warrants to purchase up to 30,250,000 shares of Common Stock. |
F-27 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
NOTE 11 - | STOCK CAPITAL (Cont.) |
B. | Issuance of shares, warrants and options (Cont.): |
1. | Private placements (Cont.): |
At each closing date, the Company would deliver to the investor the number of shares and warrants, subject to customary closing conditions and the delivery of funds, described above. The warrants had the following exercise prices: (i) the first 10,083,333 warrants had an exercise price of $0.20 per share; (ii) the next 10,083,333 warrants had an exercise price of $0.29 per share; and (iii) the final 10,083,334 warrants issued had an exercise price of $0.36 per share. All warrants expired on November 5, 2011.
On August 18, 2009, the Company entered into an amendment to the investment agreement with the investor as follows:
(a) | The investor shall invest the remaining amount of the original investment agreement at a price per share of $0.12 in monthly installments of not less than $50 starting August 1, 2009. |
(b) | The exercise price of the last 10,083,334 warrants will decrease from an exercise price of $0.36 per share to $0.29 per share. |
(c) | All warrants will expire on November 5, 2013 instead of November 5, 2011. |
(d) | The price per share of the investment agreement decreased from $0.1818 to $0.12, therefore the Company adjusted the number of Shares of Common Stock issuable pursuant to the investment agreement retroactively and issued to the investor on October 28, 2009 an additional 9,916,667 shares of Common Stock for past investment. |
(e) | The investor has the right to cease payments in the event that the price per share as of the closing on five consecutive trading days shall decrease to $0.05. |
On January 18, 2011, the Company and the investor signed an agreement to offset amounts due to the investor, totaling $22, against the remaining balance of the investment. The Company issued to the investor 10,499,999 shares of Common Stock and a warrant to purchase 4,537,500 shares of the Company's Common Stock at an exercise price of $0.29 per share
As of December 31, 2011, the Company issued to the investor and its designees an aggregate of 41,666,667 shares of Common Stock, a warrant to purchase 10,083,333 shares of the Company's Common Stock at an exercise price of $0.20 per share, and a warrant to purchase 20,166,667 shares of Common Stock at an exercise price of $0.29 per share. The warrants may be exercised at any time and expire on November 5, 2013.
In addition, the Company issued an aggregate of 1,250,000 shares of Common Stock to a related party as an introduction fee for the investment.
As of December 31, 2011, the introduction fee was paid in full.
F-28 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
NOTE 11 - | STOCK CAPITAL (Cont.) |
B. | Issuance of shares, warrants and options: (Cont.) |
1. | Private placements: (Cont.) |
(f) | In January 2010, the Company issued 1,250,000 units to a private investor for total proceeds of $250. Each unit consisted of one share of Common Stock and a two-year warrant to purchase one share of Common Stock at $0.50 per share. |
(g) | In February 2010, the Company issued 6,000,000 shares of Common Stock to three investors (2,000,000 to each investor) and warrants to purchase an aggregate of 3,000,000 shares of Common Stock (1,000,000 to each investor) with an exercise price of $0.50 for aggregate proceeds of $1,500 ($500 each). The warrants are exercisable through February 17, 2012. |
(h) | In February 2011, the Company issued 833,333 shares of Common Stock, at a price of $0.30 per share, and a warrant to purchase 641,026 shares of the Company's Common Stock at an exercise price of $0.39 per share exercisable for one year for total proceeds of $250. |
(i) | In February 2011, the Company entered into an investment agreement, pursuant to which the Company sold 12,815,000 shares of Common Stock, for an aggregate subscription price of $3.6 million and warrants to purchase up to 19,222,500 shares of Common Stock as follows: warrants to purchase 12,815,000 shares of Common Stock at $0.50 for two years, and warrants to purchase 6,407,500 shares of Common Stock at $0.28 for one year. |
In July 2011, an investor exercised a warrant to purchase 946,834 shares of Common Stock of the Company at $0.28 per share, for $265.
In addition, the Company paid 10% of the funds received for the distribution services received. Out of this amount, 4% was paid in stock and the remaining 6% in cash. Accordingly, in March 2011, the Company issued 512,600 shares of Common Stock and paid $231 for the investment banking related to the investment. |
2. | Share-based compensation to employees and to directors: |
a) | Options to employees and directors: |
On November 25, 2004, the Company's stockholders approved the 2004 Global Stock Option Plan and the Israeli Appendix thereto (which applies solely to participants who are residents of Israel) and on March 28, 2005, the Company's stockholders approved the 2005 U.S. Stock Option and Incentive Plan, and the reservation of 9,143,462 shares of Common Stock for issuance in the aggregate under these stock option plans.
Each option granted under the plans is exercisable until the earlier of ten years from the date of grant of the option or the expiration dates of the respective option plans. The 2004 and 2005 options plans will expire on November 25, 2014 and March 28, 2015, respectively. The exercise price of the options granted under the plans may not be less than the nominal value of the shares into which such options are exercised. The options vest primarily over three years. Any options that are canceled or forfeited before expiration become available for future grants. |
F-29 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
NOTE 11 - | STOCK CAPITAL (Cont.) |
B. | Issuance of shares, warrants and options: (Cont.) |
2. | Share-based compensation to employees and to directors (Cont.): |
a) | Options to employees and directors: (Cont.) |
On June 5, 2008, the Company's stockholders approved an amendment and restatement of the Company’s 2004 Global Share Option Plan and 2005 U.S. Stock Option and Incentive Plan to increase the number of shares of common stock available for issuance under these stock option plans in the aggregate by 5,000,000 shares.
On May 27, 2005, the Company granted one of its directors an option to purchase 100,000 shares of Common Stock at an exercise price of $0.75 per share. The options are fully vested and expire after 10 years.
On February 6, 2006, the Company entered into an amendment to the Company's option agreement with the Company's Chief Financial Officer. The amendment changes the exercise price of the 400,000 options granted to him on February 13, 2005 from $0.75 to $0.15 per share.
On May 2, 2006, the Company granted to one of its directors an option to purchase 100,000 shares of Common Stock at an exercise price of $0.15 per share. The options are fully vested and expire after 10 years. The compensation related to the options, in the amount of $48, was recorded as general and administrative expense.
On June 22, 2006, the Company entered into an amendment to the Company's option agreement with two of its employees. The amendment changed the exercise price of 270,000 options granted to them from $0.75 to $0.15 per share. The excess of the fair value resulting from the modification, in the amount of $2, was recorded as general and administration expense over the remaining vesting period of the option.
On September 17, 2006, the Company entered into an amendment to the Company's option agreement with one of its directors. The amendment changes the exercise price of 100,000 options granted to the director from $0.75 to $0.15 per share.
On March 21, 2007, the Company granted to one of its directors an option to purchase 100,000 shares of Common Stock at an exercise price of $0.15 per share. The option is fully vested and is exercisable for a period of 10 years. The compensation related to the option, in the amount of $43, was recorded as general and administrative expense.
On July 1, 2007, the Company granted to one of its directors an option to purchase 100,000 shares of Common Stock at an exercise price of $0.15 per share. The option is fully vested and is exercisable for a period of 10 years. The compensation related to the option, in the amount of $38, was recorded as general and administrative expense. On October 22, 2007, the Company and the director agreed to cancel and relinquish all the options which were granted on July 1, 2007.
On July 16, 2007, the Company granted to one of its directors an option to purchase 100,000 shares of Common Stock at an exercise price of $0.15 per share. The option is fully vested and is exercisable for a period of 10 years. The compensation related to the option, in the amount of $75, was recorded as general and administrative expense.
F-30 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
NOTE 11 - | STOCK CAPITAL (Cont.) |
B. | Issuance of shares, warrants and options (Cont.) |
2. | Share-based compensation to employees and to directors (Cont.): |
a) | Options to employees and directors: (Cont.) |
On August 27, 2007, the Company granted to one of its directors an option to purchase 100,000 shares of Common Stock at an exercise price of $0.15 per share. The option is fully vested and is exercisable for a period of 10 years. The compensation related to the option, in the amount of $84, was recorded as general and administrative expense.
On October 23, 2007, the Company granted to its former Chief Executive Officer and director an option to purchase 1,000,000 shares of Common Stock at an exercise price of $0.87 per share. The option vests with respect to 1/6 of the option on each six month anniversary and expires after 10 years. The total compensation related to the option is $733, which is amortized over the vesting period as general and administrative expense.
On November 5, 2008, the Company entered into an amendment to the Company's option to purchase 1,000,000 shares of common stock agreement with the Company's CEO. The amendment changed the exercise price of the option from $0.87 to $0.15 per share. The compensation related to the modification of the purchase price in the amount of $4 was recorded as general and administrative expense. In February 2011, the former CEO resigned. As of December 31, 2011, 300,727 out of the above options were exercised. After the balance sheet date, the former CEO exercised his option to purchase an additional 132,038 shares of common stock (see Note 15 C).
On June 29, 2009, the Company granted to its former Chief Executive Officer and director an option to purchase 1,000,000 shares of Common Stock at an exercise price of $0.067 per share. The option vests with respect to 1/3 of the shares subject to the option on each anniversary of the date of grant and expires after 10 years. The total compensation related to the option is $68, which is amortized over the vesting period as general and administrative expense. In February 2011, the former CEO resigned. On July 25, 2011, the Company signed a settlement agreement with the former CEO under which 483,333 shares out of the above grant became fully vested exercisable through April 30, 2012. An additional $30 was recorded as compensation in general and administrative expense.
On June 29, 2009, the Company granted to its former Chief Financial Officer an option to purchase 200,000 shares of Common Stock at an exercise price of $0.067 per share. The option vested with respect to 1/3 of the shares subject to the option. Out of the above options, 2/3 were cancelled and the remaining 66,667 were exercised.
On August 31, 2009, the Company granted to two of its directors an option to purchase 100,000 shares of Common Stock for each of them at an exercise price of $0.15 per share. The option vests with respect to 1/3 of the option on each anniversary and expires after 10 years. The total compensation related to the option is $32, which is amortized over the vesting period as general and administrative expense.
On December 13, 2009, the Company granted to one of its directors an option to purchase 100,000 shares of Common Stock at an exercise price of $0.15 per share. The option is fully vested and is exercisable for a period of 10 years. The compensation related to the option, in the amount of $21, was recorded as general and administrative expense.
F-31 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
NOTE 11 - | STOCK CAPITAL (Cont.) |
B. | Issuance of shares, warrants and options (Cont.) |
2. | Share-based compensation to employees and to directors (Cont.): |
a) | Options to employees and directors: (Cont.) |
On February 10, 2010, the Company granted to an employee an option to purchase 30,000 shares of Common Stock at an exercise price of $0.32 per share. The option vests with respect to 1/3 of the shares subject to the option on each anniversary of the date of grant and expires after 10 years. The total compensation related to the option is $9, which is amortized over the vesting period as research and development expense.
On April 13, 2010, the Company, Prof. Abraham Israeli and Hadasit Medical Research Services and Development Ltd. (“Hadasit”) entered into an Agreement (the “Agreement”) pursuant to which Mr. Israeli agreed, during the term of the Agreement, to serve as (i) the Company’s Clinical Trials Advisor and (ii) a member of the Company’s Board of Directors. In consideration of the services to be provided by Mr. Israeli to the Company under the Agreement, the Company agreed to grant options annually during the term of the Agreement for the purchase of its Common Stock, as follows:
* | An option for the purchase of 166,666 shares of Common Stock at an exercise price equal to $0.00005 per share to Mr. Israeli; and |
* | An option for the purchase of 33,334 shares of Common Stock at an exercise price equal to $0.00005 per share to Hadasit. |
* | Such options will vest and become exercisable in twelve (12) consecutive equal monthly amounts. |
In April 2010, the Company granted to Mr. Israeli an option to purchase 166,666 shares of Common Stock at an exercise price equal to $0.00005 per share. The total compensation related to the option is $50, which is amortized over the vesting period as general and administrative expense.
On June 27, 2011, the Company granted to Mr. Israeli an option to purchase 166,666 shares of Common Stock at an exercise price equal to $0.00005 per share. The total compensation related to the option is $48, which is amortized over the vesting period as general and administrative expense.
In April 2010, the Company granted Hadasit an option to purchase 33,334 shares of Common Stock at an exercise price equal to $0.00005 per share. The total compensation related to the option is $7, which is amortized over the vesting period as general and administrative expense.
In April 2011, the Company granted Hadasit an option to purchase 33,334 shares of Common Stock at an exercise price equal to $0.00005 per share. The total compensation related to the option is $11, which is amortized over the vesting period as general and administrative expense.
On December 16, 2010, the Company granted to two of its directors an option to purchase 400,000 shares of Common Stock at an exercise price of $0.15 per share. The options are fully vested and are exercisable for a period of 10 years. The compensation related to the option, in the amount of $78, was recorded as general and administrative expense.
F-32 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
On December 16, 2010, the Company approved the grant to two Board members an option to purchase 400,000 shares of Common Stock of the Company (200,000 shares each). The compensation related to the option, in the amount of $80, was recorded as general and administrative expense.
On December 16, 2010, the Company approved the grant to its three Scientific Board members 300,000 shares of Common Stock of the Company. The compensation related to the option, in the amount of $60, was recorded as research and development expense.
On December 16, 2010, the Company granted to its employees options to purchase 670,000 shares of Common Stock at an exercise price of $0.18 per share. The options are vested over three years and are exercisable for a period of 10 years. The compensation related to the option, in the amount of $32, was recorded as general and administrative expense.
On June 27, 2011, the Company granted to its CEO, an option to purchase 450,000 shares of Common Stock of the Company at $0.20. The total compensation related to the option is $177, which is amortized over the vesting period as general and administrative expense.
On June 27, 2011, the Company granted to four of its directors an option to purchase 634,999 shares of Common Stock of the Company at $0.15. The total compensation related to the option is $287, which is amortized over the vesting period as general and administrative expense.
On August 10, 2011, the Company granted to its CEO, an option to purchase 70,000 shares of Common Stock of the Company at $0.20. The total compensation related to the option is $26, which was amortized as general and administrative expense.
On November 10, 2011, the Company approved the grant to its four Advisory Board members an option to purchase 500,000 shares of Common Stock of the Company (125,000 shares each). The total compensation related to the option is $140, which is amortized over the vesting period as general and administrative expense.
On November 10, 2011, the Company approved the grant to a former director of the Company 250,000 shares of Common Stock of the Company. The compensation related to the option, in the amount of $70, was recorded as general and administrative expense.
As of December 31, 2011, 1,825,103 options are available for future grants.
F-33 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
NOTE 11 - | STOCK CAPITAL (Cont.) |
B. | Issuance of shares, warrants and options |
2. | Share-based compensation to employees and to directors: |
a) | Options to employees and directors: (Cont.) |
A summary of the Company's option activity related to options to employees and directors, and related information is as follows:
Year ended December 31, 2011 | ||||||||||||
Amount of options | Weighted average exercise price | Aggregate intrinsic value | ||||||||||
$ | $ | |||||||||||
Outstanding at beginning of period | 6,893,024 | 0.183 | ||||||||||
Granted | 1,321,665 | 0.151 | ||||||||||
Exercised | (1,286,600 | ) | 0.148 | |||||||||
Cancelled | (1,989,268 | ) | 0.188 | |||||||||
Outstanding at end of period | 4,938,821 | 0.168 | 831,684 | |||||||||
Vested and expected-to-vest at end of period | 3,663,138 | 0.138 | 507,028 |
*) | During 2008, the Company extended the exercise period for some of its employees that were terminated. The extension was accounted for as modification in accordance with ASC 718-10. According to ASC 718-10, modifications are treated as an exchange of the original award, resulting in additional compensation expense based on the difference between the fair value of the new award and the original award immediately before modification. Applying modification accounting resulted in additional compensation expense for the year ended December 31, 2008, amounted to $6. |
The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the fair market value of the Company’s shares on December 31, 2011 and 2010 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 2011 and 2010.
F-34 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
NOTE 11 - | STOCK CAPITAL (Cont.) |
B. | Issuance of shares, warrants and options (Cont.) |
2. | Share-based compensation to employees and to directors (Cont.): |
a) | Options to employees and directors: (Cont.) |
The options outstanding as of December 31, 2011, have been separated into exercise prices, as follows:
Options outstanding as of | Weighted average remaining | Options exercisable as of | ||||||||||
December 31, | contractual | December 31, | ||||||||||
Exercise price | 2 0 1 1 | Life | 2 0 1 1 | |||||||||
$ | Years | |||||||||||
0.00005 | 333,332 | 8.29 | 277,777 | |||||||||
0.067 | 586,217 | 1.59 | 551,922 | |||||||||
0.15 | 2,384,272 | 5.55 | 2,033,439 | |||||||||
0.18 | 670,000 | 8.48 | 305,000 | |||||||||
0.2 | 520,000 | 9.51 | 70,000 | |||||||||
0.32 | 30,000 | 8.12 | 10,000 | |||||||||
0.39 | 115,000 | 5.50 | 115,000 | |||||||||
0.4 | 110,000 | 4.48 | 110,000 | |||||||||
0.47 | 110,000 | 5.22 | 110,000 | |||||||||
0.75 | 80,000 | 3.18 | 80,000 | |||||||||
4,938,821 | 6.03 | 3,663,138 | ||||||||||
Compensation expense recorded by the Company in respect of its stock-based employee compensation award in accordance with ASC 718-10 for the year ended December 31, 2011 and 2010 amounted to $1,135 and $388, respectively.
The fair value of the options is estimated at the date of grant using a Black-Scholes options pricing model with the following assumptions used in the calculation:
Year ended December 31, | ||||||||
2011 | 2010 | |||||||
Expected volatility | 134%-141% | 134%-141% | ||||||
Risk-free interest | 1.14%-2.93% | 2.26%-3.47% | ||||||
Dividend yield | 0 | % | 0 | % | ||||
Expected life of up to (years) | 5-6 | 6-10 | ||||||
Forfeiture rate | 0 | 0 |
F-35 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
NOTE 11 - | STOCK CAPITAL (Cont.) |
B. | Issuance of shares, warrants and options: (Cont.) |
2. | Share-based compensation to employees and to directors: (Cont.) |
b) | Restricted shares to directors: |
On May 2, 2006, the Company issued to two of its directors 200,000 restricted shares of Common Stock (100,000 each). The restricted shares are subject to the Company's right to repurchase them at a purchase price of par value ($0.00005). The restrictions of the shares shall lapse in three annual and equal portions commencing with the grant date. The compensation related to the stock issued amounted to $104, which was amortized over the vesting period as general and administrative expenses.
On April 20, 2007, based on a board resolution dated March 21, 2007, the Company issued to a director 100,000 restricted shares of Common Stock. The restricted shares are subject to the Company's right to repurchase them at a purchase price of par value ($0.00005). The restrictions of the shares shall lapse in three annual and equal portions commencing with the grant date. The compensation related to the shares issued amounted to $47, which was amortized over the vesting period as general and administrative expenses.
In addition, on April 20, 2007, based on a board resolution dated March 21, 2007, the Company issued to another director 100,000 restricted shares of Common Stock. The restricted shares are not subject to any right to repurchase, and the compensation related to the shares issued amounted to $47 was recorded as prepaid general and administrative expenses in the three months ended March 31, 2007.
On August 27, 2008, the Company issued to its director 960,000 shares of Common Stock upon a cashless exercise by a shareholder of a warrant to purchase 1,000,000 shares of Common Stock at an exercise price of $.01 per share that was acquired by the shareholder from Ramot. The shares were allocated to the director by the shareholder.
In May 2010, based on a board resolution dated June 29, 2009, the Company issued to three of its directors 300,000 (total) restricted shares of Common Stock. The restrictions of the shares shall lapse in three annual and equal portions commencing with the grant date.
In May and in June 2010, based on a board resolution dated June 29, 2009, the Company issued to three of its Scientific Advisory Board members and two of its Advisory Board members 500,000 (total) restricted shares of Common Stock. The restrictions of the shares shall lapse in three annual and equal portions commencing with the grant date.
On December 16, 2010, the Company granted to two of its directors 400,000 (total) shares of Common Stock. Related compensation in the amount of $80 was recorded as general and administrative costs in 2010. These shares were actually granted in June 2011, and an additional related compensation in the amount of $112 was recorded as general and administrative expense.
On June 27, 2011, the Company granted to two of its directors 476,666 (total) shares of Common Stock, out of which 216,666 shares are fully vested and 260,000 shares will vest in 12 equal monthly installments through June 2012. Related compensation in the amount of $229 will be recorded as general and administrative expense.
F-36 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
On August 22, 2011, the Company entered into an agreement with Chen Schor (the “Executive Director Agreement”) pursuant to which the Company granted to Mr. Schor 923,374 shares of restricted Common Stock of the Company. The shares will vest over a three-year period. If the Company raises $10,000,000 of proceeds through the issuance of equity securities in a private or public offering after the Grant Date, or enters into a deal with a strategic partner that brings in at least $10,000,000 of gross proceeds, then 1/3 of the shares will vest upon such event, 1/3 will vest on the anniversary of the Grant Date and the remaining 1/3 will vest on the second anniversary of the Grant Date. If such capital is not raised as mentioned above, then the shares will vest over 3 years – 1/3 upon each anniversary of the Grant Date. In addition, the Company will pay $15,000 per quarter to Mr. Schor for his services as an Executive Board Member.
In August 2011, the Company issued to three of its Scientific Advisory Board members and three of its Advisory Board members a total of 300,000 restricted shares of Common Stock. The restrictions of the shares shall lapse in equal monthly portions over the service period.
In November 2011, the Company issued to four of its Advisory Board members a total of 500,000 restricted shares of Common Stock. The restrictions of the shares shall lapse in equal monthly portions over the service period.
In addition, in November 2011, the Company issued to a former director 250,000 shares of Common Stock. Related compensation in the amount of $70 was recorded as general and administrative expense.
3. | Shares and warrants to service providers: |
The Company accounts for shares and warrant grants issued to non-employees using the guidance of ASC 505-50, "Equity-Based Payments to Non-Employees" (formerly 718-10, "Accounting for Stock-Based Compensation") and EITTF 96-18, "Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling, Goods or Services," whereby the fair value of such option and warrant grants is determined using a Black-Scholes options pricing model at the earlier of the date at which the non-employee's performance is completed or a performance commitment is reached.
F-37 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
NOTE 11 - | STOCK CAPITAL (Cont.) |
B. | Issuance of shares, warrants and options: (Cont.) |
3. | Shares and warrants to service providers and investors: (Cont.) |
a) Warrants:
Issuance date | Number of warrants issued | Exercised | Forfeited | Outstanding | Exercise Price $ | Warrants exercisable | Exercisable through | |||||||||||||||||||||
November 2004 | 12,800,845 | 11,747,497 | 151,803 | 901,545 | 0.01 | 901,545 | November 2012 | |||||||||||||||||||||
December 2004 | 1,800,000 | 1,800,000 | - | 0.00005 | — | - | ||||||||||||||||||||||
February 2005 | 1,894,808 | 1,894,808 | - | 2.5 | - | - | ||||||||||||||||||||||
May 2005 | 47,500 | 47,500 | - | 1.62 | - | - | ||||||||||||||||||||||
June 2005 | 30,000 | 30,000 | 0.75 | 30,000 | June 2015 | |||||||||||||||||||||||
August 2005 | 70,000 | 70,000 | - | 0.15 | - | - | ||||||||||||||||||||||
September 2005 | 3,000 | 3,000 | - | 0.15 | - | - | ||||||||||||||||||||||
September 2005 | 36,000 | 36,000 | - | 0.75 | - | - | ||||||||||||||||||||||
September-December2005 | 500,000 | 500,000 | - | 1 | - | - | ||||||||||||||||||||||
December 2005 | 20,000 | 20,000 | - | 0.15 | - | - | ||||||||||||||||||||||
December 2005 | 457,163 | 150,000 | 307,163 | 0.15 | 307,163 | December 2015 | ||||||||||||||||||||||
February 2006 | 230,000 | 230,000 | 0.65 | 230,000 | February 2016 | |||||||||||||||||||||||
February 2006 | 40,000 | 40,000 | - | 1.5 | - | |||||||||||||||||||||||
February 2006 | 8,000 | 8,000 | - | 0.15 | - | |||||||||||||||||||||||
February 2006 | 189,000 | 97,696 | 91,304 | - | 0. 5 | - | - | |||||||||||||||||||||
May 2006 | 50,000 | 50,000 | 0.00005 | 50,000 | May 2016 | |||||||||||||||||||||||
May -December 2006 | 48,000 | 48,000 | - | 0.35 | - | |||||||||||||||||||||||
May -December 2006 | 48,000 | 48,000 | - | 0.75 | - | |||||||||||||||||||||||
May 2006 | 200,000 | 200,000 | 1 | 200,000 | May 2016 | |||||||||||||||||||||||
June 2006 | 24,000 | 24,000 | - | 0.15 | - | |||||||||||||||||||||||
May 2006 | 19,355 | 19,355 | - | 0.15 | - | |||||||||||||||||||||||
October 2006 | 630,000 | 630,000 | - | 0.3 | - | - | ||||||||||||||||||||||
December 2006 | 200,000 | 200,000 | - | 0.45 | - | - | ||||||||||||||||||||||
March 2007 | 200,000 | 200,000 | 0.47 | 200,000 | March 2012 | |||||||||||||||||||||||
March 2007 | 500,000 | 500,000 | 0.47 | 500,000 | March 2017 | |||||||||||||||||||||||
March 2007 | 50,000 | 50,000 | - | 0.15 | - | - | ||||||||||||||||||||||
March 2007 | 15,000 | 15,000 | 0.15 | 15,000 | February 2012 | |||||||||||||||||||||||
February 2007 | 50,000 | 50,000 | - | 0.45 | - | - | ||||||||||||||||||||||
March 2007 | 225,000 | 225,000 | - | 0.45 | - | - | ||||||||||||||||||||||
March 2007 | 50,000 | 50,000 | - | 0.45 | - | |||||||||||||||||||||||
April 2007 | 33,300 | 33,300 | - | 0.45 | - | - | ||||||||||||||||||||||
May 2007 | 250,000 | 250,000 | - | 0.45 | - | - | ||||||||||||||||||||||
July 2007 | 500,000 | 500,000 | 0.39 | 500,000 | July 2017 | |||||||||||||||||||||||
September 2007 | 500,000 | 500,000 | 0.15 | 500,000 | August 2017 | |||||||||||||||||||||||
August 2007 | 7,562,500 | 7,562,500 | 0.2 | 7,562,500 | November 2013 | |||||||||||||||||||||||
July 2007 | 30,000 | 30,000 | - | 0.45 | - | - | ||||||||||||||||||||||
July 2007 | 100,000 | 100,000 | - | 0.45 | - | - | ||||||||||||||||||||||
October 2007 | 200,000 | 200,000 | 0.15 | 200,000 | August-October2017 | |||||||||||||||||||||||
November 2007 | 2,520,833 | 2,520,833 | 0.20 | 2,520,833 | November 2013 | |||||||||||||||||||||||
November 2007 | 2,016,667 | 2,016,667 | 0.29 | 2,016,667 | November 2013 | |||||||||||||||||||||||
April 2008 | 4,537,500 | 4,537,500 | 0.29 | 4,537,500 | November 2013 | |||||||||||||||||||||||
August 2008 | 3,529,166 | 3,529,166 | 0.29 | 3,529,166 | November 2013 | |||||||||||||||||||||||
August 2008 | 1,008,334 | 1,008,334 | 0.29 | 1,008,334 | November 2013 | |||||||||||||||||||||||
November 2008 | 100,000 | 100,000 | 0.15 | 100,000 | September 2018 | |||||||||||||||||||||||
April 2009 | 200,000 | 200,000 | 0.1 | 200,000 | April 2019 | |||||||||||||||||||||||
October 2009 | 200,000 | 100,000 | 100,000 | 0.067 | 66,667 | October 2019 | ||||||||||||||||||||||
October 2009 | 4,537,500 | 4,537,500 | 0.29 | 4,537,500 | November 2013 | |||||||||||||||||||||||
January 2010 | 1,250,000 | 1,250,000 | 0.5 | 1,250,000 | January 2012 | |||||||||||||||||||||||
February 2010 | 125,000 | 125,000 | 0.001 | 125,000 | February 2012 | |||||||||||||||||||||||
February 2010 | 3,000,000 | 3,000,000 | 0.5 | 3,000,000 | February 2012 | |||||||||||||||||||||||
January 2011 | 4,537,500 | 4,537,500 | 0.29 | 4,537,500 | November 2013 | |||||||||||||||||||||||
February 2011 | 641,026 | 641,026 | 0.39 | 641,026 | February 2012 | |||||||||||||||||||||||
February 2011 | 6,407,500 | 946,834 | 5,460,666 | 0.28 | 5,460,666 | February 2012 | ||||||||||||||||||||||
February 2011 | 12,815,000 | 12,815,000 | 0.5 | 12,815,000 | February 2013 | |||||||||||||||||||||||
April 2010 | 33,334 | 33,334 | 0.00005 | 33,334 | April 2020 | |||||||||||||||||||||||
April 2011 | 33,334 | 33,334 | 0.00005 | 22,222 | April 2021 | |||||||||||||||||||||||
February 2010 | 1,500,000 | 1,500,000 | 0.01 | 500,000 | February 2020 | |||||||||||||||||||||||
78,604,165 | 15,495,027 | 3,967,070 | 59,142,068 | 58,064,289 |
F-38 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
NOTE 11 - | STOCK CAPITAL (Cont.) |
B. | Issuance of shares, warrants and options: (Cont.) |
3. | Shares and warrants to service providers: (Cont.) |
a) | Warrants: (Cont.) |
The fair value for the warrants to service providers was estimated on the date of grant using a Black-Scholes option pricing model, with the following weighted-average assumptions for the year ended December 31, 2011 and December 31, 2010; weighted average volatility of 138% and 126%-165%, respectively, risk free interest rates of 1.69% and 0.37%-2.12%, respectively, dividend yields of 0% and a weighted average life of the options of 5.2 and 1-9 years, respectively.
b) | Shares: |
On June 1 and June 4, 2004, the Company issued 40,000 and 150,000 shares of Common Stock for 12 months of filing services and legal and due-diligence services, respectively, with respect to a private placement. Compensation expense related to filing services, totaling $26, was amortized over a 12-month period. Compensation related to legal services, totaling $105 was recorded as equity issuance cost and had no effect on the statement of operations.
On July 1 and September 22, 2004, the Company issued 20,000 and 15,000 shares to a former director for financial services for the first and second quarters of 2004, respectively. Related compensation in the amount of $39 was recorded as general and administrative expense.
On February 10, 2005, the Company signed an agreement with one of its service providers under which the Company issued to the service provider 100,000 restricted shares at a purchase price of $0.00005 par value under the U.S. Stock Option and Incentive Plan of the Company. All restrictions on these shares have lapsed.
In March and April 2005, the Company signed an agreement with four members of its Scientific Advisory Board under which the Company issued to the members of the Scientific Advisory Board 400,000 restricted shares at a purchase price of $0.00005 par value under the U.S. Stock Option and Incentive Plan (100,000 each). All restrictions on these shares have lapsed.
F-39 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
NOTE 11 - | STOCK CAPITAL (Cont.) |
B. | Issuance of shares, warrants and options: (Cont.) |
3. | Shares and warrants to service providers: (Cont.) |
b) | Shares: (Cont.) |
In July 2005, the Company issued to its legal advisors 50,000 shares for legal services for 12 months. The compensation related to the shares in the amount of $37.5 was recorded as general and administrative expense.
In January 2006, the Company issued to two service providers 350,000 restricted shares at a purchase price of $0.00005 par value under the U.S. Stock Option and Incentive Plan of the Company. All restrictions on these shares have lapsed. Related compensation in the amount of $23 was recorded as general and administrative expense.
On March 6, 2006, the Company issued to its legal advisor 34,904 shares of Common Stock. The shares are in lieu of $18.5 payable to the legal advisor. Related compensation in the amount of $18.5 was recorded as general and administrative expense.
On April 13, 2006, the Company issued to service providers 60,000 shares at a purchase price of $0.00005 par value under the U.S Stock Option and Incentive Plan of the Company. Related compensation in the amount of $25.8 was recorded as general and administrative expense.
On May 9, 2006, the Company issued to its legal advisor 65,374 shares of Common Stock in lieu of payment for legal services. Related compensation in the amount of $33 was recorded as general and administrative expense.
On June 7, 2006, the Company issued 50,000 shares of Common Stock for filing services for 12 months. Related compensation in the amount of $24.5 was recorded as general and administrative expense.
On May 5, 2006, the Company issued 200,000 shares to a finance consultant for his services. Related compensation in the amount of $102 was recorded as general and administrative expense.
On August 14, 2006, the Company issued 200,000 shares to a service provider. Related compensation in the amount of $68 was recorded as general and administrative expense.
On August 17, 2006, the Company issued 100,000 shares to a service provider. Related compensation in the amount of $35 was recorded as general and administrative expense.
F-40 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
NOTE 11 - | STOCK CAPITAL (Cont.) |
B. | Issuance of shares, warrants and options: (Cont.) |
3. | Shares and warrants to service providers: (Cont.) |
b) | Shares: (Cont.) |
On September 17, 2006, the Company issued to its legal advisor 231,851 shares of Common Stock in lieu of $63 payable to the legal advisor. Related compensation in the amount of $63 was recorded as general and administrative expense.
On April 1 and September 30, 2006, the Company issued to its business development advisor, based on an agreement, 240,000 shares of Common Stock. Related compensation in the amount of $74 was recorded as general and administrative expense.
On January 3, 2007, the Company issued to its legal advisor 176,327 shares of Common Stock. The shares are for the $45 payable to the legal advisor. Related compensation in the amount of $49 was recorded as general and administrative expense.
On April 12, 2007, the Company issued to its filing and printing service providers 80,000 shares of Common Stock. The shares issued are for the $15 payable to the service provider. Related compensation in the amount of $30 was recorded as general and administrative expense. In addition, the Company is obligated to issue the filing and printing service providers additional shares, in the event that the total value of the shares previously issued (as quoted on the Over-the-Counter Bulletin Board or such other exchange where the Common Stock is quoted or listed) is less than $0.20, on March 20, 2008. In no event shall the Company issue more than 30,000 additional shares to the service providers. As a result, the Company recorded a liability in the amount of $20.
On April 12, 2007, the Company issued to its legal advisor 108,511 shares of Common Stock. The shares are for $29 payable to the legal advisor. Related compensation in the amount of $40 was recorded as general and administrative expense.
On May 18, 2007, the Company issued to its legal advisor 99,257 shares of Common Stock. The shares are for $33, payable to the legal advisor. Related compensation in the amount of $33 was recorded as general and administrative expense.
On October 29, 2007, the Company issued to a Scientific Advisory Board member 80,000 shares of the Company’s Common Stock for scientific services. Compensation of $67 was recorded as research and development expense.
On May 20, 2008, the Company issued to its finance advisor 90,000 shares of the Company's common stock. The shares are for $35 payable to the finance advisor for introduction fee of past convertible loans. Related compensation in the amount of $36 is recorded as finance expenses.
On April 5, 2009, the Company issued to its Chief Technology Advisor 1,800,000 shares of Common Stock. The shares are for $180 payable to the advisor. Related compensation in the amount of $144 was recorded as research and development expense.
F-41 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
NOTE 11 - | STOCK CAPITAL (Cont.) |
B. | Issuance of shares, warrants and options: (Cont.) |
3. | Shares and warrants to service providers: (Cont.) |
b) | Shares: (Cont.) |
On June 24, 2009, the Company issued to its public relations advisor 250,000 shares of Common Stock. The shares are for $25 payable to the advisor. Related compensation in the amount of $18 was recorded as general and administrative expense.
On July 8, 2009, the Company issued to its finance consultant 285,714 shares of the Company's Common Stock. The shares are for $20 payable to the finance consultant for valuation of options and warrants. Related compensation in the amount of $20 is recorded as general and administrative expense.
On July 15, 2009, the Company issued to its service provider 357,142 shares of the Company's Common Stock. The shares are for $25 payable to the service provider for filing services. Related compensation in the amount of $21 is recorded as general and administrative expense.
On August 10, 2009, the Company issued to its service provider 71,428 shares of the Company's Common Stock. The shares are for $5 payable to the service provider for IT services. Related compensation in the amount of $4 is recorded as general and administrative expense.
On October 1, 2009, the Company issued to its service provider 150,000 shares of the Company's Common Stock. The shares are for financial and investor relation services done by the provider. Related compensation in the amount of $51 is recorded as general and administrative expense.
On October 2, 2009, the Company issued to its service provider 1,250,000 shares of the Company's Common Stock. The shares are for investor and public relation services. Related compensation in the amount of $400 is recorded as general and administrative expense.
On December 30, 2009, the Company issued to Ramot 1,120,000 shares of the Company's Common Stock (see note 3).
On December 13, 2009, the Company issued a $135 Convertible Promissory Note to it legal advisor for $217 in legal fees accrued through October 31, 2009. Interest on the note accrued at the rate of 4%.
On January 5, 2010, the Company issued to its public relations advisor 50,000 shares of the Company's Common Stock for six months’ service. The issuance of the shares is part of the agreement with the public relations advisor that entitles it to a monthly grant of 8,333 shares of the Company's Common Stock.
On January 6, 2010, the Company issued to its service provider 60,000 shares of the Company's Common Stock. The shares are for $15 payable to the service provider for insurance and risk management consulting and agency services for three years.
On February 19, 2010, the Company's legal advisor converted the entire accrued principal and interest amount outstanding under the note into 402,385 shares of Common Stock.
F-42 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
NOTE 11 - | STOCK CAPITAL (Cont.) |
B. | Issuance of shares, warrants and options: (Cont.) |
3. | Shares and warrants to service providers: (Cont.) |
b) | Shares: (Cont.) |
On April 6, 2010, Prof. Melamed fully exercised his warrant to purchase 1,097,215 shares of the Company’s Common Stock. The warrant was issued to him pursuant to the agreement with the Consultants effective as of November 4, 2004 (See Note 4a).
In May 2010, based on a board resolution dated June 29, 2009, the Company issued to one of its public relations advisors 100,000 restricted shares of Common Stock. The restrictions of the shares shall lapse in three annual and equal portions commencing with the grant date.
On December 16, 2010, the Company granted to its service provider 200,000 shares of the Company's Common Stock. The shares are for investor and public relations services. Related compensation in the amount of $40 is recorded as general and administrative expense.
On December 16, 2010, the Company granted to its Chief Medical Advisor 900,000 shares of the Company's Common Stock for services rendered through December 31, 2010. Related compensation in the amount of $180 is recorded as research and development expense.
On December 16, 2010, the Company granted to its Chief Scientist 200,000 shares of the Company's Common Stock for services rendered through December 31, 2010. Related compensation in the amount of $40 is recorded as research and development expense.
On February 18, 2011, the Company's legal advisor converted the entire accrued principal and interest of the Convertible Promissory Note granted on September 15, 2010, totaling $137, into 445,617 shares of Common Stock.
On June 27, 2011, the Company granted to its legal advisor 180,000 shares of Common Stock for 2011 legal services. Half of the shares of Common Stock are fully vested and half vest in six equal monthly installments through December 2011. Related compensation in the amount of $86 is recorded as general and administrative expense.
On June 27, 2011, the Company granted to its consultant 400,000 shares of the Company's Common Stock, for services rendered through December 31, 2009. Related compensation in the amount of $192 is recorded as research and development expense. (See note 4 C)
On June 27, 2011, the Company granted to a service provider 10,870 shares of the Company's Common Stock. Related compensation in the amount of $5 is recorded as general and administrative expense.
On December 31, 2011, the Company issued to Hadasit warrants to purchase up to 1,500,000 restricted shares of the Company's Common Stock at an exercise price of $0.001 per share, exercisable for a period of 5 years. The warrants shall vest over the course of the trials as follows: 500,000 upon enrollment of 1/3 of the patients; an additional 500,000 upon enrollment of all the patients and the final 500,000 upon completion of the study.
F-43 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
In 2011, three consultants of the Company exercised 462,128 options for $31.
A summary of the Company's stock awards activity related to shares issued to service providers and related information is as follows:
Year ended December 31, | Year ended December 31, | |||||||||||||||
2011 | 2010 | |||||||||||||||
Amount of shares | Weighted average issue price | Amount of shares | Weighted average issue price | |||||||||||||
$ | $ | |||||||||||||||
Outstanding at beginning of period | 9,735,508 | 0.25 | 8,225,508 | 0.26 | ||||||||||||
Issued | 1,265,870 | 0.41 | 1,510,000 | 0.20 | ||||||||||||
Outstanding at end of period | 11,001,378 | 0.27 | 9,735,508 | 0.25 |
c) | Stock-based compensation and issuance of shares recorded by the Company in respect of shares and warrants granted to service providers amounted to $449 and $96 for the year ended December 31, 2011 and 2010, respectively. |
The total stock-based compensation expense, related to shares, options and warrants granted to employees and service providers, was comprised, at each period, as follows:
Year ended December 31, | Period from September 22, 2000 (inception date) through December 31, | |||||||||
2011 | 2010 | 2011 | ||||||||
U.S. $ in thousands | ||||||||||
Research and development | $ | 316 | $ | 325 | $ | 17,556 | ||||
General and administrative | 1,075 | 560 | 10,113 | |||||||
Financial expenses, net | 192 | - | 248 | |||||||
Total stock-based compensation expense | $ | 1,584 | $ | 885 | $ | 27,917 |
F-44 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
NOTE 12 - | RESEARCH AND DEVELOPMENT, NET |
Year ended December 31, | Period from September 22, 2000 (inception date) through December 31, | |||||||||||
2011 | 2010 | 2011 | ||||||||||
U.S. $ in thousands | ||||||||||||
Research and development | 2,077 | 1,385 | 26,833 | |||||||||
Less : Ramot reverse accruals (See Note 3) | - | (760 | ) | |||||||||
Less : Participation by the Israeli Office of the Chief Scientist | (388 | ) | (340 | ) | (1,654 | ) | ||||||
1,689 | 1,045 | 24,419 |
NOTE 13 - | TAXES ON INCOME |
A. | Tax rates applicable to the income of the subsidiary: |
The corporate tax rate in Israel is as follows: 2008 - 27%, 2009 - 26%, 2010 - 25%, 2011 - 24%. In July 2009, the “Knesset” (Israeli parliament) passed the Economic Efficiency Law (Legislative Amendments for implementation of the economic plan for 2009 and 2010) of 2009 which defines, inter alia, further gradual reductions of corporate tax rates and real capital gains tax, in Israel, starting in 2011, to the following rates: 2012 - 23%, 2013 - 22%, 2014 - 21%, 2015 - 20% and in 2016 and onwards - 18%. Such tax reductions have no significant impact on the Company's financial statements.
In February 2008, the "Knesset" passed an amendment to the Income Tax (Inflationary Adjustments) Law, 1985, which limits the scope of the law beginning in 2008 and thereafter. Beginning in 2008, the results for tax purposes will be measured in nominal values, excluding certain adjustments for changes in the Consumer Price Index carried out in the period up to December 31, 2007. The amended law includes, inter alia, the elimination of the inflationary additions and deductions and the additional deduction for depreciation starting in 2008.
On September 26, 2011, the Social-Economic Reform Committee headed by Professor Manuel Trajtenberg published a report with its recommendations. Consequently, on December 6, 2011, the Law for Change in the Tax Burden (Legislative Amendments), based on the recommendations in the Tax Section of that report, was published, after being approved in a third reading in the Israeli Knesset.
The main changes of the new law regarding corporate income taxes are as follows:
1. Cancellation of the planned gradual reduction of income taxes and corporate income taxes commencing in 2012.
2. Increase of the corporate income tax rate to 25% in 2012.
3. Increase of the capital gains tax rate and betterment tax rate to 25%.
Such tax rate changes have no significant impact on the Company's financial statements.
B. | Tax laws applicable to the income of the Subsidiary: |
Income Tax (Inflationary Adjustments) Law, 1985:
According to the law, the results for tax purposes are measured based on the changes in the Israeli Consumer Price Index ("CPI").
The Law for the Encouragement of Capital Investments, 1959 ("the Law"):
According to the Law, BCT is entitled to various tax benefits by virtue of "beneficiary enterprise" status granted, as defined by this Law.
In March 2005, the Israeli Parliament passed the Arrangements Law for fiscal year 2005, which includes a broad and comprehensive amendment to the provisions of the Law ("Amendment No. 60 to the Law").
The principal benefits by virtue of the Law are:
Tax benefits and reduced tax rates under the Alternative Track of Benefits:
The Company is tax exempt for a benefit period of two years and in the five/eight subsequent years of the benefit period is subject to a reduced tax rate of 10%-25%.
On January 6, 2011, an amendment to the Law for the Encouragement of Capital Investment-1959 (the "Law") was published. The amendment has a substantial effect on the current provisions of the Law. The following are the major changes in the amendment:
F-45 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
NOTE 13 - | TAXES ON INCOME (Cont.) |
1. | A company located in Preferred Area A can file for both grants and tax benefits. |
2. | The requisites for benefits were changed with the most significant change that the minimum investment requirement was removed. In addition, the definition of approved entity was changed. |
3. | The income attribution based on revenues was cancelled, the result is that an approved entity would be taxable on its entire income at a fixed rate. |
4. | Tax exemption was cancelled. |
5. | Dividend payable to Israeli corporations from preferred income would be tax exempt. |
6. | The Grant Rate out of the approved investment would be up to 24%. |
The Tax rates applicable to Approved Industrial Enterprise would be 6% and 12% for those located in Preferred Area A or elsewhere, respectively, with effectiveness for the taxable year 2 of 2015 and onwards. Prior to 2015, the following tax rates will be applicable:
For the years 2011-2012 10% and 15%, respectively and for the years 2013-2014 7% and 12.5%, respectively. The amendment to the law is not expected to have a material impact on the Company's consolidated financial statements.
C. | Deferred income taxes: |
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company's deferred tax assets are as follows:
December 31, | ||||||||
2011 | 2010 | |||||||
U.S. $ in thousands | ||||||||
Operating loss carryforward | 32,165 | 30,206 | ||||||
Net deferred tax asset before valuation allowance | 13,187 | 12,858 | ||||||
Valuation allowance | (13,187 | ) | (12,858 | ) | ||||
Net deferred tax asset | - | - |
As of December 31, 2010, the Company has provided valuation allowances of $13,012 in respect of deferred tax assets resulting from tax loss carryforward and other temporary differences. Management currently believes that because the Company has a history of losses, it is more likely than not that the deferred tax regarding the loss carryforward and other temporary differences will not be realized in the foreseeable future.
D. | Available carryforward tax losses: |
As of December 31, 2010, the Company has an accumulated tax loss carryforward of approximately $12,716. Carryforward tax losses in the U.S. can be carried forward and offset against taxable income in the future for a period of 20 years. Utilization of U.S. net operating losses may be subject to substantial annual limitations due to the "change in ownership" provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization.
E. | Loss from continuing operations, before taxes on income, consists of the following: |
Year ended December 31, | ||||||||
2011 | 2010 | |||||||
U.S. $ in thousands | ||||||||
United States | (1,886 | ) | (1,235 | ) | ||||
Israel | (2,032 | ) | (1,165 | ) | ||||
(3,918 | ) | (2,400 | ) |
F-46 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
U.S. dollars in thousands
NOTE 13 - | TAXES ON INCOME (Cont.) |
F. | Due to the Company’s cumulative losses, the effect of ASC 740 as codified from ASC 740-10 (formerly FIN 48) is not material. |
G. | BCT has not received final tax assessments since its incorporation. |
NOTE 14 - | TRANSACTIONS WITH RELATED PARTIES |
Year ended December 31, | ||||||||
2011 | 2010 | |||||||
U.S. $ in thousands | ||||||||
A. Fees and related benefits and compensation expenses in respect of options granted to a member of the Board who is a related party | 150 | 318 |
B. | As for transactions with Ramot, see Note 3. |
NOTE 15 - | SUBSEQUENT EVENTS |
A. | In January 2012, one of the Company’s service providers exercised a warrant for 125,000 shares of Common Stock of the Company. |
B. | On February 3, 2012, the Company filed an S-1 Registration Statement with the Securities and Exchange Commission. |
C. | In February 2012, the former CEO exercised options to purchase 132,038 shares of Common Stock. |
F-47 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands
(Except share data)
March 31, | December 31, | |||||||
2012 | 2011 | |||||||
Unaudited | Audited | |||||||
ASSETS | ||||||||
Current Assets: | ||||||||
Cash and cash equivalents | 1,145 | 1,923 | ||||||
Account receivable | 482 | 312 | ||||||
Prepaid expenses | 148 | 69 | ||||||
Total current assets | 1,775 | 2,304 | ||||||
Long-Term Investments: | ||||||||
Prepaid expenses | 17 | 17 | ||||||
Severance payment fund | 129 | 109 | ||||||
Total long-term investments | 146 | 126 | ||||||
Property and Equipment, Net | 328 | 314 | ||||||
Total assets | 2,249 | 2,744 | ||||||
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY) | ||||||||
Current Liabilities: | ||||||||
Trade payables | 325 | 244 | ||||||
Accrued expenses | 839 | 750 | ||||||
Other accounts payable | 126 | 141 | ||||||
Total current liabilities | 1,290 | 1,135 | ||||||
Accrued Severance Pay | 142 | 121 | ||||||
Total liabilities | 1,432 | 1,256 | ||||||
Commitments And Contingencies Stockholders' Equity: | ||||||||
Stock capital: (Note 8) | 6 | 6 | ||||||
Common stock of $0.00005 par value - Authorized: 800,000,000 shares at March 31, 2012 and December 31, 2011; Issued and outstanding: 126,737,158 and 126,444,309 shares at March 31, 2012 and December 31, 2011 respectively. | ||||||||
Additional paid-in-capital | 45,761 | 45,560 | ||||||
Deficit accumulated during the development stage | (44,950 | ) | (44,078 | ) | ||||
Total stockholders' equity | 817 | 1,488 | ||||||
Total liabilities and stockholders' equity | 2,249 | 2,744 |
The accompanying notes are an integral part of the consolidated financial statements.
F-48 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
CONSOLIDATED STATEMENTS OF OPERATIONS
U.S. dollars in thousands
(Except share data)
Three months | Period from September 22, 2000 (inception date) through | |||||||||||
ended March 31 | March 31, | |||||||||||
2012 | 2011 | 2012 (*) | ||||||||||
Unaudited | Unaudited | |||||||||||
Operating costs and expenses: | ||||||||||||
Research and development, net | 369 | 270 | 24,788 | |||||||||
General and administrative | 510 | 258 | 17,513 | |||||||||
Total operating costs and expenses | 879 | 528 | 42,301 | |||||||||
Financial expenses (income), net | (11 | ) | 177 | 2,536 | ||||||||
Other income | - | - | (132 | ) | ||||||||
Operating loss | 868 | 705 | 44,705 | |||||||||
Taxes on income | 4 | - | 81 | |||||||||
Loss from continuing operations | 872 | 705 | 44,786 | |||||||||
Net loss from discontinued operations | - | - | 164 | |||||||||
Net loss | 872 | 705 | 44,950 | |||||||||
Basic and diluted net loss per share from continuing operations | 0.01 | 0.01 | ||||||||||
Weighted average number of shares outstanding used in computing basic and diluted net loss per share | 126,591,262 | 108,895,199 |
(*) Out of which, $163, relating to the period from inception to March 31 2004, is unaudited.
The accompanying notes are an integral part of the consolidated financial statements
F-49 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)
U.S. dollars in thousands
(except share data)
Deficit accumulated | Total | |||||||||||||||||||||||
Common stock | Additional paid-in | Deferred Stock - based | during the development | stockholders' equity | ||||||||||||||||||||
Number | Amount | capital | compensation | stage | (deficiency) | |||||||||||||||||||
Balance as of September 22, 2000 (date of inception) (unaudited) | - | $ | - | $ | - | $ | - | $ | - | $ | - | |||||||||||||
Stock issued on September 22, 2000 for cash at $0.00188 per share | 8,500,000 | 1 | 16 | - | - | 17 | ||||||||||||||||||
Stock issued on March 31, 2001 for cash at $0.0375 per share | 1,600,000 | * - | 60 | - | - | 60 | ||||||||||||||||||
Contribution of capital | - | - | 8 | - | - | 8 | ||||||||||||||||||
Net loss | - | - | - | - | (17 | ) | (17 | ) | ||||||||||||||||
Balance as of March 31, 2001 (unaudited) | 10,100,000 | 1 | 84 | - | (17 | ) | 68 | |||||||||||||||||
Contribution of capital | - | - | 11 | - | - | 11 | ||||||||||||||||||
Net loss | - | - | - | - | (26 | ) | (26 | ) | ||||||||||||||||
Balance as of March 31, 2002 (unaudited) | 10,100,000 | 1 | 95 | - | (43 | ) | 53 | |||||||||||||||||
Contribution of capital | - | - | 15 | - | - | 15 | ||||||||||||||||||
Net loss | - | - | - | - | (47 | ) | (47 | ) | ||||||||||||||||
Balance as of March 31, 2003 (unaudited) | 10,100,000 | 1 | 110 | - | (90 | ) | 21 | |||||||||||||||||
2-for-1 stock split | 10,100,000 | * - | - | - | - | - | ||||||||||||||||||
Stock issued on August 31, 2003 to purchase mineral option at $0.065 per share | 100,000 | * - | 6 | - | - | 6 | ||||||||||||||||||
Cancellation of shares granted to Company's President | (10,062,000 | ) | * - | * - | - | - | - | |||||||||||||||||
Contribution of capital | - | * - | 15 | - | - | 15 | ||||||||||||||||||
Net loss | - | - | - | - | (73 | ) | (73 | ) | ||||||||||||||||
Balance as of March 31, 2004 (unaudited) | 10,238,000 | $ | 1 | $ | 131 | $ | - | $ | (163 | ) | $ | (31 | ) |
* Represents an amount less than $1.
The accompanying notes are an integral part of the consolidated financial statements
F-50 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)
U.S. dollars in thousands
(Except share data)
Deficit accumulated | Total | |||||||||||||||||||||||
Common stock | Additional paid-in | Deferred Stock - based | during the development | stockholders' equity | ||||||||||||||||||||
Number | Amount | capital | compensation | stage | (deficiency) | |||||||||||||||||||
Balance as of March 31, 2004 | 10,238,000 | $ | 1 | $ | 131 | $ | - | $ | (163 | ) | $ | (31 | ) | |||||||||||
Stock issued on June 24, 2004 for private placement at $0.01 per share, net of $25,000 issuance expenses | 8,510,000 | * - | 60 | - | - | 60 | ||||||||||||||||||
Contribution capital | - | - | 7 | - | - | 7 | ||||||||||||||||||
Stock issued in 2004 for private placement at $0.75 per unit | 1,894,808 | * - | 1,418 | - | - | 1,418 | ||||||||||||||||||
Cancellation of shares granted to service providers | (1,800,000 | ) | * - | - | - | - | ||||||||||||||||||
Deferred stock-based compensation related to options granted to employees | - | - | 5,979 | (5,979 | ) | - | - | |||||||||||||||||
Amortization of deferred stock-based compensation related to shares and options granted to employees | - | - | - | 584 | - | 584 | ||||||||||||||||||
Compensation related to shares and options granted to service providers | 2,025,000 | * - | 17,506 | - | - | 17,506 | ||||||||||||||||||
Net loss | - | - | - | - | (18,840 | ) | (18,840 | ) | ||||||||||||||||
Balance as of March 31, 2005 | 20,867,808 | $ | 1 | $ | 25,101 | $ | (5,395 | ) | $ | (19,003 | ) | $ | 704 |
* Represents an amount less than $1.
The accompanying notes are an integral part of the consolidated financial statements
F-51 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)
U.S. dollars in thousands
(except share data)
Deficit accumulated | Total | |||||||||||||||||||||||
Additional | Deferred | during the | stockholders' | |||||||||||||||||||||
Common stock | paid-in | Stock - based | development | equity | ||||||||||||||||||||
Number | Amount | capital | compensation | stage | (deficiency) | |||||||||||||||||||
Balance as of March 31, 2005 | 20,867,808 | $ | 1 | $ | 25,101 | $ | (5,395 | ) | $ | (19,003 | ) | $ | 704 | |||||||||||
Stock issued on May 12, 2005 for private placement at $0.8 per share | 186,875 | * - | 149 | - | - | 149 | ||||||||||||||||||
Stock issued on July 27, 2005 for private placement at $0.6 per share | 165,000 | * - | 99 | - | - | 99 | ||||||||||||||||||
Stock issued on September 30, 2005 for private placement at $0.8 per share | 312,500 | * - | 225 | - | - | 225 | ||||||||||||||||||
Stock issued on December 7, 2005 for private placement at $0.8 per share | 187,500 | * - | 135 | - | - | 135 | ||||||||||||||||||
Forfeiture of options granted to employees | - | - | (3,363 | ) | 3,363 | - | - | |||||||||||||||||
Deferred stock-based compensation related to shares and options granted to directors and employees | 200,000 | * - | 486 | (486 | ) | - | - | |||||||||||||||||
Amortization of deferred stock-based compensation related to options and shares granted to employees and directors | - | - | 51 | 1,123 | - | 1,174 | ||||||||||||||||||
Stock-based compensation related to options and shares granted to service providers | 934,904 | * - | 662 | - | - | 662 | ||||||||||||||||||
Reclassification due to application of ASC 815-40-25 (formerly EITF 00-19) | - | - | (7,906 | ) | (7,906 | ) | ||||||||||||||||||
Beneficial conversion feature related to a convertible bridge loan | - | - | 164 | - | - | 164 | ||||||||||||||||||
Net loss | - | - | - | - | (3,317 | ) | (3,317 | ) | ||||||||||||||||
Balance as of March 31, 2006 | 22,854,587 | $ | 1 | $ | 15,803 | $ | (1,395 | ) | $ | (22,320 | ) | $ | (7,911 | ) | ||||||||||
Elimination of deferred stock compensation due to implementation of ASC 718-10 (formerly SFAS 123(R)) | - | - | (1,395 | ) | 1,395 | - | - | |||||||||||||||||
Stock-based compensation related to shares and options granted to directors and employees | 200,000 | * - | 1,168 | - | - | 1,168 | ||||||||||||||||||
Reclassification due to application of ASC 815-40-25 (formerly EITF 00-19) | - | - | 7,191 | - | - | 7,191 | ||||||||||||||||||
Stock-based compensation related to options and shares granted to service providers | 1,147,225 | - | 453 | - | - | 453 | ||||||||||||||||||
Warrants issued to convertible note holder | - | - | 11 | - | - | 11 | ||||||||||||||||||
Warrants issued to loan holder | - | - | 110 | - | - | 110 | ||||||||||||||||||
Beneficial conversion feature related to convertible bridge loans | - | - | 1,086 | - | - | 1,086 | ||||||||||||||||||
Net loss | - | - | - | - | (3,924 | ) | (3,924 | ) | ||||||||||||||||
Balance as of December 31, 2006 | 24,201,812 | $ | 1 | $ | 24,427 | $ | - | $ | (26,244 | ) | $ | (1,816 | ) |
* Represents an amount less than $1. The accompanying notes are an integral part of the consolidated financial statements
F-52 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)
U.S. dollars in thousands
(Except share data)
Deficit accumulated | Total | |||||||||||||||||||||||
Additional | Deferred | during the | stockholders' | |||||||||||||||||||||
Common stock | paid-in | Stock - based | development | equity | ||||||||||||||||||||
Number | Capital | compensation | stage | stage | (deficiency) | |||||||||||||||||||
Balance as of December 31, 2006 | 24,201,812 | $ | 1 | $ | 24,427 | $ | - | $ | (26,244 | ) | $ | (1,816 | ) | |||||||||||
Stock-based compensation related to options and shares granted to service providers | 544,095 | 1,446 | - | - | 1,446 | |||||||||||||||||||
Warrants issued to convertible note holder | - | - | 109 | - | - | 109 | ||||||||||||||||||
Stock-based compensation related to shares and options granted to directors and employees | 200,000 | * - | 1,232 | - | - | 1,232 | ||||||||||||||||||
Beneficial conversion feature related to convertible loans | - | - | 407 | - | - | 407 | ||||||||||||||||||
Conversion of convertible loans | 725,881 | * - | 224 | - | - | 224 | ||||||||||||||||||
Exercise of warrants | 3,832,621 | * - | 214 | - | - | 214 | ||||||||||||||||||
Stock issued for private placement at $0.1818 per unit, net of finder's fee | 11,500,000 | 1 | 1,999 | - | - | 2,000 | ||||||||||||||||||
Net loss | - | - | - | - | (6,244 | ) | (6,244 | ) | ||||||||||||||||
Balance as of December 31, 2007 | 41,004,409 | $ | 2 | $ | 30,058 | $ | - | $ | (32,488 | ) | $ | (2,428 | ) | |||||||||||
Stock-based compensation related to options and stock granted to service providers | 90,000 | - | 33 | - | - | 33 | ||||||||||||||||||
Stock-based compensation related to stock and options granted to directors and employees | - | - | 731 | - | - | 731 | ||||||||||||||||||
Conversion of convertible loans | 3,644,610 | * - | 1,276 | - | - | 1,276 | ||||||||||||||||||
Exercise of warrants | 1,860,000 | * - | - | - | - | - | ||||||||||||||||||
Exercise of options | 17,399 | * - | 3 | - | - | 3 | ||||||||||||||||||
Stock issued for private placement at $0.1818 per unit, net of finder's fee | 8,625,000 | 1 | 1,499 | - | - | 1,500 | ||||||||||||||||||
Subscription of shares for private placement at $0.1818 per unit | - | - | 281 | - | - | 281 | ||||||||||||||||||
Net loss | - | - | - | - | (3,472 | ) | (3,472 | ) | ||||||||||||||||
Balance as of December 31, 2008 | 55,241,418 | $ | 3 | $ | 33,881 | $ | - | $ | (35,960 | ) | $ | (2,076 | ) |
* Represents an amount less than $1. The accompanying notes are an integral part of the consolidated financial statements
F-53 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)
U.S. dollars in thousands
(Except share data)
Common stock | Additional paid-in | Deferred stock - based | Deficit
accumulated during the development | Total
stockholders' equity | ||||||||||||||||||||
Number | Amount | capital | compensation | stage | (deficiency) | |||||||||||||||||||
Balance as of December 31, 2008 | 55,241,418 | $ | 3 | $ | 33,881 | $ | - | $ | (35,960 | ) | $ | (2,076 | ) | |||||||||||
Stock-based compensation related to options and stock granted to service providers | 5,284,284 | (* | ) | 775 | - | - | 775 | |||||||||||||||||
Stock-based compensation related to stock and options granted to directors and employees | - | - | 409 | - | - | 409 | ||||||||||||||||||
Conversion of convertible loans | 2,500,000 | (* | ) | 200 | - | - | 200 | |||||||||||||||||
Exercise of warrants | 3,366,783 | (* | ) | - | - | - | - | |||||||||||||||||
Stock issued for amendment of private placement | 9,916,667 | 1 | - | - | - | 1 | ||||||||||||||||||
Subscription of shares | - | - | 729 | - | - | 729 | ||||||||||||||||||
Net loss | - | - | - | - | $ | (1,781 | ) | (1,781 | ) | |||||||||||||||
Balance as of December 31, 2009 | 76,309,152 | $ | 4 | $ | 35,994 | $ | - | $ | (37,741 | ) | $ | (1,743 | ) |
* Represents an amount less than $1.
The accompanying notes are an integral part of the consolidated financial statements
F-54 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)
U.S. dollars in thousands
(Except share data)
Deficit | ||||||||||||||||||||||||
accumulated | Total | |||||||||||||||||||||||
Common stock | Additional
paid-in | Deferred
Stock - based | during the
development | stockholders'
equity | ||||||||||||||||||||
Number | Amount | capital | compensation | stage | (deficiency) | |||||||||||||||||||
Balance as of December 31, 2009 | 76,309,152 | $ | 4 | $ | 35,994 | $ | - | $ | (37,741 | ) | $ | (1,743 | ) | |||||||||||
Stock-based compensation related to options and stock granted to service providers | 443,333 | * - | 96 | - | - | 96 | ||||||||||||||||||
Stock-based compensation related to stock and options granted to directors and employees | 466,667 | * - | 388 | - | - | 388 | ||||||||||||||||||
Stock issued for amendment of private placement | 7,250,000 | 1 | 1,750 | - | - | 1,751 | ||||||||||||||||||
Conversion of convertible note | 402,385 | * - | 135 | - | - | 135 | ||||||||||||||||||
Conversion of convertible loans | 1,016,109 | * - | 189 | - | - | 189 | ||||||||||||||||||
Issuance of shares | 2,475,000 | 400 | 400 | |||||||||||||||||||||
Exercise of options | 1,540,885 | * - | 77 | - | - | 77 | ||||||||||||||||||
Exercise of warrants | 3,929,446 | * - | 11 | - | - | 11 | ||||||||||||||||||
Subscription of shares for private placement at $0.12 per unit | - | 455 | - | - | 455 | |||||||||||||||||||
Conversion of trade payable to stock | - | 201 | - | - | 201 | |||||||||||||||||||
Issuance of shares on account of previously subscribed shares (See also Note 8 B.1.f) | 2,000,001 | * - | - | - | - | - | ||||||||||||||||||
Net loss | (2,419 | ) | (2,419 | ) | ||||||||||||||||||||
Balance as of December 31, 2010 | 95,832,978 | $ | 5 | $ | 39,696 | $ | - | $ | (40,160 | ) | $ | (459 | ) |
* Represents an amount less than $1.
The accompanying notes are an integral part of the consolidated financial statements
F-55 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)
U.S. dollars in thousands
(except share data)
Deficit | ||||||||||||||||||||||||
accumulated | Total | |||||||||||||||||||||||
Common stock | Additional paid-in | Deferred Stock - based | during the development | stockholders' equity | ||||||||||||||||||||
Number | Amount | capital | compensation | Stage | (deficiency) | |||||||||||||||||||
Balance as of December 31, 2010 | 95,832,978 | $ | 5 | $ | 39,696 | $ | - | $ | (40,160 | ) | $ | (459 | ) | |||||||||||
Stock-based compensation related to options and stock granted to service providers | - | (20 | ) | - | - | (20 | ) | |||||||||||||||||
Stock-based compensation related to stock and options granted to directors and employees | - | 27 | - | - | 27 | |||||||||||||||||||
Stock issued for private placement | 833,333 | - | 250 | - | - | 250 | ||||||||||||||||||
Conversion of convertible note | 445,617 | - | 137 | - | - | 137 | ||||||||||||||||||
Exercise of options , net | 94,764 | - | 55 | - | - | 55 | ||||||||||||||||||
Stock issued for private placement | 13,327,600 | 1 | 3,356 | - | - | 3,357 | ||||||||||||||||||
Issuance of shares on account of previously subscribed shares (See also Note 8 B.1.f) | 10,499,999 | - | 24 | - | - | 24 | ||||||||||||||||||
Net loss | (705 | ) | (705 | ) | ||||||||||||||||||||
Balance as of March 31, 2011 | 121,034,291 | $ | 6 | $ | 43,525 | $ | - | $ | (40,865 | ) | $ | 2,666 |
* Represents an amount less than $1.
The accompanying notes are an integral part of the consolidated financial statements.
F-56 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)
U.S. dollars in thousands
(Except share data)
Deficit | ||||||||||||||||||||||||
Accumulated | Total | |||||||||||||||||||||||
Common stock | Additional paid-in | Deferred Stock - based | during the
development | stockholders'
equity | ||||||||||||||||||||
Number | Amount | capital | compensation | Stage | (deficiency) | |||||||||||||||||||
Balance as of December 31, 2010 | 95,832,978 | $ | 5 | $ | 39,696 | $ | - | $ | (40,160 | ) | $ | (459 | ) | |||||||||||
Stock-based compensation related to options and stock granted to service providers | 474,203 | - | 449 | - | - | 449 | ||||||||||||||||||
Stock-based compensation related to stock and options granted to directors and employees | 2,025,040 | - | 1,135 | - | - | 1,135 | ||||||||||||||||||
Conversion of convertible note | 755,594 | - | 140 | - | - | 140 | ||||||||||||||||||
Exercise of options | 1,648,728 | - | 243 | - | - | 243 | ||||||||||||||||||
Exercise of warrants | 1,046,834 | - | 272 | - | - | 272 | ||||||||||||||||||
Issuance of shares for private placement | 14,160,933 | 1 | 3,601 | - | - | 3,602 | ||||||||||||||||||
Issuance of shares on account of previously subscribed shares (See Note 8 B.1.f) | 10,499,999 | - | 24 | - | - | 24 | ||||||||||||||||||
Net loss | - | - | - | - | (3,918 | ) | (3,918 | ) | ||||||||||||||||
Balance as of December 31, 2011 | 126,444,309 | $ | 6 | $ | 45,560 | $ | - | $ | (44,078 | ) | $ | 1,488 |
* Represents an amount less than $1.
The accompanying notes are an integral part of the consolidated financial statements.
F-57 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)
U.S. dollars in thousands
(except share data)
Deficit | ||||||||||||||||||||||||
accumulated | Total | |||||||||||||||||||||||
Common stock | Additional
paid-in | Deferred
Stock - based | during the
development | stockholders'
equity | ||||||||||||||||||||
Number | Amount | capital | compensation | stage | (deficiency) | |||||||||||||||||||
Balance as of December 31, 2011 | 126,444,309 | $ | 6 | $ | 45,560 | $ | - | $ | (44,078 | ) | $ | 1,488 | ||||||||||||
Stock-based compensation related to options and stock granted to service providers | - | 4 | - | - | 4 | |||||||||||||||||||
Stock-based compensation related to stock and options granted to directors and employees | - | 177 | - | - | 177 | |||||||||||||||||||
Exercise of options | 167,849 | - | 20 | - | - | 20 | ||||||||||||||||||
Exercise of warrants | 125,000 | - | (* | ) | - | - | (* | ) | ||||||||||||||||
Net loss | - | - | - | - | (872 | ) | (872 | ) | ||||||||||||||||
Balance as of March 31, 2012 | 126,737,158 | $ | 6 | $ | 45,761 | $ | - | $ | (44,950 | ) | $ | 817 |
* Represents an amount less than $1.
The accompanying notes are an integral part of the consolidated financial statements.
F-58 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
CONSOLIDATED STATEMENTS OF CASH FLOWS
U.S. dollars in thousands
(except share data)
Period from | ||||||||||||
September 22, 2000 | ||||||||||||
Three months | (inception date) | |||||||||||
ended March 31 | through March 31, | |||||||||||
2012 | 2011 | 2012 (*) | ||||||||||
Unaudited | Unaudited | |||||||||||
Cash flows from operating activities: | ||||||||||||
Net loss | (872 | ) | (705 | ) | (44,950 | ) | ||||||
Less - loss for the period from discontinued operations | - | - | 164 | |||||||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||||||
Depreciation and amortization of deferred charges | 38 | 38 | 1,039 | |||||||||
Severance pay, net | 1 | (8 | ) | 13 | ||||||||
Accrued interest on loans | - | - | 451 | |||||||||
Amortization of discount on short-term loans | - | - | 1,864 | |||||||||
Change in fair value of options and warrants | - | - | (795 | ) | ||||||||
Expenses related to shares and options granted to service providers | 4 | (20 | ) | 21,490 | ||||||||
Stock-based compensation related to options granted to employees | 177 | 27 | 6,998 | |||||||||
Decrease (increase) in accounts receivable and prepaid expenses | (249 | ) | 265 | (630 | ) | |||||||
Increase in trade payables and convertible note | 81 | 94 | 798 | |||||||||
Increase in other accounts payable and accrued expenses | 74 | 254 | 1,471 | |||||||||
Erosion of restricted cash | - | - | (6 | ) | ||||||||
Net cash used in continuing operating activities | (746 | ) | (55 | ) | (12,093 | ) | ||||||
Net cash used in discontinued operating activities | - | - | (23 | ) | ||||||||
Total net cash used in operating activities | (746 | ) | (55 | ) | (12,116 | ) | ||||||
Cash flows from investing activities: | ||||||||||||
Purchase of property and equipment | (52 | ) | (37 | ) | (1,185 | ) | ||||||
Restricted cash | - | - | 6 | |||||||||
Investment in lease deposit | - | 1 | (17 | ) | ||||||||
Net cash used in continuing investing activities | (52 | ) | (36 | ) | (1,196 | ) | ||||||
Net cash used in discontinued investing activities | - | - | (16 | ) | ||||||||
Total net cash used in investing activities | (52 | ) | (36 | ) | (1,212 | ) | ||||||
Cash flows from financing activities: | ||||||||||||
Proceeds from issuance of Common stock, net | - | 3,607 | 12,319 | |||||||||
Proceeds from loans, notes and issuance of warrants, net | - | - | 2,061 | |||||||||
Proceeds from exercise of warrants and options | 20 | 55 | 651 | |||||||||
Repayment of short-term loans | - | - | (601 | ) | ||||||||
Net cash provided by continuing financing activities | 20 | 3,662 | 14,430 | |||||||||
Net cash provided by discontinued financing activities | - | - | 43 | |||||||||
Total net cash provided by financing activities | 20 | 3,662 | 14,473 | |||||||||
Increase (decrease) in cash and cash equivalents | (778 | ) | 3,571 | 1,145 | ||||||||
Cash and cash equivalents at the beginning of the period | 1,923 | 93 | - | |||||||||
Cash and cash equivalents at end of the period | 1,145 | 3,664 | 1,145 | |||||||||
Non-cash financing activities: | ||||||||||||
Conversion of convertible loan and convertible note to shares Conversion of a debt to a trade payable to Common Stock $ 84 | - | 137 | ||||||||||
Conversion of other accounts payable to Common Stock | - | 24 |
(*) Out of the which, cash flows used in discontinued operating activities of $36, cash flows used in discontinued investing activities of $16 and cash flows provided in discontinued financing activities of $57, relating to the period from inception to March 31, 2004, is unaudited.
The accompanying notes are an integral part of the consolidated financial statements.
F-59 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
NOTE 1 - | GENERAL |
A. | Brainstorm Cell Therapeutics Inc. (formerly: Golden Hand Resources Inc.) (the "Company") was incorporated in the State of Washington on September 22, 2000. |
B. | On May 21, 2004, the former major stockholders of the Company entered into a purchase agreement with a group of private investors, who purchased from the former major stockholders 6,880,000 shares of the then issued and outstanding 10,238,000 shares of Common Stock. |
C. | On July 8, 2004, the Company entered into a licensing agreement with Ramot of Tel Aviv University Ltd. ("Ramot"), to acquire certain stem cell technology (see Note 4). Subsequent to this agreement, the Company decided to focus on the development of novel cell therapies for neurodegenerative diseases based on the acquired technology and research to be conducted and funded by the Company. |
Following the licensing agreement dated July 8, 2004, the management of the Company decided to abandon all old activities related to the sale of the digital data recorder product. The discontinuation of this activity was accounted for under the provision of Statement of Financial Accounting Standard ASC 360-10 (formerly "SFAS" 144), "Accounting for the Impairment or Disposal of Long-Lived Assets".
D. | On October 25, 2004, the Company formed a wholly-owned subsidiary in Israel, Brainstorm Cell Therapeutics Ltd. ("BCT"). |
E. | On November 22, 2004, the Company changed its name from Golden Hand Resources Inc. to Brainstorm Cell Therapeutics Inc. to better reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. BCT, as defined below, owns all operational property and equipment. |
F. | On September 17, 2006, the Company changed the Company's fiscal year-end from March 31 to December 31. |
G. | In December 2006, the Company changed its state of incorporation from Washington to Delaware. |
H. | Since its inception, the Company has devoted substantially all of its efforts to research and development, recruiting management and technical staff, acquiring assets and raising capital. In addition, the Company has not generated revenues. Accordingly, the Company is considered to be in the development stage, as defined in Statement of Financial Accounting Standards No. 7, "Accounting and reporting by development Stage Enterprises" ASC 915-10 (formerly "SFAS No. 7"). |
I. | In October 2010, the Israeli Ministry of Health (“MOH”) granted clearance for a Phase I/II clinical trial using the Company’s autologous NurOwn™ stem cell therapy in patients with amyotrophic lateral sclerosis (“ALS”), subject to some additional process specifications as well as completion of the sterility validation study for tests performed. |
On February 23, 2011, the Company submitted to the MOH all the required documents. Following approval of the MOH, a Phase I/II clinical study for ALS patients using the Company’s autologous NurOwn™ stem cell therapy (the “Clinical Trial”) was initiated in June 2011.
In January 2012, the Company reported on an interim safety follow-up of the first 4 patients enrolled in its Clinical Trial indicating that no significant treatment-related adverse events were reported. The NurOwn™ treatment has thus so far proven to be safe, and has shown some initial indications of beneficial clinical effects.
J. | In February 2011, the U.S. Food and Drug Administration (“FDA”) granted orphan drug designation to the Company’s NurOwn™ autologous adult stem cell product candidate for the treatment of ALS. |
F-60 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
NOTE 1 - | GENERAL (Cont.) |
GOING CONCERN
As reflected in the accompanying financial statements, the Company’s operations for the three months ended March 31, 2012, resulted in a net loss of $872. The Company’s balance sheet reflects an accumulated deficit of $44,950. These conditions, together with the fact that the Company is a development stage Company and has no revenues nor are revenues expected in the near future, raise substantial doubt about the Company's ability to continue to operate as a going concern. The Company’s ability to continue operating as a “going concern” is dependent on several factors, among them is its ability to raise sufficient additional working capital.
In 2009, the Company decided to focus only on the effort to commence clinical trials for ALS and such trials did commence in 2011.
In February 2011, the Company raised approximately $3.8 million from institutional and private investors. However, there can be no assurance that additional funds will be available on terms acceptable to the Company, or at all.
These financial statements do not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount and classification of liabilities that may be required should the Company be unable to continue as a going concern.
NOTE 2 - | SIGNIFICANT ACCOUNTING POLICIES |
The significant accounting policies applied in the annual financial statements of the Company as of December 31, 2011 are applied consistently in these financial statements.
NOTE 3 - | UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS |
The accompanying unaudited interim financial statements have been prepared in a condensed format and include the consolidated financial operations of the Company and its wholly-owned subsidiary as of March 31, 2012 and for the three months then ended, in accordance with accounting principles generally accepted in the United States relating to the preparation of financial statements for interim periods. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2012, are not necessarily indicative of the results that may be expected for the year ended December 31, 2012.
NOTE 4 - | RESEARCH AND LICENSE AGREEMENT |
The Company has a Research and License Agreement, as amended and restated, with Ramot. The Company obtained a waiver and release from Ramot pursuant to which Ramot agreed to an amended payment schedule regarding the Company's payment obligations under the Research and License Agreement and waived all claims against the Company resulting from the Company's previous defaults and non-payment under the Research and License Agreement. The waiver and release amended and restated the original payment schedule under the original agreement providing for payments during the initial research period and additional payments for any extended research period.
F-61 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
NOTE 4 - | RESEARCH AND LICENSE AGREEMENT (Cont.) |
As of December 24, 2009, the Company had paid to Ramot $400 but did not make payments totaling $240 for the initial research period and payments totaling $380 for the extended research period.
On December 24, 2009, the Company and Ramot entered into a settlement agreement which amended the Research and License Agreement, as amended and restated pursuant to which, among other things, the following matters were agreed upon:
a) | Ramot released the Company from its obligation to fund the extended research period in the total amount of $1,140. Therefore, the Company deleted an amount in 2009, equal to $760 from it research and development expenses that were previously expensed. |
b) | Past due amounts of $240 for the initial research period plus interest of $32 owed by the Company to Ramot was converted into 1,120,000 shares of common stock on December 30, 2009. Ramot was required to deposit the shares with a broker and only sell the shares in the open market after 185 days from the issuance date. |
c) | In the event that the total proceeds generated by sales of the shares on December 31, 2010, together with the March 31, 2010 payment, are less than $240 on or prior to December 31, 2010, then on such date the Company shall pay to Ramot the difference between the proceeds that Ramot has received from sales of the shares up to such date together with the September Payment (if any) that has been transferred to Ramot up to such date, and $240. Related compensation in the amount of $51 was recorded as research and development expenses. |
In January 2011 Ramot exercised additional 167,530 Common Stock of the Company, for $35, which finalized the sale of the 1,120,000 Common Stock of the Company granted to Ramot for $235. In February 2011 the Company paid the remaining $5 and finalized the balance due to Ramot according to the settlement agreement between the parties dated December 24, 2009.
NOTE 5 - | CONSULTING AGREEMENTS |
A. | On July 8, 2004, the Company entered into two consulting agreements with Prof. Eldad Melamed and Dr. Daniel Offen (together, the "Consultants"), under which the Consultants provide the Company scientific and medical consulting services in consideration for a monthly payment of $6 each. In addition, the Company granted each of the Consultants, a fully vested warrant to purchase 1,097,215 shares of Common Stock at an exercise price of $0.01 per share. The warrants issued pursuant to the agreement were issued to the Consultants effective as of November 4, 2004. Each of the warrants is exercisable for a seven-year period beginning on November 4, 2005. As of September 2010, all the above warrants had been exercised. |
B. | On December 16, 2010, the Company approved a grant of 1,100,000 shares of the Company's Common Stock to the two Consultants, for services rendered through December 31, 2010. Related compensation in the amount of $220 was recorded as research and development expense. A sum of $487 was cancelled concurrently with the issuance of the 1,100,000 shares of Common Stock of the Company. |
C. | On June 27, 2011, the Company approved an additional grant of 400,000 shares of the Company's Common Stock to Prof. Daniel Offen, for services rendered through December 31, 2009. Related compensation in the amount of $192 is recorded as research and development expense. |
D. | As of March 31, 2012, the Company has a total obligation of $135 for services rendered by the Consultants under the abovementioned agreements. |
F-62 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
NOTE 6 - | SHORT-TERM CONVERTIBLE NOTE |
On December 13, 2009, the Company issued a $135 Convertible Promissory Note to its legal advisor for $217 in legal fees accrued through October 31, 2009. Interest on the Note accrued at the rate of 4%. The legal advisor has the right at any time to convert all or part of the outstanding principal and interest amount of the note into shares of Common Stock based on the five day average closing stock price prior to conversion election.
The gap between the amount the Company owed to the legal advisor and the principal of the Convertible Promissory Note in the amount of $82 was deducted from general and administrative expenses.
On February 19, 2010, the Company's legal advisor converted the entire accrued principal and interest of $135 Convertible Promissory Note into 402,385 shares of Common Stock.
On September 15, 2010, the Company issued a $135 Convertible Promissory Note to its legal advisor for legal fees accrued through December 31, 2010. Interest on the Note was at the rate of 4%. The legal advisor has the right at any time to convert all or part of the outstanding principal and interest amount of the note into shares of Common Stock based on the five day average closing stock price prior to conversion election.
On February 18, 2011, the legal advisor converted the entire accrued principal and interest into 445,617 shares of Common Stock.
NOTE 7 - | SHORT-TERM LOANS |
In March 2007, the Company issued a $150 convertible note to a lender, with an annual interest rate of 8% for the first year, with an increase up to 10% after the first year. On January 27, 2010, the lender converted the entire accrued principal and interest of $189 into 1,016,109 shares of Common Stock of the Company. In July 2011, the Company issued to the lender an additional 309,977 shares of Common Stock of the Company with regard to the above conversion.
Since the outcome of the issuance of the shares was to relieve the debtor from its obligation, based on guidance in ASC 860-10 (formerly FASB No 140) and ASC 450-20 Extinguishment of Liabilities” the Company derecognized the liability with the difference recognized in earnings.
NOTE 8 - | STOCK CAPITAL |
A. | The rights of Common Stock are as follows: |
Holders of Common Stock have the right to receive notice to participate and vote in general meetings of the Company, the right to a share in the excess of assets upon liquidation of the Company and the right to receive dividends, if declared.
The Common Stock is registered and publicly traded on the Over-the-Counter Bulletin Board service of the National Association of Securities Dealers, Inc. under the symbol BCLI.
F-63 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
NOTE 8 - | STOCK CAPITAL (Cont.) |
B. | Issuance of shares warrants and options: |
1. | Private placements: |
a) | On June 24, 2004, the Company issued to investors 8,510,000 shares of Common Stock for total proceeds of $60 (net of $25 issuance expenses). |
b) | On February 23, 2005, the Company completed a private placement for sale of 1,894,808 units for total proceeds of $1,418. Each unit consists of one share of Common Stock and a three-year warrant to purchase one share of Common Stock at $2.50 per share. This private placement was consummated in three tranches which closed in October 2004, November 2004 and February 2005. |
c) | On May 12, 2005, the Company issued to an investor 186,875 shares of Common Stock at a price of $0.8 per share for total proceeds of $149. |
d) | On July 27, 2005, the Company issued to investors 165,000 shares of Common Stock at a price of $0.6 per share for total proceeds of $99. |
e) | On August 11, 2005, the Company signed a private placement agreement with investors for the sale of up to 1,250,000 units at a price of $0.8 per unit. Each unit consists of one share of Common Stock and one warrant to purchase one share of Common Stock at $1.00 per share. The warrants are exercisable for a period of three years from issuance. On March 31, 2005, the Company sold 312,500 units for total net proceeds of $225. On December 7, 2005, the Company sold 187,500 units for total net proceeds of $135. |
f) | On July 2, 2007, the Company entered into an investment agreement, pursuant to which the Company agreed to sell up to 27,500,000 shares of Common Stock, for an aggregate subscription price of up to $5 million and warrants to purchase up to 30,250,000 shares of Common Stock. Separate closings of the purchase and sale of the shares and the warrants were originally scheduled to take place as follows: |
Purchase date | Purchase price | Number of subscription shares | Number of warrant shares | |||||||||
August 30, 2007 | $ | 1,250 (includes $250 paid as a convertible loan) | 6,875,000 | 7,562,500 | ||||||||
November 15, 2007 | $ | 750 | 4,125,000 | 4,537,500 | ||||||||
February 15, 2008 | $ | 750 | 4,125,000 | 4,537,500 | ||||||||
May 15, 2008 | $ | 750 | 4,125,000 | 4,537,500 | ||||||||
July 30, 2008 | $ | 750 | 4,125,000 | 4,537,500 | ||||||||
November 15, 2008 | $ | 750 | 4,125,000 | 4,537,500 |
On August 18, 2009, the Company entered into an amendment to the investment agreement with the investor providing for the following:
(a) | The investor shall invest the remaining amount of the original investment agreement at price per share of $0.12 in monthly installments of not less than $50 starting August 1, 2009. The investor may accelerate such payments at his discretion. |
F-64 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
NOTE 8 - | STOCK CAPITAL (Cont.) |
B. | Issuance of shares warrants and options: (Cont.) |
1. | Private placements: (Cont.) |
(b) | The exercise price of the last 10,083,334 warrants decreased from an exercise price of $0.36 per share to $0.29 per share. |
(c) | All warrants expire on November 5, 2013 instead of November 5, 2011. |
(d) | The price per share of the investment agreement decreased from $0.1818 to $0.12, therefore the Company adjusted the number of Shares of Common Stock issuable pursuant the investment agreement retroactively and issued to the investor on October 28, 2009 an additional 9,916,667 shares of Common Stock for past investment. |
(e) | The investor has the right to cease payments in the event that the price per share as of the closing on five consecutive trading days shall decrease to $0.05. |
On January 18, 2011 the Company and an investor signed an agreement to balance amounts due to the investor, totaling $20, against the remaining balance of the investment. The Company issued to the investor 10,499,999 shares of Common Stock and a warrant to purchase 4,539,500 shares of the Company's Common Stock at an exercise price of $0.20 per share
As of March 31, 2011, the Company issued to the investor and its designees an aggregate of 41,666,667 shares of common stock and a warrant to purchase 10,083,333 shares of the Company's common stock at an exercise price of $0.20 per share and a warrant to purchase 20,166,667 shares of common stock at an exercise price of $0.29 per share. The warrants may be exercised at any time and expire on November 5, 2013.
In addition, the Company agreed to issue an aggregate of 1,250,000 shares of Common Stock to a related party as an introduction fee for the investment. The shares shall be issued pro rata to the funds received from the investor.
As of December 31, 2010, the introduction fee was paid in full.
g) | In January 2010, the Company issued 1,250,000 units to a private investor for total proceeds of $250. Each unit consists of one share of Common Stock and a two-year warrant to purchase one share of Common Stock at $0.50 per share. |
h) | In February 2010, the Company issued 6,000,000 shares of Common Stock to 3 investors (2,000,000 to each investor) and warrants to purchase an aggregate of 3,000,000 shares of Common Stock (1,000,000 to each investor) with an exercise price of $0.5 for aggregate proceeds of $1,500 ($500 each). |
i) | On February 7, 2011, the Company issued 833,333 shares of Common Stock, at a price of $0.3 per share, and a warrant to purchase 641,026 shares of the Company's Common Stock at an exercise price of $0.39 per share for one year for total proceeds of $250. |
F-65 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
NOTE 8 - | STOCK CAPITAL (Cont.) |
B. | Issuance of shares warrants and options: (Cont.) |
1. | Private placements: (Cont.) |
j) | On February 23, 2011, the Company entered into an investment agreement, pursuant to which the Company agreed to sell up to 12,815,000 shares of Common Stock, for an aggregate subscription price of up to $3.6 million and warrants to purchase up to 19,222,500 shares of Common Stock as follows: warrant to purchase 12,815,000 shares of Common Stock at $0.5 for two years, and warrants to purchase 6,407,500 shares of Common Stock at $0.28 for one year. |
In addition, the Company agreed to pay 10% of the funds received for the distribution services received, out of this amount, 4% was be paid in stock and the remaining 6% in cash. Accordingly, in March 2011, the company issued 512,600 Common Stock and paid $231.
2. | Share-based compensation to employees and to directors: |
a) | Options to employees and directors: |
On November 25, 2004, the Company's stockholders approved the 2004 Global Stock Option Plan and the Israeli Appendix thereto (which applies solely to participants who are residents of Israel) and on March 28, 2005, the Company's stockholders approved the 2005 U.S. Stock Option and Incentive Plan, and the reservation of 9,143,462 shares of Common Stock for issuance in the aggregate under these stock option plans.
Each option granted under the plans is exercisable until the earlier of ten years from the date of grant of the option or the expiration dates of the respective option plans. The 2004 and 2005 options plans will expire on November 25, 2014 and March 28, 2015, respectively. The exercise price of the options granted under the plans may not be less than the nominal value of the shares into which such options are exercised. The options vest primarily over three or four years. Any options that are canceled or forfeited before expiration become available for future grants.
On June 5, 2008, the Company's stockholders approved an amendment and restatement of the Company’s 2004 Global Share Option Plan and 2005 U.S. Stock Option and Incentive Plan to increase the number of shares of common stock available for issuance under these stock option plans in the aggregate by 5,000,000 shares.
In June 2011, the Company's stockholders approved an increase the number of shares of common stock available for issuance under these stock option plans in the aggregate by 5,000,000 shares.
As of March 31, 2012, 1,825,103 options are available for future grants.
On May 27, 2005, the Company granted one of its directors an option to purchase 100,000 shares of Common Stock at an exercise price of $0.75 per share. The option is fully vested and expires after 10 years.
On February 6, 2006, the Company entered into an amendment to the Company's option agreement with the Company's former Chief Financial Officer. The amendment changed the exercise price of the 400,000 options granted to him on February 13, 2005 from $0.75 to $0.15 per share.
F-66 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
NOTE 8 - | STOCK CAPITAL (Cont.) |
B. | Issuance of shares, warrants and options: (Cont.) |
2. | Share-based compensation to employees and to directors: (Cont.) |
a) | Options to employees and directors: (Cont.) |
On May 2, 2006, the Company granted to one of its directors an option to purchase 100,000 shares of Common Stock at an exercise price of $0.15 per share. The option is fully vested and expires after 10 years. The compensation related to the option, in the amount of $48, was recorded as general and administrative expense.
On June 22, 2006, the Company entered into an amendment to the Company's option agreement with two of its employees. The amendment changed the exercise price of 270,000 options granted to them from $0.75 to $0.15 per share. The excess of the fair value resulting from the modification, in the amount of $2, was recorded as general and administration expense over the remaining vesting period of the options.
On September 17, 2006, the Company entered into an amendment to the Company's option agreement with one of its directors. The amendment changed the exercise price of 100,000 options granted to the director from $0.75 to $0.15 per share.
On March 21, 2007, the Company granted to one of its directors an option to purchase 100,000 shares of Common Stock at an exercise price of $0.15 per share. The option is fully vested and is exercisable for a period of 10 years. The compensation related to the option, in the amount of $43, was recorded as general and administrative expense.
On July 1, 2007, the Company granted to one of its directors an option to purchase 100,000 shares of Common Stock at an exercise price of $0.15 per share. The option is fully vested and is exercisable for a period of 10 years. The compensation related to the option, in the amount of $38, was recorded as general and administrative expense. On October 22, 2007, the Company and the director agreed to cancel and relinquish all the options which were granted on July 1, 2007.
On July 16, 2007, the Company granted to one of its directors an option to purchase 100,000 shares of Common Stock at an exercise price of $0.15 per share. The option is fully vested and is exercisable for a period of 10 years. The compensation related to the option, in the amount of $75, was recorded as general and administrative expense.
On August 27, 2007, the Company granted to one of its directors an option to purchase 100,000 shares of Common Stock at an exercise price of $0.15 per share. The option is fully vested and is exercisable for a period of 10 years. The compensation related to the option, in the amount of $84, was recorded as general and administrative expense.
On October 23, 2007, the Company granted to its Chief Executive Officer an option to purchase 1,000,000 shares of Common Stock at an exercise price of $0.87 per share. The option is fully vested and expires after 10 years. The total compensation related to the option is $733, which is amortized over the vesting period as general and administrative expense.
F-67 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
NOTE 8 - | STOCK CAPITAL (Cont.) |
B. | Issuance of shares, warrants and options: (Cont.) |
2. | Share-based compensation to employees and to directors: (Cont.) |
a) | Options to employees and directors: (Cont.) |
On November 5, 2008, the Company entered into an amendment to the Company's option agreement with the Company's Chief Executive Officer. The amendment changed the exercise price of the 1,000,000 options from $0.87 to $0.15 per share. The compensation related the modification of the purchase price in the amount of $4 was recorded as general and administrative expense.
On June 29, 2009, the Company granted to its former Chief Executive Officer and director an option to purchase 1,000,000 shares of Common Stock at an exercise price of $0.067 per share. The option vests with respect to 1/3 of the shares subject to the option on each anniversary of the date of grant and expires after 10 years. The total compensation related to the option is $68, which is amortized over the vesting period as general and administrative expense. In February 2011, the former CEO resigned. On July 25, 2011 the Company signed a settlement agreement with the former CEO under which 483,333 shares out of the above grant became fully vested exercisable through April 30 2012. An additional $30 was written as compensation in general and administrative expense.
After the balance sheet date, the former CEO exercised the option to 483,333 shares of Common Stock for an exercise price of $32.
On June 29, 2009, the Company granted to its former Chief Financial Officer an option to purchase 200,000 shares of Common Stock at an exercise price of $0.067 per share. The option vested with respect to 1/3 of the shares subject to the option. In connection with the former Chief Financial Officer’s resignation, 2/3 of the above shares were cancelled and the remaining 66,667 are valid through April 7, 2011.
On August 31, 2009, the Company granted to two of its directors an option to purchase 100,000 shares of Common Stock at an exercise price of $0.15 per share. Each option vests with respect to 1/3 of the shares subject to the option on each anniversary of the date of grant and expires after 10 years. The total compensation related to the option is $32, which is amortized over the vesting period as general and administrative expense.
On December 13, 2009, the Company granted to one of its directors an option to purchase 100,000 shares of Common Stock at an exercise price of $0.15 per share. The option is fully vested and is exercisable for a period of 10 years. The compensation related to the option, in the amount of $21, was recorded as general and administrative expense.
On February 10, 2010, the Company granted to an employee an option to purchase 30,000 shares of Common Stock at an exercise price of $0.32 per share. The option vests with respect to 1/3 of the shares subject to the option on each anniversary of the date of grant and expires after 10 years. The total compensation related to the option is $9, which is amortized over the vesting period as research and development expense.
F-68 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
NOTE 8 - | STOCK CAPITAL (Cont.) |
B. | Issuance of shares, warrants and options: (Cont.) |
2. | Share-based compensation to employees and to directors: (Cont.) |
a) | Options to employees and directors: (Cont.) |
On April 13, 2010, the Company, Abraham Israeli and Hadasit Medical Research Services and Development Ltd. (“Hadasit”) entered into an Agreement (the “Agreement”) pursuant to which Mr. Israeli agreed, during the term of the Agreement, to serve as (i) the Company’s Clinical Trials Advisor and (ii) a member of the Company’s Board of Directors. In consideration of the services to be provided by Mr. Israeli to the Company under the Agreement, the Company agreed to grant options annually during the term of the Agreement for the purchase of its Common Stock, as follows:
· | An option for the purchase of 166,666 shares of Common Stock at an exercise price equal to $0.00005 per share to Mr. Israeli; and |
· | An option for the purchase of 33,334 shares of Common Stock at an exercise price equal to $0.00005 per share to Hadasit, |
· | * Such options will vest and become exercisable in twelve (12) consecutive equal monthly amounts. |
In April 2010, the Company granted to Mr. Israeli an option to purchase 166,666 shares of Common Stock at an exercise price equal to $0.00005 per share. The total compensation related to the option was $50, which is amortized over the vesting period as general and administrative expense.
On January 30, 2011 the Company signed an agreement with a new COO and acting CEO. According to the employment agreement, the new COO received 450,000 options to purchase Common Stock of the Company at $0.20.
On June 27 2011, the Company granted to Mr. Israeli an option to purchase 166,666 shares of Common Stock at an exercise price equal to $0.00005 per share. The total compensation related to the option was $48, which is amortized over the vesting period as general and administrative expense.
On June 27 2011, the Company granted to four of its directors an option to purchase 634,999 shares of Common Stock of the Company at $0.15. The total compensation related to the option was $287, which is amortized over the vesting period as general and administrative expense.
On August 10 2011, the Company granted to its CEO, an option to purchase 70,000 shares of Common Stock of the Company at $0.20. The total compensation related to the option was $26, which was amortized as general and administrative expense.
In the three months ended March 31 2012, 167,849 options were exercised by former CEO of the Company for $20.
After the balance sheet date, the Company granted to Mr. Israeli an option to purchase 166,666 shares of Common Stock at an exercise price equal to $0.00005 per share.
F-69 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
NOTE 8 - | STOCK CAPITAL (Cont.) |
B. | Issuance of shares, warrants and options: (Cont.) |
2. | Share-based compensation to employees and to directors: (Cont.) |
b) | Restricted shares to directors (Cont.): |
A summary of the Company's option activity related to options to employees and directors, and related information is as follows:
For the period ended March 31, 2012 | ||||||||||||
Amount of options | Weighted average exercise price | Aggregate intrinsic value | ||||||||||
$ | $ | |||||||||||
Outstanding at beginning of period | 4,938,821 | 0.168 | ||||||||||
Granted | - | |||||||||||
Exercised | 167,849 | 0.150 | ||||||||||
Reclassified | 13,784 | 0.067 | ||||||||||
Outstanding at end of period | 4,784,756 | 0.169 | 807,430 | |||||||||
Vested and expected-to-vest at end of period | 3,784,617 | 0.166 | 627,162 |
On May 2, 2006, the Company issued to two of its directors 200,000 restricted shares of common stock (100,000 each). The restrictions on the shares have fully lapsed. The compensation related to the stocks issued amounted to $104, which was amortized over the vesting period as general and administrative expenses.
On April 20, 2007, based on a board resolution dated March 21, 2007, the Company issued to a director 100,000 restricted shares of Common Stock. The restrictions on the shares have fully lapsed. The compensation related to the shares issued amounted to $47, which was amortized over the vesting period as general and administrative expenses.
In addition, on April 20, 2007, based on a board resolution dated March 21, 2007, the Company issued to another director 100,000 restricted shares of Common Stock. The restricted shares are not subject to any right to repurchase, and the compensation related to the shares issued amounted to $47 was recorded as prepaid general and administrative expenses in the three months ended March 31, 2007.
On August 27, 2008, the Company issued to one of its directors 960,000 shares of Common Stock upon a cashless exercise by a shareholder of a warrant to purchase 1,000,000 shares of Common Stock at an exercise price of $.01 per share that was acquired by the shareholder from Ramot. The shares were allocated to the director by the shareholder.
F-70 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
NOTE 8 - | STOCK CAPITAL (Cont.) |
B. | Issuance of shares, warrants and options: (Cont.) |
2. | Share-based compensation to employees and to directors: (Cont.) |
b) | Restricted shares to directors (Cont.): |
In May 2010, based on a board resolution dated June 29, 2009, the Company issued to three of its directors 300,000 restricted shares of Common Stock. The restrictions of the shares shall lapse in three annual and equal portions commencing with the grant date.
In May and in June 2010, based on a board resolution dated June 29, 2009, the Company issued to three of its Scientific Advisory Board members and two of its Advisory Board members 500,000 restricted shares of common stock. The restrictions of the shares shall lapse in three annual and equal portions commencing with the grant date.
On April 6, 2010, Prof. Melamed fully exercised his warrant to purchase 1,097,215 shares of the Company’s Common Stock; the warrant was issued to him pursuant to the agreement with the Consultants effective as of November 4, 2004.
3. | Shares and warrants to investors and service providers: |
The Company accounts for shares and warrants issued to non-employees using the guidance of ASC 718-10 (formerly "SFAS" 123(R)), "Accounting for Stock-Based Compensation" and ASC 505-50-30 (formerly "EITF" 96-18), "Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling, Goods or Services," whereby the fair value of such option and warrant grants is determined using a Black-Scholes options pricing model at the earlier of the date at which the non-employee's performance is completed or a performance commitment is reached.
F-71 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
NOTE 8 - | STOCK CAPITAL (Cont.) |
B. | Issuance of shares, warrants and options: (Cont.) |
3. | Shares and warrants to investors and service providers: (Cont.) |
a) | Warrants to investors and service providers and investors: |
Issuance date | Number of warrants issued | Exercised | Forfeited | Outstanding | Exercise Price $ | Warrants exercisable | Exercisable through | |||||||||||||||||||||
November 2004 | 12,800,845 | 11,761,281 | 151,803 | 887,761 | 0.01 | 887,761 | April 2012 | |||||||||||||||||||||
December 2004 | 1,800,000 | 1,800,000 | - | 0.00005 | – | - | ||||||||||||||||||||||
February 2005 | 1,894,808 | 1,894,808 | - | 2.5 | - | - | ||||||||||||||||||||||
May 2005 | 47,500 | 47,500 | - | 1.62 | - | - | ||||||||||||||||||||||
June 2005 | 30,000 | 30,000 | 0.75 | 30,000 | June 2015 | |||||||||||||||||||||||
August 2005 | 70,000 | 70,000 | - | 0.15 | - | - | ||||||||||||||||||||||
September 2005 | 3,000 | 3,000 | - | 0.15 | - | - | ||||||||||||||||||||||
September 2005 | 36,000 | 36,000 | - | 0.75 | - | - | ||||||||||||||||||||||
September-December 2005 | 500,000 | 500,000 | - | 1 | - | - | ||||||||||||||||||||||
December 2005 | 20,000 | 20,000 | - | 0.15 | - | - | ||||||||||||||||||||||
December 2005 | 457,163 | 150,000 | 307,163 | 0.15 | 307,163 | December 2015 | ||||||||||||||||||||||
February 2006 | 230,000 | 230,000 | 0.65 | 230,000 | February 2016 | |||||||||||||||||||||||
February 2006 | 40,000 | 40,000 | - | 1.5 | - | |||||||||||||||||||||||
February 2006 | 8,000 | 8,000 | - | 0.15 | - | |||||||||||||||||||||||
February 2006 | 189,000 | 97,696 | 91,304 | - | 0. 5 | - | - | |||||||||||||||||||||
May 2006 | 50,000 | 50,000 | 0.0005 | 50,000 | May 2016 | |||||||||||||||||||||||
May -December 2006 | 48,000 | 48,000 | - | 0.35 | - | - | ||||||||||||||||||||||
May -December 2006 | 48,000 | 48,000 | - | 0.75 | - | - | ||||||||||||||||||||||
May 2006 | 200,000 | 200,000 | 1 | 200,000 | May 2011 | |||||||||||||||||||||||
June 2006 | 24,000 | 24,000 | - | 0.15 | - | - | ||||||||||||||||||||||
May 2006 | 19,355 | 19,355 | - | 0.15 | - | - | ||||||||||||||||||||||
October 2006 | 630,000 | 630,000 | - | 0.3 | - | - | ||||||||||||||||||||||
December 2006 | 200,000 | 200,000 | - | 0.45 | - | - | ||||||||||||||||||||||
March 2007 | 200,000 | 200,000 | - | 0.47 | - | - | ||||||||||||||||||||||
March 2007 | 500,000 | 500,000 | 0.47 | 500,000 | March 2017 | |||||||||||||||||||||||
March 2007 | 50,000 | 50,000 | - | 0.15 | - | - | ||||||||||||||||||||||
March 2007 | 15,000 | 15,000 | - | 0.15 | - | - | ||||||||||||||||||||||
February 2007 | 50,000 | 50,000 | - | 0.45 | - | - | ||||||||||||||||||||||
March 2007 | 225,000 | 225,000 | - | 0.45 | - | - | ||||||||||||||||||||||
March 2007 | 50,000 | 50,000 | - | 0.45 | - | - | ||||||||||||||||||||||
April 2007 | 33,300 | 33,300 | - | 0.45 | - | - | ||||||||||||||||||||||
May 2007 | 250,000 | 250,000 | - | 0.45 | - | - | ||||||||||||||||||||||
July 2007 | 500,000 | 500,000 | 0.39 | 500,000 | July 2017 | |||||||||||||||||||||||
September 2007 | 500,000 | 500,000 | 0.15 | 500,000 | August 2017 | |||||||||||||||||||||||
August 2007 | 7,562,500 | 7,562,500 | 0.2 | 7,562,500 | November 2013 | |||||||||||||||||||||||
July 2007 | 30,000 | 30,000 | - | 0.45 | - | - | ||||||||||||||||||||||
July 2007 | 100,000 | 100,000 | - | 0.45 | - | - | ||||||||||||||||||||||
October 2007 | 200,000 | 200,000 | 0.15 | 200,000 | August-October 2017 | |||||||||||||||||||||||
November 2007 | 2,520,833 | 2,520,833 | 0.20 | 2,520,833 | November 2013 | |||||||||||||||||||||||
November 2007 | 2,016,667 | 2,016,667 | 0.29 | 2,016,667 | November 2013 | |||||||||||||||||||||||
April 2008 | 4,537,500 | 4,537,500 | 0.29 | 4,537,500 | November 2013 | |||||||||||||||||||||||
August 2008 | 3,529,166 | 3,529,166 | 0.29 | 3,529,166 | November 2013 | |||||||||||||||||||||||
August 2008 | 1,008,334 | 1,008,334 | 0.29 | 1,008,333 | November 2013 | |||||||||||||||||||||||
November 2008 | 100,000 | 100,000 | 0.15 | 100,000 | September 2018 | |||||||||||||||||||||||
April 2009 | 200,000 | 200,000 | 0.1 | 200,000 | April 2019 | |||||||||||||||||||||||
October 2009 | 200,000 | 100,000 | 100,000 | 0.067 | 66,667 | October 2019 | ||||||||||||||||||||||
October 2009 | 4,537,500 | 4,537,500 | 0.29 | 4,537,500 | November 2013 | |||||||||||||||||||||||
January 2010 | 1,250,000 | 1,250,000 | - | 0.5 | - | - | ||||||||||||||||||||||
February 2010 | 125,000 | 125,000 | - | 0.01 | - | - | ||||||||||||||||||||||
February 2010 | 3,000,000 | 3,000,000 | - | 0.5 | - | - | ||||||||||||||||||||||
January 2011 | 4,537,500 | 4,537,500 | 0.29 | 4,537,500 | November 2013 | |||||||||||||||||||||||
February 2011 | 641,026 | 641,026 | - | 0.39 | - | - | ||||||||||||||||||||||
February 2011 | 6,407,500 | 946,834 | 5,460,666 | - | 0.28 | - | - | |||||||||||||||||||||
February 2011 | 12,815,000 | 12,815,000 | 0.5 | 12,815,000 | February 2013 | |||||||||||||||||||||||
April 2010 | 33,334 | 33,334 | 0.00005 | 33,334 | April 2020 | |||||||||||||||||||||||
April 2011 | 33,334 | 33,334 | 33,334 | April 2021 | ||||||||||||||||||||||||
February 2010 | 1,500,000 | 1,500,000 | 500,000 | February 2020 | ||||||||||||||||||||||||
78,604,165 | 15,633,811 | 14,533,762 | 48,436,590 | 47,403,257 |
F-72 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
NOTE 8 - | STOCK CAPITAL (Cont.) |
B. | Issuance of shares, warrants and options: (Cont.) |
3. | Shares and warrants to service providers: (Cont.) |
a) | Warrants: (Cont.) |
The fair value for the warrants to service providers was estimated on the date of grant using a Black-Scholes option pricing model, with the following weighted-average assumptions for the 3 month activity ended on March 31, 2011; weighted average volatility of 134%-141%, risk free interest rates of 2.26%-3.47% dividend yields of 0% and a weighted average life of the options of 6-10 years.
b) | Shares: |
On June 1 and June 4, 2004, the Company issued 40,000 and 150,000 shares of Common Stock for 12 months of filing services and legal and due-diligence services, respectively, with respect to a private placement. Compensation expense related to filing services, totaling $26, was amortized over a 12-month period. Compensation related to legal services, totaling $105 was recorded as equity issuance cost and had no effect on the statement of operations.
On July 1 and September 22, 2004, the Company issued 20,000 and 15,000 shares to a former director for financial services for the first and second quarters of 2004, respectively. Related compensation in the amount of $39 was recorded as general and administrative expense.
On February 10, 2005, the Company signed an agreement with one of its service providers under which the Company issued the service provider 100,000 restricted shares at a purchase price of $0.00005 par value under the U.S. Stock Option and Incentive Plan of the Company. All restrictions on these shares have lapsed.
In March and April 2005, the Company signed an agreement with four members of its Scientific Advisory Board under which the Company issued to the members of the Scientific Advisory Board 400,000 restricted shares at a purchase price of $0.00005 par value under the U.S. Stock Option and Incentive Plan (100,000 each). All restrictions on these shares have lapsed.
In July 2005, the Company issued to its legal advisors 50,000 shares for legal services for 12 months. The compensation related to the shares in the amount of $37.5 was recorded as general and administrative expense.
In January 2006, the Company issued to two service providers 350,000 restricted shares at a purchase price of $0.00005 par value under the U.S. Stock Option and Incentive Plan of the Company. All restrictions on these shares have lapsed. Related compensation in the amount of $23 was recorded as general and administrative expense.
On March 6, 2006, the Company issued to its legal advisor 34,904 shares of Common Stock. The shares are in lieu of $18.5 payable to the legal advisor. Related compensation in the amount of $18.5 was recorded as general and administrative expense.
On April 13, 2006, the Company issued to service providers 60,000 shares of Common Stock at a purchase price of $0.00005 par value under the U.S. Stock Option and Incentive Plan of the Company. Related compensation in the amount of $25.8 was recorded as general and administrative expense.
F-73 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
On May 9, 2006, the Company issued to its legal advisor 65,374 shares of Common Stock in lieu of payment for legal services. Related compensation in the amount of $33 was recorded as general and administrative expense.
F-74 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
NOTE 8 - | STOCK CAPITAL (Cont.) |
B. | Issuance of shares, warrants and options: (Cont.) |
3. | Shares and warrants to service providers: (Cont.) |
b) | Shares: (Cont.) |
On June 7, 2006, the Company issued to a service provider 50,000 shares of Common Stock for filing services for 12 months. Related compensation in the amount of $24.5 was recorded as general and administrative expense.
On May 5, 2006, the Company issued 200,000 shares of Common Stock to a finance consultant for his services. Related compensation in the amount of $102 was recorded as general and administrative expense.
On August 14, 2006, the Company issued 200,000 shares of Common Stock to a service provider. Related compensation in the amount of $68 was recorded as general and administrative expense.
On August 17, 2006, the Company issued 100,000 shares of Common Stock to a service provider. Related compensation in the amount of $35 was recorded as general and administrative expense.
On September 17, 2006, the Company issued to its legal advisor 231,851 shares of Common Stock in lieu of $63 payable to the legal advisor. [Related compensation in the amount of $63 was recorded as general and administrative expense.]
On April 1 and September 30, 2006, the Company issued to its business development advisor, based on an agreement, 240,000 shares of Common Stock. Related compensation in the amount of $74 was recorded as general and administrative expense.
On January 3, 2007, the Company issued to its legal advisor 176,327 shares of Common Stock in lieu of $45 payable to the legal advisor. Related compensation in the amount of $49 was recorded as general and administrative expense.
On April 12, 2007, the Company issued to its filing and printing service providers 80,000 shares of Common Stock in lieu of $15 payable to the service provider. Related compensation in the amount of $30 was recorded as general and administrative expense. In addition, the Company was obligated to issue the filing and printing service providers additional shares, in the event that the total value of the shares previously issued (as quoted on the Over-the-Counter Bulletin Board or such other exchange where the Common Stock is quoted or listed) was less than $0.20 on March 20, 2008. As a result, the Company recorded a liability in the amount of $20.
On April 12, 2007, the Company issued to its legal advisor 108,511 shares of Common Stock in lieu of $29 payable to the legal advisor. Related compensation in the amount of $40 was recorded as general and administrative expense.
On May 18, 2007, the Company issued to its legal advisor 99,257 shares of Common Stock in lieu of $33 payable to the legal advisor. Related compensation in the amount of $33 was recorded as general and administrative expense.
F-75 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
NOTE 8 - | STOCK CAPITAL (Cont.) |
B. | Issuance of shares, warrants and options: (Cont.) |
3. | Shares and warrants to service providers: (Cont.) |
b) | Shares: (Cont.) |
On October 29, 2007, the Company issued to a scientific advisory board member 80,000 shares of the Company’s Common Stock for scientific services. Compensation of $67 was recorded as research and development expense.
On May 20, 2008, the Company issued to its financial advisor 90,000 shares of the Company's Common Stock. The shares were for $35 payable to the financial advisor for introduction fee of past convertible loans. Related compensation in the amount of $36 was recorded as financial expenses.
On April 5, 2009, the Company issued to its Chief Technology Advisor 1,800,000 shares of Common Stock. The shares were for $180 payable to the advisor. Related compensation in the amount of $144 was recorded as research and development expense.
On June 24, 2009, the Company issued to its public relations advisor 250,000 shares of Common Stock. The shares were for $25 payable to the advisor. Related compensation in the amount of $18 was recorded as general and administrative expense.
On July 8, 2009, the Company issued to its financial consultant 285,714 shares of the Company's Common Stock. The shares were for $20 payable to the financial consultant for valuation of options and warrants. Related compensation in the amount of $20 was recorded as general and administrative expense.
On July 15, 2009, the Company issued to a service provider 357,142 shares of the Company's Common Stock. The shares were for $25 payable to the service provider for filing services. Related compensation in the amount of $21 was recorded as general and administrative expense.
On August 10, 2009, the Company issued to a service provider 71,428 shares of the Company's Common Stock. The shares were for $5 payable to the service provider for IT services. Related compensation in the amount of $4 was recorded as general and administrative expense.
On January 5, 2010, the Company issued to its public relations advisor 50,000 shares of the Company's Common Stock for six months service. The issuance of the shares is part of the agreement with the public relations advisor that entitled them to a monthly grant of 8,333 shares of the Company's Common Stock. Related compensation in the amount of $12 was recorded as general and administrative expense.
On January 6, 2010, the Company issued to a service provider 60,000 shares of the Company's Common Stock. The shares were for $15 payable to the service provider for insurance and risk management consulting and agency services for three years. Related compensation in the amount of $16 was recorded as general and administrative expense.
On March 5, 2007, the Company issued a $150 Convertible Promissory Note to a third party. Interest on the note accrued at the rate of 8% per annum for the first year and 10% per annum after the first year. On January 27, 2010, the third party converted the entire accrued principle and interest outstanding under the note, amounting to $189, into 1,016,109 shares of Common Stock.
F-76 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
NOTE 8 - | STOCK CAPITAL (Cont.) |
B. | Issuance of shares, warrants and options: (Cont.) |
3. | Shares and warrants to service providers: (Cont.) |
b) | Shares: (Cont.) |
On December 13, 2009, the Company issued a $135 Convertible Promissory Note to it legal advisor for $217 in legal fees accrued through October 31, 2009. Interest on the note accrued at the rate of 4%. On February 19, 2010, the Company’s legal advisor converted the entire accrued principal and interest of outstanding under the note into 402,385 shares of Common Stock.
In May 2010, based on a board resolution dated June 29, 2009 the Company issued to one of its public relations advisors 100,000 restricted shares of Common Stock. The restrictions of the shares shall lapse in three annual and equal portions commencing with the grant date.
On December 16, 2010, the Company issued to a service provider 83,333 shares of the Company's Common Stock. The shares were for public relations services. Related compensation in the amount of $40 is recorded as general and administrative expense.
On December 16, 2010, the Company granted to its Chief Medical Advisor 900,000 shares of the Company's Common Stock for services rendered through December 31 2010. Related compensation in the amount of $180 is recorded as research and development expense (see Note 5B).
On December 16, 2010 the Company granted to its Chief Scientist 200,000 shares of the Company's Common Stock for services rendered through December 31 2010. Related compensation in the amount of $40 is recorded as research and development expense (see Note 5B).
On February 16, 2011 one of the Company's consultants exercised 100,000 warrants to Common Stock for $33.
On February 18, 2011, the Company's legal advisor converted the entire accrued principal and interest of the Convertible Promissory Note granted on September 15, 2010, totaling $137, into 445,617 shares of Common Stock.
The total stock-based compensation expense, related to shares, options and warrants granted to employee’s directors and service providers, was comprised, at each period, as follows:
Three months ended March 31 | Period from September 22, 2000 (inception date) through March 31, | |||||||||||
2012 | 2011 | 2012 | ||||||||||
Unaudited | Unaudited | |||||||||||
Research and development | 13 | 9 | 17,556 | |||||||||
General and administrative | 168 | -2 | 10,281 | |||||||||
Financial expenses, net | - | - | 248 | |||||||||
Total stock-based compensation expense | 181 | 7 | 28,098 |
F-77 |
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARY
(A development stage company)
Notes to the financial statements
NOTE 9 - | SUBSEQUENT EVENTS |
A. | In April 2012, the former CEO exercised 1,014,757 options to shares of Common Stock of the Company. An exercise fee of $112 was paid to the Company. (See note 8 B 2 (a)) |
B. | In April 2012, the Company granted to Mr. Israeli an option to purchase 166,666 shares of Common Stock at an exercise price equal to $0.00005 per share. (See note 8 B 2 (a)) |
C. | In April 2012, the Company granted to Hadasit a warrant to purchase 33,334 shares of Common Stock at an exercise price equal to $0.00005 per share. (See note 8 B 2 (a)) |
F-78 |
ANNEX A
SECURITIES PURCHASE AGREEMENT
This Securities Purchase Agreement (this “Agreement”) is dated as of July 17, 2012, between Brainstorm Cell Therapeutics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Securities Act”), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.
NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:
ARTICLE I.
DEFINITIONS
1.1 Definitions. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings set forth in this Section 1.1:
“Acquiring Person” shall have the meaning ascribed to such term in Section 4.5.
“Action” shall have the meaning ascribed to such term in Section 3.1(j).
“Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and construed under Rule 405 under the Securities Act.
“Board of Directors” means the board of directors of the Company.
“Business Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.
“Closing” means the closing of the purchase and sale of the Securities pursuant to Section 2.1.
“Closing Date” means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and all conditions precedent to (i) the Purchasers’ obligations to pay the Subscription Amount and (ii) the Company’s obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the third Trading Day following the date hereof.
1 |
“Commission” means the United States Securities and Exchange Commission.
“Common Stock” means the common stock of the Company, par value $0.00005 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.
“Common Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.
“Company Counsel” means BRL Law Group LLC, with offices located at 425 Boylston Street, 3rd Floor, Boston, Massachusetts 02116.
“Disclosure Schedules” means the Disclosure Schedules of the Company delivered concurrently herewith.
“EGS” means Ellenoff Grossman & Schole LLP, with offices located at 150 East 42nd Street, New York, New York 10017.
“Escrow Agent” means American Stock Transfer & Trust Company LLC, the current transfer of the Company, with a mailing address of 6201 15th Avenue, Brooklyn, New York 11219.
“Escrow Agreement” means the escrow agreement entered into prior to the date hereof, by and among the Company, the Escrow Agent and Maxim Group LLC pursuant to which the Purchasers shall deposit Subscription Amounts with the Escrow Agent to be applied to the transactions contemplated hereunder.
“Evaluation Date” shall have the meaning ascribed to such term in Section 3.1(r).
“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
“Exempt Issuance” means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, (b) securities upon the exercise or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement or securities issuable pursuant to agreements to which the Company is a party as of the date hereof (such as the April 13, 2010 Agreement by and among the Company, Dr. Abraham Israeli and Hadasit Medical Research Services and Development Ltd., as amended), provided that such securities and such agreements to issue securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities, (c) up to 300,000 shares of Common Stock to be issued to Company Counsel as payment for general corporate legal work that was provided to Company during 2012, and (d) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.
2 |
“FCPA” means the Foreign Corrupt Practices Act of 1977, as amended.
“FDA” shall have the meaning ascribed to such term in Section 3.1(gg).
“FDCA” shall have the meaning ascribed to such term in Section 3.1(gg).
“GAAP” shall have the meaning ascribed to such term in Section 3.1(h).
“Indebtedness” shall have the meaning ascribed to such term in Section 3.1(z).
“Intellectual Property Rights” shall have the meaning ascribed to such term in Section 3.1(o).
“Liens” means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.
“Material Adverse Effect” shall have the meaning assigned to such term in Section 3.1(b).
“Material Permits” shall have the meaning ascribed to such term in Section 3.1(m).
“Per Share Purchase Price” equals $0.29, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.
“Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.
“Pharmaceutical Product” shall have the meaning ascribed to such term in Section 3.1(gg).
“Proceeding” means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced or threatened.
3 |
“Prospectus” means the final prospectus filed for the Registration Statement.
“Prospectus Supplement” means the supplement to the Prospectus complying with Rule 430A of the Securities Act that is filed with the Commission and delivered by the Company to each Purchaser at the Closing.
“Purchaser Party” shall have the meaning ascribed to such term in Section 4.8.
“Registration Statement” means the effective registration statement with Commission file No. 333-179331 which registers the sale of the Shares, the Warrants and the Warrant Shares to the Purchasers.
“Required Approvals” shall have the meaning ascribed to such term in Section 3.1(e).
“Rule 144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.
“Rule 424” means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.
“Rule 430A” means Rule 430A promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.
“SEC Reports” shall have the meaning ascribed to such term in Section 3.1(h).
“Securities” means the Shares, the Warrants and the Warrant Shares.
“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
“Shares” means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.
“Short Sales” means all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include the location and/or reservation of borrowable shares of Common Stock).
“Subscription Amount” means, as to each Purchaser, the aggregate amount to be paid for Shares and Warrants purchased hereunder as specified below such Purchaser’s name on the signature page of this Agreement and next to the heading “Subscription Amount,” in United States dollars and in immediately available funds.
4 |
“Subsidiary” means any subsidiary of the Company as set forth on Schedule 3.1(a), and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.
“Trading Day” means a day on which the principal Trading Market is open for trading.
“Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE MKT (formerly NYSE AMEX), the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange or the OTC Bulletin Board (or any successors to any of the foregoing).
“Transaction Documents” means this Agreement, the Warrants and any other documents or agreements executed in connection with the transactions contemplated hereunder.
“Transfer Agent” means American Stock Transfer & Trust Company LLC, the current transfer agent of the Company, with a mailing address of 6201 15th Avenue, Brooklyn, New York 11219 and a facsimile number of (718) 765-8717, and any successor transfer agent of the Company.
“Variable Rate Transaction” shall have the meaning ascribed to such term in Section 4.12(b).
“Warrants” means, collectively, the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof, which Warrants shall be exercisable immediately and have a term of exercise equal to 30 months, in the form of Exhibit A attached hereto.
“Warrant Shares” means the shares of Common Stock issuable upon exercise of the Warrants.
ARTICLE II.
PURCHASE AND SALE
2.1 Closing. On the Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution and delivery of this Agreement by the parties hereto, the Company agrees to sell, and the Purchasers, severally and not jointly, agree to purchase, up to an aggregate of $[________] of Shares and Warrants. Each Purchaser shall deliver to the Escrow Agent, via wire transfer or a certified check, immediately available funds equal to such Purchaser’s Subscription Amount as set forth on the signature page hereto executed by such Purchaser and the Company shall deliver to each Purchaser its respective Shares and a Warrant as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall occur at the offices of EGS or such other location as the parties shall mutually agree.
5 |
2.2 Deliveries.
(a) On or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:
(i) this Agreement duly executed by the Company;
(ii) a legal opinion of Company Counsel, substantially in the form of Exhibit B attached hereto;
(iii) a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver on an expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (“DWAC”) Shares equal to such Purchaser’s Subscription Amount divided by the Per Share Purchase Price, registered in the name of such Purchaser;
(iv) a Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 75% of such Purchaser’s Shares, with an exercise price equal to $0.29, subject to adjustment therein (such Warrant may be delivered within three Trading Days of the Closing Date); and
(v) the Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act).
(b) On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company or the Escrow Agent, as applicable, the following:
(i) this Agreement duly executed by such Purchaser; and
(ii) to the Escrow Agent, such Purchaser’s Subscription Amount by wire transfer to the account specified in the Escrow Agreement.
2.3 Closing Conditions.
(a) The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:
(i) the accuracy in all material respects on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in which case they shall be accurate as of such date);
(ii) all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed; and
(iii) the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.
6 |
(b) The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:
(i) the accuracy in all material respects when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of a specific date therein);
(ii) all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;
(iii) the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;
(iv) there shall have been no Material Adverse Effect with respect to the Company since the date hereof; and
(v) from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company’s principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.
ARTICLE III.
REPRESENTATIONS AND WARRANTIES
3.1 Representations and Warranties of the Company. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall be deemed a part hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained in the corresponding section of the Disclosure Schedules, the Company hereby makes the following representations and warranties to each Purchaser:
(a) Subsidiaries. All of the direct and indirect subsidiaries of the Company are set forth on Schedule 3.1(a). The Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities.
7 |
(b) Organization and Qualification. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company’s ability to perform in any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a “Material Adverse Effect”) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.
(c) Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, the Board of Directors or the Company’s stockholders in connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.
8 |
(d) No Conflicts. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby do not and will not (i) conflict with or violate any provision of the Company’s or any Subsidiary’s certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.
(e) Filings, Consents and Approvals. Except for those that have already been obtained, the Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings required pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission of the Prospectus Supplement, (iii) application(s) to each applicable Trading Market for the listing of the Shares and Warrant Shares for trading thereon in the time and manner required thereby and (iv) such filings as are required to be made under applicable state securities laws (collectively, the “Required Approvals”).
(f) Issuance of the Securities; Registration. The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Warrant Shares, when issued in accordance with the terms of the Warrants, will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock the maximum number of shares of Common Stock issuable pursuant to this Agreement and the Warrants. The Company has prepared and filed the Registration Statement in conformity with the requirements of the Securities Act, which became effective on July 13, 2012 (the “Effective Date”), including the Prospectus, and such amendments and supplements thereto as may have been required to the date of this Agreement. The Registration Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use of the Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the Company, are threatened by the Commission. The Company, if required by the rules and regulations of the Commission, proposes to file the Prospectus, with the Commission pursuant to Rule 424(b) or Rule 430A. At the time the Registration Statement and any amendments thereto became effective, at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading; and the Prospectus and any amendments or supplements thereto, at time the Prospectus or any amendment or supplement thereto was issued and at the Closing Date, conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.
9 |
(g) Capitalization. The capitalization of the Company is as set forth on Schedule 3.1(g). The Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant to the exercise of employee stock options under the Company’s stock option plans, the issuance of shares of Common Stock to employees pursuant to the Company’s employee stock purchase plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act. Except as set forth on Schedule 3.1(g), no Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as a result of the purchase and sale of the Securities or as set forth on Schedule 3.1(g), there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents. The issuance and sale of the Securities will not obligate the Company to issue shares of Common Stock or other securities to any Person (other than the Purchasers) and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. Except as set forth on Schedule 3.1(g), there are no stockholders agreements, voting agreements or other similar agreements with respect to the Company’s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders.
10 |
(h) SEC Reports; Financial Statements. Except as set forth on Schedule 3.1(h) attached hereto, the Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus and the Prospectus Supplement, being collectively referred to herein as the “SEC Reports”). As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (“GAAP”), except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.
(i) Material Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements included within the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date hereof, (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock option plans. The Company does not have pending before the Commission any request for confidential treatment of information. Except for the issuance of the Securities contemplated by this Agreement or as set forth on Schedule 3.1(i), no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made.
(j) Litigation. Except for Actions (as defined herein) disclosed in the Prospectus, there is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an “Action”) which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.
11 |
(k) Labor Relations. No material labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company’s or its Subsidiaries’ employees is a member of a union that relates to such employee’s relationship with the Company or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.
(l) Compliance. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be expected to result in a Material Adverse Effect.
(m) Regulatory Permits. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (“Material Permits”), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit.
12 |
(n) Title to Assets. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made in accordance with GAAP and, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.
(o) Intellectual Property. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to so have could have a Material Adverse Effect (collectively, the “Intellectual Property Rights”). None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their Intellectual Property Rights, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.
(p) Insurance. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not limited to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount. Neither the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.
13 |
(q) Transactions With Affiliates and Employees. Except as set forth in the SEC Reports, none of the officers or directors of the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock option agreements under any stock option plan of the Company.
(r) Sarbanes-Oxley; Internal Accounting Controls. The Company and the Subsidiaries are in compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective and applicable to the Company as of the date hereof, and any and all applicable rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. Except as set forth in the SEC Reports, the Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Except as set forth in the SEC Reports, the Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. The Company’s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the “Evaluation Date”). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.
14 |
(s) Certain Fees. Except as set forth in the Prospectus Supplement, no brokerage or finder’s fees or commissions are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.
(t) Investment Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct its business in a manner so that it will not become an “investment company” subject to registration under the Investment Company Act of 1940, as amended.
(u) Registration Rights. Except for Persons which have waived such rights in writing, no Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities Act of any securities of the Company or any Subsidiary on the Registration Statement.
(v) Listing and Maintenance Requirements. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration. The Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading Market. The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements.
(w) Application of Takeover Protections. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the Company’s certificate of incorporation (or similar charter documents) or the laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the Company’s issuance of the Securities and the Purchasers’ ownership of the Securities.
15 |
(x) Disclosure. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed in the Prospectus Supplement. The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the Disclosure Schedules to this Agreement, is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. The press releases disseminated by the Company during the twelve months preceding the date of this Agreement taken as a whole do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made and when made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.
(y) No Integrated Offering. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions of any Trading Market on which any of the securities of the Company are listed or designated.
(z) Solvency. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company’s assets exceeds the amount that will be required to be paid on or in respect of the Company’s existing debts and other liabilities (including known contingent liabilities) as they mature, (ii) the Company’s assets do not constitute unreasonably small capital to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. Schedule 3.1(z) sets forth as of the date hereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, “Indebtedness” means (x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company’s consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.
16 |
(aa) Tax Status. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim.
(bb) Foreign Corrupt Practices. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA.
(cc) Accountants. The Company’s accounting firm is set forth on Schedule 3.1(cc) of the Disclosure Schedules. To the knowledge and belief of the Company, such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall express its opinion with respect to the financial statements to be included in the Company’s Annual Report for the fiscal year ending December 31, 2012.
(dd) Acknowledgment Regarding Purchasers’ Purchase of Securities. The Company acknowledges and agrees that each of the Purchasers is acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely incidental to the Purchasers’ purchase of the Securities. The Company further represents to each Purchaser that the Company’s decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.
17 |
(ee) Acknowledgement Regarding Purchaser’s Trading Activity. Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except for Sections 3.2(e) and 4.14 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or “derivative” securities based on securities issued by the Company or to hold the Securities for any specified term; (ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales or “derivative” transactions, before or after the closing of this or future private placement transactions, may negatively impact the market price of the Company’s publicly-traded securities; (iii) any Purchaser, and counter-parties in “derivative” transactions to which any such Purchaser is a party, directly or indirectly, presently may have a “short” position in the Common Stock, and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm’s length counter-party in any “derivative” transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities at various times during the period that the Securities are outstanding, including, without limitation, during the periods that the value of the Warrant Shares deliverable with respect to Securities are being determined, and (z) such hedging activities (if any) could reduce the value of the existing stockholders' equity interests in the Company at and after the time that the hedging activities are being conducted. The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.
(ff) Regulation M Compliance. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Company’s placement agent in connection with the placement of the Securities.
18 |
(gg) FDA. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (“FDA”) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (“FDCA”) that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a “Pharmaceutical Product”), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.
(hh) Office of Foreign Assets Control. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”).
(ii) U.S. Real Property Holding Corporation. The Company is not and has never been a U.S. real property holding corporation within the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser’s request.
(jj) Bank Holding Company Act. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956, as amended (the “BHCA”) and to regulation by the Board of Governors of the Federal Reserve System (the “Federal Reserve”). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.
19 |
(kk) Money Laundering. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the “Money Laundering Laws”), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.
3.2 Representations and Warranties of the Purchasers. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein):
(a) Organization; Authority. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company or similar power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement and performance by such Purchaser of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.
(b) Understandings or Arrangements. Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation and warranty not limiting such Purchaser’s right to sell the Securities pursuant to the Registration Statement or otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business.
(c) Purchaser Status. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which it exercises any Warrants, it will be either: (i) an “accredited investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act or (ii) a “qualified institutional buyer” as defined in Rule 144A(a) under the Securities Act. Such Purchaser is not required to be registered as a broker-dealer under Section 15 of the Exchange Act.
20 |
(d) Experience of Such Purchaser. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.
(e) Certain Transactions and Confidentiality. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser’s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser’s assets, the representation set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to the identification of the availability of, or securing of, available shares to borrow in order to effect Short Sales or similar transactions in the future.
The Company acknowledges and agrees that the representations contained in Section 3.2 shall not modify, amend or affect such Purchaser’s right to rely on the Company’s representations and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transaction contemplated hereby.
ARTICLE IV.
OTHER AGREEMENTS OF THE PARTIES
4.1 Warrant Shares. If all or any portion of a Warrant is exercised at a time when there is an effective registration statement to cover the issuance or resale of the Warrant Shares or if the Warrant is exercised via cashless exercise, the Warrant Shares issued pursuant to any such exercise shall be issued free of all legends. If at any time following the date hereof the Registration Statement (or any subsequent registration statement registering the sale or resale of the Warrant Shares) is not effective or is not otherwise available for the sale or resale of the Warrant Shares, the Company shall immediately notify the holders of the Warrants in writing that such registration statement is not then effective and thereafter shall promptly notify such holders when the registration statement is effective again and available for the sale or resale of the Warrant Shares (it being understood and agreed that the foregoing shall not limit the ability of the Company to issue, or any Purchaser to sell, any of the Warrant Shares in compliance with applicable federal and state securities laws). The Company shall use best efforts to keep a registration statement (including the Registration Statement) registering the issuance or resale of the Warrant Shares effective during the term of the Warrants.
21 |
4.2 Furnishing of Information. Until the earliest of the time that (i) no Purchaser owns Securities or (ii) the Warrants have expired, the Company covenants to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act.
4.3 Integration. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction.
4.4 Securities Laws Disclosure; Publicity. The Company shall (a) by 9:30 a.m. (New York City time) on the Trading Day immediately following the date hereof, issue a press release disclosing the material terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees or agents in connection with the transactions contemplated by the Transaction Documents. The Company and each Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a) as required by federal securities law in connection with the filing of final Transaction Documents with the Commission and (b) to the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted under this clause (b).
22 |
4.5 Shareholder Rights Plan. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser is an “Acquiring Person” under any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers.
4.6 Non-Public Information. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company covenants and agrees that neither it, nor any other Person acting on its behalf will provide any Purchaser or its agents or counsel with any information that the Company believes constitutes material non-public information, unless prior thereto such Purchaser shall have entered into a written agreement with the Company regarding the confidentiality and use of such information. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.
4.7 Use of Proceeds. Except as set forth on Schedule 4.7 attached hereto, the Company shall use the net proceeds from the sale of the Securities hereunder for working capital purposes and shall not use such proceeds: (a) for the satisfaction of any portion of the Company’s debt (other than payment of trade payables in the ordinary course of the Company’s business and prior practices), (b) for the redemption of any Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC regulations.
4.8 Indemnification of Purchasers. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a “Purchaser Party”) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents (unless such action is based upon a breach of such Purchaser Party’s representations, warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which constitutes fraud, gross negligence, willful misconduct or malfeasance). If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel, a material conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party effected without the Company’s prior written consent, which shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party’s breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction Documents. The indemnification required by this Section 4.8 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant to law.
23 |
4.9 Reservation of Common Stock. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants.
4.10 Listing of Common Stock. The Company hereby agrees to use best efforts to maintain the listing or quotation of the Common Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all of the Shares and Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and Warrant Shares on such Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then include in such application all of the Shares and Warrant Shares, and will take such other action as is necessary to cause all of the Shares and Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects with the Company’s reporting, filing and other obligations under the bylaws or rules of the Trading Market.
4.11 [RESERVED]
4.12 Subsequent Equity Sales.
(a) From the date hereof until 90 days after the Closing Date, neither the Company nor any Subsidiary shall issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents.
24 |
(b) From the date hereof until 90 days after the Closing Date, the Company shall be prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination of units thereof) involving a Variable Rate Transaction. “Variable Rate Transaction” means a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into any agreement, including, but not limited to, an equity line of credit, whereby the Company may issue securities at a future determined price. Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages.
(c) Notwithstanding the foregoing, this Section 4.12 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall be an Exempt Issuance.
4.13 Equal Treatment of Purchasers. No consideration (including any modification of any Transaction Document) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of any of this Agreement unless the same consideration is also offered to all of the parties to this Agreement. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of Securities or otherwise.
4.14 Certain Transactions and Confidentiality. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short Sales of any of the Company’s securities during the period commencing with the execution of this Agreement and ending at such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described in Section 4.4, such Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information included in the Disclosure Schedules. Notwithstanding the foregoing and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality to the Company or its Subsidiaries after the issuance of the initial press release as described in Section 4.4. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser’s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser’s assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.
25 |
ARTICLE V.
MISCELLANEOUS
5.1 Termination. This Agreement may be terminated by any Purchaser, as to such Purchaser’s obligations hereunder only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not been consummated on or before July 24, 2012; provided, however, that no such termination will affect the right of any party to sue for any breach by any other party (or parties).
5.2 Fees and Expenses. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.
5.3 Entire Agreement. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus Supplement, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.
5.4 Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2nd) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.
26 |
5.5 Amendments; Waivers. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and the Purchasers holding at least a majority in interest of the Shares based on the initial Subscription Amounts hereunder or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.
5.6 Headings. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.
5.7 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of the Transaction Documents that apply to the “Purchasers.”
5.8 No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8.
5.9 Governing Law. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under Section 4.8, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.
27 |
5.10 Survival. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.
5.11 Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof.
5.12 Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.
5.13 Rescission and Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to its future actions and rights; provided, however, that, in the case of a rescission of an exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for such shares and the restoration of such Purchaser’s right to acquire such shares pursuant to such Purchaser’s Warrant (including, issuance of a replacement warrant certificate evidencing such restored right).
28 |
5.14 Replacement of Securities. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.
5.15 Remedies. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby agree to waive and not to assert in any action for specific performance of any such obligation the defense that a remedy at law would be adequate.
5.16 Payment Set Aside. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.
5.17 Independent Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under any Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. For reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to communicate with the Company through EGS. EGS does not represent any of the Purchasers and only represents Maxim Group LLC. The Company has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers.
29 |
5.18 Liquidated Damages. The Company’s obligations to pay any partial liquidated damages or other amounts owing under the Transaction Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts are due and payable shall have been canceled.
5.19 Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.
5.20 Construction. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.
5.21 WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.
(Signature Pages Follow)
30 |
IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.
Brainstorm cell therapeutics inc. | Address for Notice: |
12 Bazel St., POB 10019, | |
Kiryat Aryeh, Petach Tikva, | |
Israel 49001 |
By: | Fax: (9723-923-6385 | ||
Name: | |||
Title: | |||
With a copy to (which shall not constitute notice): |
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK
SIGNATURE PAGE FOR PURCHASER FOLLOWS]
31 |
PURCHASER SIGNATURE PAGES TO BCLI SECURITIES PURCHASE AGREEMENT
IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.
Name of Purchaser: ________________________________________________________
Signature of Authorized Signatory of Purchaser: _________________________________
Name of Authorized Signatory: _______________________________________________
Title of Authorized Signatory: ________________________________________________
Email Address of Authorized Signatory:_________________________________________
Facsimile Number of Authorized Signatory: __________________________________________
Address for Notice to Purchaser:
Address for Delivery of Securities to Purchaser (if not same as address for notice):
Subscription Amount: $_________________
Shares: _________________
Warrant Shares: __________________
EIN Number: _______________________
¨ Notwithstanding anything contained in this Agreement to the contrary, by checking this box (i) the obligations of the above-signed to purchase the securities set forth in this Agreement to be purchased from the Company by the above-signed, and the obligations of the Company to sell such securities to the above-signed, shall be unconditional and all conditions to Closing shall be disregarded, (ii) the Closing shall occur on the third (3rd) Trading Day following the date of this Agreement and (iii) any condition to Closing contemplated by this Agreement (but prior to being disregarded by clause (i) above) that required delivery by the Company or the above-signed of any agreement, instrument, certificate or the like or purchase price (as applicable) shall no longer be a condition and shall instead be an unconditional obligation of the Company or the above-signed (as applicable) to deliver such agreement, instrument, certificate or the like or purchase price (as applicable) to such other party on the Closing Date.
[SIGNATURE PAGES CONTINUE]
32 |
DISCLOSURE
SCHEDULES
TO THE
SECURITIES PURCHASE AGREEMENT
BY AND AMONG
Brainstorm Cell Therapeutics Inc.
and
the purchasers named therein
Dated as of July 17, 2012 (the “Agreement”)
1 |
These disclosure schedules are a series of schedules (the “Disclosure Schedules”) corresponding to the sections contained in the Securities Purchase Agreement dated as of July 17, 2012 (the “Agreement”), by and among Brainstorm Cell Therapeutics Inc., a Delaware corporation (the “Company”), and the purchasers identified on the signature pages thereto (the “Buyer”). Capitalized terms used in these Disclosure Schedules and not otherwise defined herein shall have the respective meanings assigned to them in the Agreement. These Disclosure Schedules contain the information required to be disclosed pursuant to, and certain exceptions to, the representations and warranties in the corresponding sections of the Agreement. The section headings and subject headings in the Disclosure Schedules are for convenience of reference only and shall not be deemed to alter or affect any disclosure in these Disclosure Schedules or any provision of the Agreement. Matters set forth in the Disclosure Schedules are not necessarily limited to matters required by the Agreement to be reflected in the Disclosure Schedules. Nothing in the Agreement or in the Disclosure Schedules constitutes an admission that any information disclosed, set forth or incorporated by reference in the Disclosure Schedules or in the Agreement is material, constitutes a Material Adverse Effect or is otherwise required by the terms of the Agreement to be so disclosed, set forth or incorporated by reference. Information disclosed (including the terms of any agreements referenced herein) by the Company in any one Section of the Disclosure Schedules will also be deemed a disclosure as to all other applicable Sections of the Disclosure Schedules and the Agreement where such disclosure is readily apparent from the face of such disclosure.
The annexes, attachments, and exhibits to these Disclosure Schedules, if any, form an integral part of these Disclosure Schedules and are incorporated by reference for all purposes as if set forth fully herein.
2 |
Schedule 3.1(a)
Subsidiaries
Brainstorm Cell Therapeutics Ltd.
3 |
Schedule 3.1(g)
Capitalization*
Capitalization Overview:
Authorized shares: 800,000,000 shares of common stock, $0.00005 par value.
Issued and outstanding: 128,586,644 (as of June 15, 2012).
Option pool: As of June 6, 2012, there were 3,225,103 shares available for issuance under the Plans. On May 6, 2012, the Board approved another amendment and restatement of the Plans to increase the number of shares available for issuance under the Plans by an additional 9,000,000 shares, subject to the approval of the Company’s stockholders. Our stockholders approved the amendment and restatement of the Plans on June 12, 2012.
Options issued: As of June 28, 2012, there were 3,936,665 options outstanding under Company plans.
Warrants: 47,582,162 shares of common stock issuable upon exercise of outstanding warrants as of June 28, 2012, with exercise prices ranging from $0.00005 per share to $0.75 per share.
Convertible notes: None.
Agreements to issue stock:
In addition to the Options and Warrants described above:
· | On April 13, 2010, the Company, Dr. Israeli and Hadasit Medical Research Services and Development Ltd. (“Hadasit”) entered into an Agreement, which was amended to clarify certain terms on December 31, 2011 (together, the “Hadasit Agreement”) pursuant to which the Company agreed to grant, for every year of service: (i) options to Dr. Israeli annually during the term of the Agreement for the purchase of 166,666 shares of our common stock at an exercise price equal to $0.00005 per share and (ii) warrants to Hadasit annually during the term of the Agreement for the purchase of 33,334 shares of our common stock at an exercise price equal to $0.00005 per share. Such options and warrants will vest and become exercisable in twelve (12) consecutive equal monthly amounts. |
· | Thomas B. Rosedale, the Managing Member of BRL Law Group LLC, beneficially owned 180,000 shares of our common stock and may receive additional shares as part of compensation for certain legal services performed by BRL Law Group LLC in 2012. The Company is in discussion with BRL Law Group LLC regarding the issuance of up to 300,000 shares of Common Stock in exchange for certain 2012 general corporate legal work provided to the Company (which shares are expected to be issued in or about June 2012). |
4 |
· | Under the Company’s Director Compensation Plan for non-employee directors (the “Director Compensation Plan”) each eligible director is granted an annual award immediately following each annual meeting of shareholders beginning with the 2011 annual meeting. For non-U.S. directors, this annual award consists of a nonqualified stock option to purchase 100,000 shares of common stock. For U.S. directors, at their option, this annual award is either (i) a nonqualified stock option to purchase 100,000 shares of common stock or (ii) 100,000 shares of restricted stock. Additionally, each member of the GNC Committee or Audit Committee receives (i) a nonqualified stock option to purchase 30,000 shares of common stock or (ii) in the case of U.S. directors and at their option, 30,000 shares of restricted stock. A chairperson of the GNC Committee or Audit Committee will instead of the above committee award receive (i) a nonqualified stock option to purchase 50,000 shares of common stock or (ii) in the case of U.S. directors and at their option, 50,000 shares of restricted stock. Any eligible participant who is serving as chairperson of the Board of Directors of the Company shall also receive (i) a nonqualified stock option to purchase 100,000 shares of common stock or (ii) in the case of U.S. directors and at their option, 100,000 shares of restricted stock. |
Right of First Refusal, etc.:
ACCBT Corp. (“ACCBT”) has certain rights and privileges as set forth in the July 2, 2007 Subscription Agreement by and between the Company and ACCBT, as amended, and other related agreements including a Registration Rights Agreement and Security Holders Agreement, which include but are not limited to the following:
For so long as ACCBT or its affiliates hold at least 5% of our issued and outstanding share capital:
(i) | Board Appointment Right: ACCBT has the right to appoint 50.1% (any fractions to be rounded up to the nearest whole number) of the members of the Company’s Board of Directors and any of its committees and the Board of Directors of the Subsidiary. |
(ii) | Preemptive Right: ACCBT has the right to receive thirty day notice of, and to purchase a pro rata portion (or greater under certain circumstances where offered shares are not purchased by other subscribers) of, securities issued by the Company, including options and rights to purchase shares. This preemptive right does not include issuances under the Company’s equity incentive plans. ACCBT has waived any such rights it may have in connection with the transactions contemplated by the Agreement. |
(iii) | Consent Right: ACCBT’s written consent is required for certain Company corporate actions, including issuance of shares (other than existing warrants and issuances under our incentive plans), amendment of our charter or bylaws, repurchase of shares, declaration or payment of dividends or distributions, related party transactions, non-ordinary course transactions involving $25,000 or more, liquidation or dissolution, the creation, acquisition or disposition of a subsidiary or entry into a joint venture or strategic alliance, a material change to our business, merger, change of control, sale of the company, any acquisition, and any payment of cash compensation over $60,000 per year. ACCBT has consented to the transactions contemplated by the Agreement. |
5 |
In addition ACCBT is entitled to demand and piggyback registration rights, whereby ACCBT may request, upon ten days written notice, that the Company file, or include within a registration statement to be filed, with the Securities and Exchange Commission for ACCBT’s resale of the ACCBT Subscription Shares, as adjusted, and the shares of the Company’s common stock issuable upon exercise of the ACCBT Warrants. ACCBT has waived any such rights it may have in connection with the transactions contemplated by the Agreement.
* All of the above Capitalization numbers are pre-Closing and do not reflect actions contemplated by the Transaction Documents.
6 |
Schedule 3.1(h)
SEC Reports
None.
7 |
Schedule 3.1(i)
Material Changes; Undisclosed Events, Liabilities or Developments
Pursuant to the Hadasit Agreement, on April 13, 2012, the Company issued to Dr. Israeli 166,666 shares of common stock at an exercise price equal to $0.00005 per share and issued warrants to Hadasit for the purchase of 33,334 shares of common stock at an exercise price equal to $0.00005 per share.
8 |
Schedule 3.1(o)
Intellectual Property
None.
9 |
Schedule 3.1(z)
Solvency - Indebtedness
All outstanding secured and unsecured Indebtedness of the Company:
The Company has received from the Israeli Office of the Chief Scientist (“OCS”) approximately $1.8 million in grants. The Company is obligated to pay royalties to the OCS, amounting to 3% to 5% of revenues derived from sales of the products funded with the OCS grant, up to an amount equal to 100% of the grant received.
All outstanding secured and unsecured Indebtedness of the Subsidiary:
1) Agreement with Kiriat Hamada for Petach Tikva office rent – $9,500 per month through March 31, 2013
2) Albar – leasing of cars - $90,000 (approximately $3,500 per month). This agreement has a three month early termination penalty.
3) Hadasit – rental of GMP in Jerusalem – approximately $77,000 per month. Note: this agreement for the use of 2 clean rooms can be terminated with 30 days prior notice. It is anticipated that the Company will continue using this space for at least 6 more months.
10 |
Schedule 3.1(cc)
Accountants
Brightman Almagor Zohar & Co.
Certified Public Accountants
A Member Firm of Deloitte Touche Tohmatsu.
11 |
ANNEX B
COMMON STOCK PURCHASE WARRANT
brainstorM cell therapeutics inc.
Warrant Shares: _______ | Initial Exercise Date: July [__], 2012 |
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the 30 month anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Brainstorm Cell Therapeutics Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Section 1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the “Purchase Agreement”), dated July 17, 2012, among the Company and the purchasers signatory thereto.
Section 2. Exercise.
a) Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company) of a duly executed facsimile copy of the Notice of Exercise Form annexed hereto. Within three (3) Trading Days following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is available and specified in the applicable Notice of Exercise. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise Form within one (1) Business Day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.
1 |
b) Exercise Price. The exercise price per share of the Common Stock under this Warrant shall be $0.29, subject to adjustment hereunder (the “Exercise Price”). Except as where otherwise permitted in accordance with Section 2(c), this Warrant may only be exercised by means of payment by wire transfer or cashier’s check drawn on a United States bank.
c) Cashless Exercise. If, and only if, at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then, and only then, this Warrant may at the option of the Holder be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:
(A) = | the VWAP on the Trading Day immediately preceding the date on which Holder elects to exercise this Warrant by means of a “cashless exercise,” as set forth in the applicable Notice of Exercise; |
(B) = | the Exercise Price of this Warrant, as adjusted hereunder; and |
(X ) = | the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise. |
“VWAP” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the OTC Bulletin Board is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the OTC Bulletin Board, (c) if the Common Stock is not then listed or quoted for trading on the OTC Bulletin Board and if prices for the Common Stock are then reported in the “Pink Sheets” published by Pink OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.
2 |
d) Mechanics of Exercise.
i. Delivery of Warrant Shares Upon Exercise. The Company shall use best efforts to cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder’s prime broker with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery to the address specified by the Holder in the Notice of Exercise by the date that is three (3) Trading Days after the latest of (A) the delivery to the Company of the Notice of Exercise, (B) surrender of this Warrant (if required) and (C) payment of the aggregate Exercise Price as set forth above (including by cashless exercise, if permitted) (such date, the “Warrant Share Delivery Date”). The Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date the Warrant has been exercised, with payment to the Company of the Exercise Price (or by cashless exercise, if permitted) and all taxes required to be paid by the Holder, if any, pursuant to Section 2(d)(vi) prior to the issuance of such shares, having been paid.
ii. Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.
iii. Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.
3 |
iv. Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.
v. No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.
vi. Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that, in the event Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise.
4 |
vii. Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.
e) Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within two Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon not less than 61 days’ prior notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any such increase or decrease will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.
5 |
Section 3. Certain Adjustments.
a) Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.
6 |
b) [RESERVED]
c) Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time during which this Warrant is outstanding the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).
d) Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a "Distribution"), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).
7 |
e) Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction that is (1) an all cash transaction, (2) a “Rule 13e-3 transaction” as defined in Rule 13e-3 under the Exchange Act, or (3) a Fundamental Transaction involving a person or entity not traded on a national securities exchange, including, but not limited to, the NYSE MKT, the Nasdaq Global Select Market, the Nasdaq Global Market, or the Nasdaq Capital Market, the Company or any Successor Entity (as defined below) shall, at the Holder’s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction, purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction. “Black Scholes Value” means the value of this Warrant based on the Black and Scholes Option Pricing Model obtained from the “OV” function on Bloomberg, L.P. (“Bloomberg”) determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.
8 |
f) Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.
9 |
g) Notice to Holder.
i. Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly mail to the Holder a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.
ii. Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed to the Holder at its last address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the mailing thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.
10 |
Section 4. Transfer of Warrant.
a) Transferability. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.
b) New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.
c) Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.
Section 5. Miscellaneous.
a) No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3.
b) Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.
11 |
c) Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.
d) Authorized Shares.
The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).
Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.
Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.
12 |
e) Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.
f) Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.
g) Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.
h) Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.
i) Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.
j) Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.
k) Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.
13 |
l) Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.
m) Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.
n) Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.
********************
(Signature Page Follows)
14 |
IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.
Brainstorm Cell Therapeutics inc. | ||
By: | ||
Name: | ||
Title: |
15 |
NOTICE OF EXERCISE
To: Brainstorm Cell Therapeutics inc.
(1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.
(2) Payment shall take the form of (check applicable box):
£ in lawful money of the United States by wire transfer or cashier’s check drawn on a United States bank; or
£ if permitted by the terms of the Warrant, the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).
(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:
_______________________________ |
The Warrant Shares shall be delivered to the following DWAC Account Number:
_______________________________ | ||
_______________________________ | ||
_______________________________ |
[SIGNATURE OF HOLDER]
Name of Investing Entity: ____________________________________________________________________________
Signature of Authorized Signatory of Investing Entity: ______________________________________________________
Name of Authorized Signatory: ________________________________________________________________________
Title of Authorized Signatory: _________________________________________________________________________
Date: _____________________________________________________________________________________________
ASSIGNMENT FORM
(To assign the foregoing warrant, execute
this form and supply required information.
Do not use this form to exercise the warrant.)
FOR VALUE RECEIVED, [____] all of or [_______] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to
_______________________________________________ whose address is
_______________________________________________________________.
_______________________________________________________________
Date: ______________, _______ |
Holder’s Signature: | _____________________________ | ||
Holder’s Address: | _____________________________ | ||
_____________________________ |
Signature Guaranteed: ___________________________________________
NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever, and must be guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.